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Abstract 
 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized 
by chronic inflammation within the synovial tissues in multiple joints leading to 
progressive, erosive destruction of cartilage and underlying joints. The severity 
of RA is associated with the overexpression of proinflammatory cytokines within 
the synovial tissue, such as TNF-a, IL-1 and IL-6. Recently, IL-17 is thought to 
play a critical role in maintaining the inflammatory processes within the arthritic 
joints. Although the etiology and pathogenesis of RA has not been completely 
elucidated, neutralizing Antibodies against the inflammatory components have 
been shown to successfully suppress joint inflammation, reduce the relapse rate 
and delay disease onset in RA patients. Therefore, the expression and regulation 
of  cytokines  produced  during  the  disease  progression  has  been  the  centre  of 
interest  in  therapeutic  studies.  Cytokines  are  important  mediators  of  immune 
functions in humans and animals. In this thesis, a murine model of RA has been 
used to investigate the roles of new cytokines Interleukin (IL)-27 and Interleukin 
(IL)-35.  
 
Interleukin (IL)-27, is a heterodimeric cytokine comprised of an IL-12p40 related 
protein, Epstein-Barr virus-induced gene 3 (EBI3) and a unique IL-12p35 like 
protein p28. IL-27 is a member of IL-12 family, mainly generated by activated 
macrophages  and  dendritic  cells.  IL-27  binds  a  receptor  composed  of  WSX-
1/TCCR,  a  ligand-specific  chain,  and  gp130,  a  signal-transducing  molecule 
shared with other cytokines such as IL-6. IL-27 can promote both pro- and anti-
inflammatory immune responses. A novel role of IL-27 regulating autoimmunity 
has  been  suggested  by  experiments  on  experimental  autoimmune   3 
encephalomyelitis (EAE) and central nervous system (CNS) inflammation when 
infected  with  Toxoplasma  gondii.  IL-27  suppresses  these  chronic  diseases 
through inhibiting Th17 activity. Thus, IL-27 may have an important therapeutic 
potential for treatment of RA in humans. A major aim of this project has been to 
clone and express a recombinant murine IL-27 in sufficient quantities to study 
the role of IL-27 in a murine model of RA closely related to the human disease, 
collagen-induced arthritis (CIA). A short term administration of IL-27 to mice at 
the onset of the disease had a significantly suppressive effect on disease severity 
and  incidence  compared  with  untreated  controls.  Mice  treated  with  the 
recombinant IL-27 also showed reduced serum IL-6, IL-17 and collagen-specific 
IgG2a.  Spleen  and  lymph  node  cells  from  the  IL-27-treated  mice  produced 
significantly less IFN-g and IL-17 compared with cells from the control mice 
when cultured with collagen in vitro. In contrast, administration of IL-27 to mice 
during the late phase of CIA significantly exacerbated disease severity. IL-27-
treated mice also showed elevated IFN-γ and IL-6 production by the lymphoid 
cells  when  compared  to  untreated  mice.  However,  IL-17  synthesis  was  not 
affected  between  IL-27-treated  mice  and  untreated  mice.  Consistent  with  this 
finding, in vitro IL-27 markedly inhibited the development of Th17 from naïve 
CD4
+,  CD4
+CD25
-  and  CD4
+CD25
+  T  cells,  but  had  little  or  no  effect  on 
differentiated  Th17  cells.  Together,  these  results  demonstrated  that  IL-27  had 
both  pro-inflammatory  and  anti-inflammatory  effects  on  chronic  articular 
inflammation, mainly associated with Th17 functions.   
 
Interleukin  (IL)-35,  another  novel  heterodimeric  cytokine  belonging  to  IL-12 
family, is composed of EBI3 and the IL-12p35 subunit. Little is known about the   4 
biological function of IL-35. To study the role of IL-35 in immune responses, 
murine recombinant IL-35 was cloned and expressed in a mammalian GS system 
to  produce  sufficient  quantities.  IL-35  induced  proliferation  of  murine 
CD4
+CD25
+ and CD4
+CD25
- T cells when stimulated with immobilized anti-
CD3 and anti-CD28 antibodies in vitro. The IL-35-expanded CD4
+CD25
+ T cell 
population expressed Foxp3 and produced elevated levels of IL-10, whereas the 
IL-35-induced  CD4
+CD25
-  T  cells  produced  IFN-γ  but  not  IL-4.  The  IL-35-
expanded  CD4
+CD25
+  T  cells  maintained  their  suppressive  functions  against 
CD4
+CD25
-  effector  cells.  Furthermore,  when  cultured  with  soluble  anti-CD3 
and  antigen-presenting  cells,  IL-35  directly  suppressed  the  proliferation  of 
CD4
+CD25
- effector cells. Moreover, IL-35 inhibited the differentiation of Th17 
cells in vitro. In vivo, IL-35 effectively suppressed established collagen-induced 
arthritis in mice with the suppression of IL-17 production but enhanced IFN-γ 
synthesis. Therefore, IL-35 is a novel cytokine suppressing the immune response 
through  the  expansion  of  regulatory  T  cells  and  suppression  of  Th17  cell 
development. For the future study of human IL-35, human EBI3 and p35 were 
cloned and linked together with an Fc fusion part. Human IL-35 was expressed in 
GS system and the function of the recombinant protein needs further study. 
 
These  data  in  this  thesis  provide  direct  evidence  that  IL-27  and  IL-35  are 
important mediators in murine collagen-induced arthritis disease. This implicated 
that IL-27 and IL-35 could represent potential new targets for novel therapeutic 
agents in human RA. However, the findings on the dual role of IL-27  at the 
different  disease  process  suggested  that  the  involvement  of  IL-27  in  the   5 
pathogenesis  of  human  RA  should  be  carefully  investigated  before  clinical 
therapy application.  
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1.1 T helper (Th) lymphocytes 
 
 
1.1.1 Introduction 
 
 
Inflammation  plays  an  important  role  in  the  host  defense  against  pathogenic 
infection, tissue repair and regulation of innate and adaptive immune responses. 
However,  the  skewed  regulation  of  immune  responses  can  result  in  chronic 
inflammation,  such  as  autoimmune  diseases  and  cancer.  The  autoimmune 
diseases such as rheumatoid arthritis (RA) are the consequence of the action of a 
diverse cell population that includes B cells, macrophages and T cells. The major 
proportion of the inflammatory cells in RA is T cells. Activated CD4
+ T cells are 
the  dominant  subset  of  T  cells  in  initiation  and  perpetuation  of  the  chronic 
inflammation prevalent in RA (Feldmann et al., 1996; Namekawa et al., 1998). 
Classically, upon activation, CD4
+ T cells have been divided into Th1 or Th2 
effector cells (reviewed in Mosmann & Sad., 1996; Murphy & Reiner, 2002). It 
has  been  known  for  many  years  that  Th1  and  Th2  cells  provide  immune 
responses to intracellular and extracelluar pathogens respectively, depending on 
their signature cytokine production. IFN-g is the signature cytokine of Th1 subset, 
whereas IL-4, IL-5 and IL-13 are secreted by Th2 subset. Recently, a new lineage 
of effector CD4
+ T cell preferentially produces IL-17 (Th17) has been discovered. 
Th17 subset is distinct from Th1 and Th2 subsets, and provides diverse effector 
functions during immune responses. The importance of Th17 responses has been 
demonstrated in varieties of chronic autoimmune diseases including RA, which 
had been formally regarded as Th1 diseases. Another critical subset of CD4
+ T 
cells is regulatory T cells (Treg). There are two major types of Treg cells, the 
naturally  occurring  CD4
+  CD25
+  Tregs  originated  from  the  thymus  and  the   25 
inducible Tregs generated in the periphery. Treg cells have important functions in 
the  regulation  of  autoimmune  diseases.  Since  Th1  and  Th2  cells  are  well 
established, the following parts will focus on Th17 cells and Treg cells.  
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Figure 1.1 Differentiation of CD4
+ T cell lineages. 
Naïve CD4
+ T cells can differentiate into three subsets of effector T cells (Th1, 
Th2, and Th17) and two subsets of Treg cells (Tr1 and Th3). Naturally occurring 
Treg cells are generated from CD4
+ thymic T cell precursors. The differentiation 
of these subsets is governed by selective cytokines and transcription factors, and 
each subset provides specialized functions. (Adapted from Bettelli et al., 2007) 
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1.1.2 Th2 cells 
 
Th2 cells are characterised by the production of IL-4, IL-5, and IL-13, and these 
Th2 cytokines promote activation of innate cells and help B cells in IgG1 and IgE 
class switching (reviewed by Abbas, et al., 1996). The development of Th2 cells 
is  initiated  via  TCR  signalling  acting  in  concert  with  IL-4  receptor  through 
STAT6 (Paul, 1997). Signals derived from TCR and IL-4 receptor cooperatively 
upregulate the expression of GATA-3, a master regulator of Th2 differentiation 
(Zheng  &  Flavell,  1997).  GATA-3  enhances  its  own  expression,  and  drives 
epigenetic changes in the Th2 cytokine gene cluster (for IL-4, IL-5 and IL-13). 
Meanwhile,  GATA-3  suppresses  the  dominant  factors  for  Th1  polarization, 
including  IL-12Rb2  and  STAT4  to  block  Th1  development  (Ouyang  et  al., 
1998).  Furthermore,  IL-4  is  a  negative  regulator  of  Th17  effector  cells 
(Harrington et al., 2005). Usually, the cytokines produced by a given Th lineage 
often act as potent self inducers of their own lineage, as well as inhibitors of 
other Th lineages. Thus, IL-4 produced by mature Th2 cells can reinforce Th2 
development  and  inhibit  Th1  and  Th17  developments  through  positive  and 
negative feedback loops.  
 
Appropriate induction of Th2 effector cells promotes humoral immunity that is 
crucial  for  controlling  infections  by  extracellular  pathogens  (Reiner,  2001). 
Furthermore, Th2 responses can down-regulate autoimmune diseases. It has been 
shown that IL-4 delays the onset of CIA, reduces the symptoms severity and 
prevents joints damage and bone erosion (Horsfall et al., 1997; Joosten et al., 
1997). However, inappropriate action of Th2 cells can cause allergic reactions, 
such as asthma (Abbas, et al., 1996).   28 
1.1.3 Th1 cells    
  
In  contrast  to  Th2  cells,  Th1  cells  came  to  be  defined  on  the  basis  of  their 
production of the signature cytokine, interferon (IFN)-g. IFN-g is important in the 
clearance of certain intracellular pathogens and promote IgG2a class switching in 
mice on B cells (reviewed in O’ Garra, et al., 2000). The process of Th1 helper 
cells differentiation is initiated by TCR signalling in association with cytokine 
receptors via STAT1 (Gubler, et al., 1991; Murphy, et al., 2000). Type I IFNs, 
type  II  IFNs  and  the  newly  discovered  IL-27  can  activate  STAT1,  via  their 
receptors on naïve CD4
+ T cells. STAT1 signalling sequentially up-regulates the 
expression  of  the  transcription  factor  T-bet,  a  master  regulator  of  Th1 
differentiation. T-bet enhances the expression of IFN-g and induces the IL-12 
receptor  b2  chain  while  suppressing  GATA-3  and  other  Th2  differentiation 
factors  (Kamiya,  et  al.,  2004,  Hibbert  2003).  The  induction  of  IL-12Rb2  on 
developing Th1 cells allows IL-12 signaling via STAT4. This in turn leads to the 
maturation  of  Th1  effector  cells  that  can  produce  IFN-g.  Furthermore,  IL-12 
induces IL-18 receptor, allowing IL-18 to synergize with IL-12 to enhance IFN-g 
production from Th1 effector cells (Yoshimoto et al., 1998). It also has been 
revealed that IL-23 preferentially acts on the proliferation of memory T cells and 
the continuation of Th1 development (Oppmann, et al., 2000). 
 
Appropriate induction of Th1 cells is required for effective cellular immunity to 
clear  intracellular  pathogens,  such  as  Leishmania  genus,  Mycobacteria  and 
Salmonella. Overactivation of Th1 cells have been thought to cause autoimmune 
inflammatory diseases, including RA, EAE, and certain allergic disorders, such   29 
as delayed-type hypersensitivities (DTH) and contact hypersensitivity (Leonard 
et al., 1995; Kageyama et al., 1998; Doing & Flavell 2000). However, there is 
controversy
 over the role of Th1 cells in the onset phase of rheumatoid arthritis
 
based on the observations that  IFN-  was not  always highly  expressed in the 
lesion (Husby et al., 1985; Kinne et al., 1997). Furthermore, mice deficient in 
IFN-g or STAT1 were still susceptible to CIA and EAE (Ferber et al., 1996; 
Mattys 1998; Bettelli et al., 2004). CIA is exacerbated in mice lacking
 IFN-  
receptors  (Manoury-Schwartz  et  al.,  1997;  Vermeire  et  al.,  1997).  These 
observations suggested that an additional Th cell type other than Th1 cells plays a 
more important role in these autoimmune diseases. This additional Th cell type 
was recently defined as Th17 cells. 
 
1.1.4 Th17 cells 
 
1.1.4.1  Introduction  
 
Although the cytokine IL-17 was identified more than 10 years ago, Th17 cells as 
a new subset of CD4
+T cells was proposed from the recent observations on IL-23 
and IL-12 deficient mice. It was demonstrated that IL-23 rather than IL-12 plays 
a critical role in the development of CIA and EAE (Cua et al., 2003; Murphy et 
al., 2003; Langrish et al., 2005; Chen et al., 2006). On gene expression profiles 
analysis,  IL-23-cultured  T  cells  preferentially  express  chronic  inflammatory 
cytokines including IL-17, IL-6, and TNF-a, unlike that of IL-12-cultured Th1 
cells. Furthermore, Langrish, et al. (2005) demonstrated that mice induced a more 
severe EAE upon the transfer of IL-17-producing CD4
+ T cells pre-cultured by 
IL-23, while mice did not induce severe EAE upon the transfer of Th1 cells.   30 
Thus,  IL-17-producing  CD4
+  T  cells  are  distinct  from  Th1  cells.  It  was  also 
recognized  that  Th1  signaling  (STAT1,  T-Bet,  STAT4)  and  Th2  signaling 
(STAT6) are not required by Th17 development (Harrington et al., 2005; Park et 
al., 2005) In contrast, IFN-g and IL-4 actively suppress Th17 development, and 
neutralization of IFN-g and IL-4 is important for Th17 development (Harrington 
et al., 2005; Park et al., 2005). Therefore, Th17 cells represent a distinct lineage 
of CD4
+ T cells.  
  
1.1.4.2 Characteristics of Th17 cells  
 
Th17 cells are characterized by their production of a distinct profile of cytokines, 
including IL-17 (or IL-17A) and IL-17F. Recently it has been shown that IL-21, a 
member of the common gamma chain family of cytokines, is secreted by Th17 
cells in mouse (Korn et al., 2007; Nurieva et al., 2007). Instead of IL-21, human 
Th17 cells express IL-22 and IL-26; both belonging to IL-10 cytokine family 
(Acosta-Rodriguez et al., 2007; Wilson et al., 2007).    
 
1.1.4.2.1  IL-17 
 
IL-17, which was originally named as cytotoxic T lymphocyte-associated factor 8 
(CTLA8),  is  a  signature  cytokine  of  Th17  lineage,  first  described  as  a  gene 
product without clear functions by Rouvier et al in 1993. IL-17 gene is located in 
chromosome 6p12, and shows 58% homology with an open reading frame of the 
T  lymphotrophic  herpesvirus  Saimiri  gene  13.  IL-17  is  a  disulfide-linked 
homodimeric  glycoprotein  consisting  of  155  amino  acids  (Yao  et  al.,  1995).   31 
Human IL-17 displays close structural homology with mouse and rat IL-17, and 
they  all  have  remarkably  conserved  glycosylation  sites  (Yao  et  al.,  1995(2)). 
Besides being produced by Th17 cells, IL-17 is also expressed by CD8
+ T cells, 
gd T cells, NK cells, eosinophils and neutrophils (summarized by Kawaguchi et 
al., 2004).  
 
IL-17, also termed IL-17A, is a member of a newly identified cytokine family 
which comprises of six members. Five additional IL-17 cytokine family members 
have been identified and designated IL-17B, IL-17C, IL-17D, IL-17E (termed IL-
25), and IL-17F. (Li et al., 2000; Lee et al., 2001; Hymowitz et al., 2001). The 
IL-17s are all expressed as homodimers with disulfide bridge link, except IL-17 
B is expressed as a non-covalent dimer. IL-17 cytokine family members have a 
similar C-terminal region, with five well conserved cysteine residues accounting 
for a characteristic cysteine-knot formation. IL-17 family shows no resemblance 
with other known cytokines, thus it is a unique cytokine family. IL-17 B, C, D 
and  E  have  low  homology  with  IL-17A.  In  contrast,  IL-17F  has  nearly  50% 
identity to IL-17A at the amino acid level (Moseley et al., 2003). IL-17F gene is 
located closely to IL-17A in all species (Moseley et al., 2003). Probably due to 
their close location, IL-17A and IL-17F are both expressed by Th17 cells. 
 
Like other known cytokines, the biological activity of IL-17 is dependent on its 
receptors. There have been five IL-17 receptors described to date: IL-17RA, IL-
17RB, IL-17RC, IL-17RD, and IL-17RE (Weaver et al., 2007). Despite extensive 
studies on IL-17, the studies of IL-17 receptor family have been limited. It has   32 
been  recently  reported  that  IL-17  signaling  requires  a  multimeric  receptor 
complex consisting of IL-17RA and IL-17RC (Toy et al., 2006). 
 
IL-17RA, the first identified member of the IL-17 receptor family, is a single-
pass transmembrane receptor consisting of an extracellular amino acid domain 
and a long cytoplasmic tail (Yao et al., 1995). In contrast to relatively restricted 
expression of IL-17, IL -17RA has been found to be ubiquitously expressed at 
mRNA level in many cell types, including epithelial cells, neutrophils, fibroblasts, 
B and T lymphocytes, myelomonocytic cells, marrow stromal cells and vascular 
endothelial cells (Yao et al., 1995; Moseley et al., 2003). IL-17RA binds both IL-
17  and  IL-17F.  However,  in  human,  IL-17RA  binds  to  IL-17  with  100-fold 
higher affinities than it binds to IL-17F (Hymowitz et al., 2001; Kuestner et al., 
2007).  IL-17RA  deficient  mice  exhibit  enhanced  susceptibility  to  multiple 
infectious agents, which is consistent with the important role for IL-17A and IL-
17F in host defence (Ye et al., 2001).  
 
IL-17RC,  also  named  IL-17RL,  is  another  IL-17R  family  member  and  has 
recently  been  recognised  as  an  essential  component  in  IL-17-mediated  signal 
transduction (Toy et al., 2006). IL-17 RC mRNA has been detected in human 
prostate  cells,  cartilage,  heart,  kidney,  liver  and  muscle  cells,  and  mouse  tail 
fibroblast cells (Haudenschild et al., 2002; Moseley  et al., 2003).  It has been 
recently reported that human IL-17RC binds to IL-17A and IL-17F with similar 
high affinity, but m IL-17RC only binds m IL-17F (Kuestner et al., 2007).  Like 
IL-17RA, IL-17RC is also a single-pass transmembrane receptor protein with a 
unique, long cytoplasmic tail (Haudenschild et al., 2002). IL-17RC shows 23%   33 
homology with IL-17RA.  However, IL-17RC has an alternative splice variant, 
which leads to over 90 splice isoforms of human IL-17RC. Some of the isoforms 
are  secreted  soluble  proteins  and  they  retain  their  ligand-binding  properties 
(Haudenschild et al., 2002; 2006). It has been demonstrated that a soluble form of 
IL-17RC effectively inhibits the sigaling response of both IL-17A and IL-17F 
through blocking their bindings (Kuestner et al., 2007).  
 
With co-immunoprecipitation, it was demonstrated that IL-17RA and IL-17RC 
have a physical interaction (Toy et al., 2006). IL-17RA was recently shown to be 
multimeric existing as a preformed complex in the absence of ligand binding, 
Upon  binding  to  IL-17A  and  IL-17F,  IL-17RA  multimer  complex  undergo  a 
major  conformational  alternation  (Kramer  et  al.,  2006).Therefore,  it  was 
suggested  that  this  conformational  alternation  may  induce  a  productive, 
heterotypic interaction with IL-17RC (Toy et al., 2006). 
 
IL-17RA  and  IL-17RC  contain  a  conserved  cytoplasmic  SEFIR  (similar 
expression to fibroblast growth factor (FGF) genes, IL-17 receptors and Toll-IL-
1R)  domain  (Novatchkova  et  al.,  2003).  The  SEFIR  domain  provides  an 
important  interaction  for  downstream  signalling  molecules  of  IL-17.  Initial 
studies indicated that IL-17 signaling may depend on the activation of mitogen-
activated protein kinases and the transcription of NF-kB, two classical signalling 
pathways associated with proinflammatory signals (Shalom-Barak et al., 1998; 
Awane et al., 1999). However, the exact intermediate pathways between IL-17R 
and  the  downstream  signals  are  still  not  fully  elucidated.  Recent  studies 
suggested that the cytoplasmic adaptor protein Act1 is a crucial mediator of IL-  34 
17 signalling (Chang et al., 2006). It seems that Act1 bridges IL-17R ligation by 
IL-17  and  downstream  signals.  IL-17R-Act1-mediated  signalling  pathway  is 
associated with IL-17- dependent autoimmune and inflammatory diseases in the 
intestine and central nervous system respectively (Qian et al., 2007).  
 
IL-17, as an important inflammatory cytokine, acts on a large variety of cells, 
including  epithelial  cells,  endothelial  cells,  fibroblasts,  synoviocytes,  and 
myeloid  cells  (Kolls  et  al.,  2004).  IL-17  induces  the  expression  of 
proinflammatory  cytokines,  such  as  IL-6,  TNF,  IL-1b,  GM-CSF,  and  CSF; 
chemokines, such as KC, MCP-1, and MCP-2, CXCL1, and IL-8; and matrix 
metalloproteases,  which  mediate  tissue  inflammation,  tissue  infiltration  and 
destruction.  Predominant  cytokines  and  chemokines  stimulated  by  IL-17  are 
especially  involved  in  the  proliferation,  maturation,  and  chemotaxis  of 
neutrophils,  which  features  the  coordination  between  innate  and  adaptive 
immunity (Kolls et al., 2004).  
 
1.1.4.3 Cytokine Regulation of Th17 differentiation 
 
It was initially thought that IL-23 induces the generation of Th17 cells. However, 
three  independent  groups  simultaneously  found  that  IL-23  failed  to  drive  the 
differentiation of naïve CD4
+ T cells to Th17 cells in mice (Veldhoen et al., 2006; 
Mangan et al., 2006; Bettelli et al., 2006). This is consistent with the expression 
of IL-23R, as IL-23R is not expressed on naive T cells in mice (Parham et al., 
2002). The further study suggested that IL-23 may provide a survival signal for 
already differentiated Th17 (Veldhoen et al., 2006). Subsequently, it has been   35 
shown that TGF-b and IL-6 act cooperatively to induce the differentiation of 
Th17  commitment  in  mice.  TGF-b,  conventionally  regarded  as  an  anti-
inflammatory agent, inhibits the differentiation of Th1 and Th2 cells (Gorelik et 
al.,  2000;  2002).  Previously  it  has  been  reported  that  TGF-b  is  an  important 
factor in inducing Foxp3+ Treg cells in vitro (which will be further discussed in 
the following Treg cells section). During the generation of Th17 cells, TGF-b is 
also identified as a critical factor. The deviation is associated with the action of 
IL-6. TGF-b alone induces Foxp3+ Treg generation, while the presence of IL-6 
directs TGF-b to drive Th17 cells generation rather than Treg cells (Bettelli et al., 
2006). Furthermore, it has been reported that the combination of TGF-b and IL-6 
up-regulates the expression of IL-23R on Th17 cells. Thereby, the expression of 
IL-23R allows IL-23 to amplify and stabilize the Th17 phenotype (Veldhoen et 
al., 2006).   
 
Recent studies have revealed that IL-21 also can control the generation of Th17 
cells in mice (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007). They 
showed that IL-21, in combination with TGF-b, induces naïve CD4
+ T cells to 
produce IL-17. The ability of IL-21 to drive Th17 cells is independent of IL-6. 
Like IL-6, IL-21 also suppresses the induction of Foxp3+ Treg by TGF-b and 
upregulates the expression of IL-23R on Th17 cells accompanied by TGF-b. The 
combination of IL-6 and TGF-b can induce Th17 cells to produce IL-21, and 
then IL-21 with TGF-b can also induce Th17 cells themselves to produce IL-21, 
which shows like an autocrine loop to amplify Th17 response in mice (Zhou et 
al., 2007). 
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Several  other  cytokines  have  been  shown  to  regulate  the  development  or 
proliferation  of  Th-17  cells.  IL-1  and  TNF  may  play  a  role  in  Th17  cells 
expansion  in  vitro  (Veldhoen  et  al.,  2006).  Neutralization  of  IFN-g  and  IL-4 
increases the expansion of Th17 cells driven by IL-23. In addition, type I and II 
IFNs, IL-12, and IL-27(which will be discussed in the following section) can 
suppress  Th17  differentiation  (Harrington  et  al.,  2005;  Murphy  et  al.,  2003; 
Batten et al., 2006). IL-2, a cytokine important for growth and survival of Th1 
and  Th2  cells,  has  been  found  to  strongly  inhibit  Th17  development  in  mice 
(Laurence et al., 2007).  
 
Surprisingly, the generation of Th17 cells in human is different from that in mice. 
Despite the critical role of TGF-b in Th17 commitment in mice, human Th17 
differentiation does not require TGF-b. In fact, TGF-b inhibits the production of 
IL-17 in human (Acosta-Rodriguez et al., 2007; Wilson et al., 2007; Chen et al., 
2007).  Interestingly,  these  studies  have  shown  that  IL-1b  is  a  chief  factor  in 
induction  of  Th17  cells,  and  IL-6  acts  to  enhance  IL-1b-induced  Th17 
differentiation (Acosta-Rodriguez et al., 2007; Wilson et al., 2007). However, 
there is debate about IL-23. The studies from Wilson et al (2007) and Chen et al 
(2007) showed that IL-23 is an effective inducer of human Th17 cells. Acosta-
Rodriguez et al (2007) demonstrated that IL-23 is more likely to expand Th17 
cells. Moreover, it has been shown that IL-2 plays a dual role in the regulation of 
human Th17 cells. Large doses of IL-2 at the early stage of Th17 differentiation 
can downregulate Th17 differentiation, whereas differentiated Th17 cells can be 
expanded by IL-2 (Acosta-Rodriguez et al., 2007; Wilson et al., 2007; Amadi-
Obi et al., 2007). In addition, human memory CD4
+ T cells can rapidly express   37 
high levels of IL-17 upon anti-CD3/anti-CD28 stimulation alone, while human 
naïve CD4
+ express low levels of IL-17 (Chen et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Th17 lineage commitments in humans versus mice. (Adapted from 
Laurence & J O'Shea, 2007) 
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1.1.4.4 Effect of Transcription factors on Th17 differentiation 
 
1.1.4.4.1 STAT3 
 
The  transcription  factors  STATs  family  are  key  factors  during  Th  effectors 
differentiation. As mentioned before, Th1 differentiation is through the activation 
of STAT1 and STAT4. On the other hand, Th2 differentiation is via selective 
STAT6 activation. It has been shown that Th17 differentiation is unimpaired in 
STAT4 or STAT6 deficient mice, which suggested that these transcription factors 
are not involved in the differentiation of Th17 lineage ((Harrington et al 2005; 
Park  et  al.,  2005).  Thus,  Th17  differentiation  is  mediated  by  different 
transcription factors.  
 
Recent  studies  have  demonstrated  that  STAT3  is  the  essential  regulator  to 
mediate Th17 differentiation in mice (Yang et al., 2007; Nishihara et al., 2007). It 
has been observed that Th17 generation is greatly impaired in STAT3 deficient 
cells (Yang et al., 2006). Upon TCR stimulation, IL-6 and TGF-b rapidly activate 
STAT3 to direct the development of Th17 cells (Nishihara et al., 2007). It also 
has  been  found  that  IL-21  drives  IL-17  production  in  a  STAT3-dependent 
pathway  (Wei  et  al.,  2007).  Furthermore,  IL-6  and  IL-21  can  upregulate 
expression of the IL-23R through STAT3 signaling (Nurieva et al., 2007; Zhou et 
al., 2007).  
 
In  contrast  to  STAT3,  STAT1  appears  to  be  a  negative  regulator  of  Th17 
generation  (Harrington  et  al  2005;  Kimura  et  al.,  2007).  Similarly,  STAT5   39 
activated  by  IL-2  inhibits  Th17  cell  differentiation  in  mice  (Laurence  et  al., 
2007). The STATs family in human Th17 cell development has not been clearly 
elucidated. 
 
1.1.4.4.2 RORg g g gt and RORa a a a  
 
It has been identified that every lineage of T cells has a special key transcription 
factor,  like  T-bet  for  Th1  development,  GATA-3  for  Th2  development,  and 
Foxp3 for Treg development. The study by Ivanov and his colleages (2006) has 
identified  the  orphan  nuclear  receptor,  retinoic  acid-related  orphan  receptor 
(ROR)  gt,  as  a  transcription  factor  for  Th17  lineage  differentiation.  Recently, 
Yang group (2008) has found that RORa is another specific transcription factor 
to direct Th17 differentiation. 
 
RORgt is a specific isoform of RORg that belongs to the retinoic acid-related 
orphan nuclear hormone receptor family. RORgt and RORg are both encoded by 
Rorc locus and differ only in their terminal sequences through the utilization of 
different promoters (Dzhagalov, et al 2004). RORg is broadly expressed, while 
RORgt is predominantly expressed in populations of intestinal lamina propria T 
lymphocytes, and many of these cells constitutively express IL-17 (Ivanov et al., 
2006). In contrast, these expressing IL-17+ T cells are absent in RORgt deficient 
mice. These data proposed a strong correlation between RORgt and IL-17. In 
vitro,  under  Th17-polarizing  conditions,  RORgt-deficient  T  cells  showed 
impaired  Th17  development  compared  with  wild-type  control  T  cells. 
Importantly, the RORgt-deficient mice produce normal (or slightly higher) IFN-g   40 
under the Th1-polarizing conditions. Forced retrovirus-mediated expression of 
RORgt  in  naïve  CD4
+  T  cells  resulted  in  the  increased  expression  of  IL-17 
(Ivanov et al., 2006). This strongly indicated that the differentiation of Th17 cells 
requires the induction of RORgt. Murine CD4
+ T cells cultured with IL-6 and 
TGF-b express RORgt to become Th17 cells. It has also been reported that IL-21 
with TGF-b induces the expression of RORgt (Zhou et al., 2007). These data 
together established that RORgt plays an important role in Th17 differentiation. 
In  addition,  it  has  been  found  that  Retinoic  Acid,  Vitamin  A  metabolite,  can 
reduce the expression of RORgt induced by TGF-b and inhibit the differentiation 
of Th17 cells (Mucida et al., 2007; Elias et al., 2008). In human, the combination 
of IL-6 and IL-1b promotes the expression of RORgt (Acosta-Rodriguez et al., 
2007). Some studies also showed that IL-23 increases RORgt expression (Chen et 
al., 2007).   
 
Another member of the ROR family, RORa has been found to be preferentially 
expressed in Th17 cells, but not in Th1 and Th2 cells (Yang et al., 2008). The 
combination of IL-6 and TGF-b are strong inducers of RORa in CD4
+ T cells. 
Overexpression of RORa could promote Th17 differentiation and upregulate IL-
17  and  IL-17F  expression.  Furthermore,  coexpression  of  RORa  and  RORgt 
synergistically result in the increased expression of IL-17, IL-17F and IL-23R 
(Yang et al., 2008). Mice doubly deficient in RORa and RORgt function were 
profoundly impaired in Th17 generation and completely protected against EAE. 
In contrast, mice deficient only in RORa or RORgt developed moderate but less   41 
severe  diseases  compared  to  wild-type  mice  (Yang  et  al.,  2008).  Therefore, 
RORa and RORgt together direct Th17 lineage differentiation. 
 
1.1.4.4.3 Interferon-regulatory factor 4 (IRF4) 
 
Interferon-regulatory factor 4 (IRF4) is a member of mammalian transcription 
factors that participate in the production of type 1 interferon, Toll-like receptor 
signalling and the differentiation of T helper cells (Negishi et al., 2005; Honda & 
Taniguchi 2006). IRF4 was originally known as a key inducer of GATA-3 and 
played an essential role in Th2 development (Hu et al., 2002; Rengarajan et al., 
2002).  Recently,  a  study  has  identified  that  the  development  of  Th17  cells 
requires  IRF4  (Brustle  et  al.,  2007).  In  vitro  under  the  Th17  polarization 
condition, T cells from IRF4 deficient mice fail to produce IL-17. In vivo, IRF4 
deficient mice are completely protected from EAE. Notably, IRF4 deficient mice 
are far more resistant to this disease than those deficient in RORgt. Interestingly, 
further investigations found that IRF4 deficient mice showed a defective IL-6 
response that was only confined to Th17 development. IL-6 decreases the ability 
to upregulate the expression of RORgt and downregulate the expression of Foxp3 
for  IRF4-deficient  T  helper  cells  in  Th17  condition.  Collectively,  IRF4  is 
essential for Th17 development.  
 
1.1.4.5 Role of Th17 in inflammation and autoimmune diseases 
 
Th17 cells have been implicated to play an important role in host defence. IL-17 
and IL-17F stimulate cytokines and chemokines, such as G-CSF and IL-8, to   42 
generate neutrophils and attract these cells to the sites of inflammation, which 
might provide the early defence against trauma that would lead to tissue necrosis 
or sepsis (Mckenzie et al., 2006). IL-17 is also involved in protection against 
several  bacteria,  such  as  Klebsiella  pneumoniae  (Happel  et  al.,  2005), 
Streptococcus pneumoniae (Malley et al., 2006) and bacteroides species (Chung 
2003). Th17 cells also are important in protective response against fungus and 
yeast infection (Huang et al., 2004; Hohl et al., 2006). In addition, Th17 cells 
were  shown  to  be  indispensable  against  other  pathogens,  including 
Mycobacterium  tuberculosis  (Khader  et  al.,  2007)  or  Borrelia  burgdorferi 
(Burchill et al., 2003).  
  
Apart  from  the  beneficial  role  of  Th17  in  protection  against  microbes, 
dysregulated  function  of  Th17  cells  is  clearly  associated  with  chronic 
inflammatory diseases. The overexpression of IL-17 has been detected in sera 
and  target  tissues  in  various  human  autoimmune  diseases,  including  multiple 
sclerosis  (Matusevicius  et  al.,  1999;  Lock  et  al.,  2002),  systemic  lupus 
erythematosus, inflammatory bowel diseases, asthma and rheumatoid arthritis ( 
summarized by Bettelli et al., 2007). Consistent with those observations, Th17 
cells play a pivotal role in murine autoimmune diseases models, including EAE, 
colitis, and CIA (Nakae et al., 2003; Langrish et al., 2005).  
 
1.1.4. 6 Th17 in Rheumatoid Arthritis  
 
RA  is  a  common  systemic  autoimmune  disease  with  a  prevalence  of 
approximately 1% of the population. The clinical symptoms are characterized by   43 
chronic  inflammation  and  cellular  proliferation  within  the  synovial  lining  of 
joints which ultimately result in erosive destruction of cartilage and underlying 
bones.  Although  there  are  various  studies  done  in  RA,  the  aetiology  and 
pathogenesis of the diseases remain poorly understood. Although macrophages, 
B cells, mast cells, DCs, and fibroblast-like synoviocytes are involved in RA, the 
role of T cells infiltrating the synovium in RA has been emphasized. 
 
RA was previously considered a Th1 mediated autoimmune disease because of a 
relative predominance of Th1 cells and IFN-g in RA joints (Miltenburg et al., 
1992;  Dolhain  et  al.,  1996;  Smolen  et  al.,  1996).  The  consequence  of  Th1 
predominant response has been shown to contribute to induction and progression 
of chronicity. However, recent studies demonstrated that Th17 but not Th1 cells 
played a predominant pathogenic role in RA. Elevated levels of IL-17 expression 
have been detected in the synovial fluid from most RA patients (Kotake et al., 
1999; Hwang et al., 2004; Hwang & Kim 2005). Th17 cells were found in T cell 
rich area of synovial tissue in RA patients (Chabaud et al., 1999). Then, T cell 
clones developed from RA patients were found to release IL-17 (Aarak et al., 
1999). Furthermore, it has been reported that human RA T cells secreted IL-17 in 
response to IL-15, which can be found at a high level in the inflamed synovium 
(Ziolkowska et al., 2000).   
 
Th17 promotes inflammation through enhancing the expression of TNFa and IL-
1b by human macrophages (Jovanovic et al., 1998). TNFa  and IL-1b have been 
demonstrated to be important mediators of RA. IL-17 has synergistic effects on 
TNFa  on  inducing  IL-1,  IL-6,  and  IL-8  synthesis  in  the  synovial  fibroblasts   44 
(Katz  et  al.,  2001).  IL-17  also  enhances  the  IL-1-induced  synthesis  of  IL-6, 
leukaemia inhibitory factor (LIF) and MIP-3a by RA synoviocytes (Chabaud et 
al., 1998). IL-6 and LIF may contribute to cartilage destruction, while MIP-3a 
may  recruit  dendritic  cells  and  T  cells.  IL-17  has  a  direct  role  in  joint 
inflammation, cartilage damage, and bone erosion (Koenders et al., 2006). IL-17 
stimulates IL-6 and IL-8 secretion in fibroblasts, endothelial and epithelial cells 
(Fossiez et al., 1996). IL-17 also induces CXC chemokines in the inflamed joint, 
which may attract neutrophils. Futhermore, IL-17 reduces proteoglycan synthesis 
and enhances collagen destruction in bone explants (Lubberts et al., 2000). In 
addition,  IL-17  induces  RANKL  expression,  which  is  essential  for 
osteoclastogenesis and bone resorption (Kotake et al., 1999). Recently, it was 
found  that  Th17  cells  express  membrane  bound  RANKL  and  stimulate 
osteoclastogenesis (Sato et al, 2006). These observations mplicated that Th17 
cells  possibly  play  an  important  role  in  the  bone  destruction  phase  of 
autoimmune arthritis.   
 
Further evidence of Th17 involvement in the  pathogenesis of RA came from 
animal studies. It has been shown that intraarticular injection of IL-17 in mice 
resulted in joint inflammation and cartilage destruction (Chabaud et al., 2001). 
Similarly, systemic as well as local overexpression of IL-17 via an adenoviral 
vector in the course of CIA was shown to accelerate synovial inflammation and 
joint destruction (Lubberts et al., 2002).  In  contrast,  IL-17 deficient mice are 
resistant to CIA development (Nakae et al., 2003). It has also been reported that 
neutralization of endogenous IL-17 during the initial phase of arthritis suppressed 
the  onset  of  experimental  arthritis  (Lubberts  et  al.,  2001).  Moreover,   45 
neutralization of IL-17 in the established CIA can decrease the severity of CIA 
(Lubberts et al., 2004). These results suggested that Th17 is a potential novel 
target for the treatment of destructive arthritis. 
 
1.1.5 Regulatory T cells  
 
1.1.5.1 Introduction 
 
The immune system is tightly regulated in response to self and non-self antigens. 
The  fundamental  mechanism  of  self-tolerance  and  how  autoimmune  diseases 
occur  became  a  growing  interest  with  the  discovery  of  regulatory  T  cells.  In 
1995, Sakaguchi et al. identified and characterized a naturally occurring subset of 
CD4
+CD25
+ regulatory T cells, which are found to suppress the activation and 
expansion  of  self-active  T  cells,  thereby  controlling  the  development  of 
autoimmune  diseases.  In  contrast  with  naturally  occurring  CD4
+CD25
+ 
regulatory  T  cells,  inducible  CD4
+  Treg  cells  developed  from  conventional 
CD4
+CD25
-  T  cells  were  identified.  There  are  two  well  described  types  of 
inducible CD4
+ Treg cells: IL-10-secreting T regulatory type 1 cells (Tr1) and 
TGF-b–secreting T helper type 3 cells (Th3) (Groux et al., 1997; Chen et al., 
2003).  Tr1  cells  were  shown  to  be  effective  at  controlling  chronic  intestinal 
inflammation,  and  Th3 cells  were  shown  to  maintain  the  tolerance  of  dietary 
antigen. Naturally Treg cells, Tr1 cells, and Th3 cells may cooperate to prevent 
autoimmune diseases in vivo. 
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1.1.5.2 Naturally CD4
+CD25
+ regulatory T cells (nTreg) 
 
nTreg cells are produced in the thymus during ontogeny and constitute 5-10% of 
the  total  peripheral  CD4
+  T  cell  population  in  normal  human  and  mouse. 
Disruption of the thymic maturation or peripheral maintenance of nTreg cells 
results  in  severe  autoimmune  diseases  (reviewed  in  Sakaguchi  et  al.,  2004). 
nTreg cells are capable of suppressing a wide variety of immune cells from both 
the innate and adaptive immune systems, including effector CD4
+CD25
- T cells 
(reviewed in Mills 2004; Von Boehmer 2005), CD8
+ T cells (Trzonkowski et al., 
2004), NK cells (Azuma et al., 2003; reviewed in Ralainirina et al., 2007), B cells 
(Lim et al., 2005), or macrophages (Taams et al., 2005).  
 
nTreg  cells  are  anergic,  and  they  poorly  proliferate  and  produce  cytokines  in 
response  to  TCR  stimulation.  However,  this  anergy  can  be  reversed  by  the 
addition of IL-2 (Fontenot et al., 2005). nTreg cells proliferate in the presence of 
higher than physiologically normal concentration of IL-2, and high concentration 
of IL-2 also abrogates the suppressive capacity of nTreg cells on the proliferation 
of effector CD4
+CD25
- T cells in vitro. In contrast, the population of nTreg cells 
in the peripheral circulation is reduced in IL-2, IL-2Ra, or IL-2Rb deficient mice 
(Papiernik et al., 1998; Furtado et al., 2002; Almeida et al., 2002; Bayer et al., 
2005). These deficient mice died early due to severe lymphoproliferation and 
autoimmune diseases (Sadlack et al., 1993; Suzuki et al., 1995; Willerford et al., 
1995).  Correction  or  restoration  of  the  production  of  nTreg  cells  can  prevent 
lethal  autoimmunity  in  these  deficient  mice  (Wolf  et  al.,  2001;  Malek  et  al.,   47 
2002).  These  results  suggest  that  IL-2/IL-2R  pathway  is  important  in  the 
development, expansion, and function of nTreg cells in vivo. 
 
Various  studies  have  been  concentrated  on  identifying  specific  markers 
exclusively expressed by nTreg cells. Although no definitive markers have yet to 
be  identified  to  date,  the  nTreg  cells  are  currently  characterized  by  the 
constitutive  expression  of  several  markers.  The  most  widely  recognized  and 
useful  marker  is  CD25,  a  component  of  the  IL-2  receptor.  CD25  is  a  highly 
specific marker constitutively expressed on the surface of nTreg cells. Depletion 
of  CD4
+CD25
+  T  cells  results  in  spontaneous  development  of  various 
autoimmune diseases, and reconstitution of normal CD4
+CD25
+ T cells prevents 
these disorders (Sakaguchi et al., 1995; Singh et al., 2001). Although CD25 is 
also expressed on activated T cells, the induction of CD25 on CD4
+CD25
- T cells 
appears to have no suppressive function (Shevach et al., 2000). Thus, CD25 is a 
useful marker for separating nTreg cells from naïve CD4
+CD25
- T cells. Besides 
CD25,  there  are  other  cell  surface  markers  found  on  nTreg  cells,  including 
cytotoxic T lymphocyte-associated antigen (CTLA-4), and glucocortioid-induced 
tumor  necrosis  factor  receptor  family  related  gene  (GITR),  CD40,  CD28  and 
OX40 (Reviewed in Yong et al., 2007). Furthermore, there are increasingly more 
findings on new molecule markers, like lymphocyte activation gene-3 (LAG-3), 
and  programmed  death  receptor  1(reviewed  in  Liu  &  Leung  2006).  These 
markers all may play a role in nTreg cells –mediated suppression. 
 
The key finding that elucidates nTreg cells as a distinct lineage from other T cells 
is the specific transcription factor Foxp3, a member of the forkhead/winged-helix   48 
family.  The  gene  Foxp3  was  identified  from  a  lethal  X-linked 
lymphoproliferative  disorder  of  the  scurfy  mouse  strain  and  human  disorder 
IPEX  syndrome  (immune  dysregulation,  polyendocrinopathy,  X-linked 
syndrome), in which Foxp3 gene is mutated (Lyon et al., 1990; Fontenot et al., 
2003; Bennett et al., 2001). Foxp3 is required for the function of nTreg cells 
(Fontenot et al., 2003). Foxp3 is predominantly expressed within the CD4
+CD25
+ 
T cells population in both thymus and periphery, whereas activated CD4
+CD25
- 
T cells, Th1 cells, Th2 cells, and Th17 cells do not express Foxp3 (Yagi et al., 
2004;  Sakaguchi  et  al.,  2006).  Forced  expression  of  Foxp3  can  convert 
CD4
+CD25
- T cells to CD4
+CD25
+ T cells with a similar phenotype and function 
of nTreg cells (Fontenot et al., 2003; Hori et al., 2003). For example, Foxp3 
transduction  induces  the  expression  of  CD25,  CTLA-4,  GITR,  and  CD103, 
which are comparable with those found in nTreg cells (Hori et al., 2003). Foxp3-
transduced  CD4
+CD25
- T  cells  are  able  to  suppress  the  proliferation  of  other 
responder T cells in vitro and inhibit the development of autoimmune diseases in 
vivo (Hori et al., 2003). It has been shown that Foxp3 is an indispensable factor 
for the development of nTreg cells. Analysis of Foxp3-transgenic mice revealed 
the  increased  number  of  CD4
+CD25
+  T  cells  (Khattri  et  al.,  2003).  On  the 
contrary, Foxp3-deficient mice exhibited reduced number of CD4
+CD25
+ T cells 
(Fontenot  et  al.,  2003).  However,  a  recent  study  has  reported  that  only  the 
function of nTreg cells is required for the expression of functional Foxp3 protein, 
but the expression of Foxp3 is not indispensable for nTreg cells development 
(Lin et al., 2007).  
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1.1.5.3 Tr1 cells 
 
The definition of Tr1 cells refers to the IL-10 producing CD4
+ T cells population 
with regulatory function (Groux et al., 1997; Asseman et al., 1999). Tr1 cells are 
inducible cells, and they can be generated from naïve precursors stimulated with 
antigen in the presence of IL-10. It has also been reported that Tr1 cells can be 
generated from fully differentiated Th1 and Th2 cells under specific repeated 
stimulation (Hawrylowicz et al., 2005). Upon activation, Tr1 cells produce high 
levels of IL-10, moderate amounts of IL-5, low levels of IFN-g and IL-2, but no 
detectable IL-4 levels (Wu et al., 2007). In some studies, Tr1 cells have also been 
shown to produce TGF-b. In contrast to nTreg cells, Tr1 cells do not express 
Foxp3 (Wakkach et al., 2003; Vieira et al., 2004). Tr1 cells can suppress the 
proliferation and cytokine production of naïve CD4
+CD25
- T cells, Th1 and Th2 
cells  (Roncarolo  et  al.,  2001).  This  regulatory  activity  of  Tr1  cells  can  be 
reversed by neutralizing anti-IL-10 antibody or/and anti-TGF-b antibody, which 
indicated that Tr1-mediated suppression is mainly through the secretion of IL-10.  
 
1.1.5.4 Th3 cells 
 
Th3  cells  are  characterized  by  TGF-b.  Th3  cells  can  be  induced  from  naïve 
precursors under the influence of TGF-b (Chen et al., 2003; Fantini et al., 2004). 
In an autoregulatory loop, induced Th3 can trigger the secretion of TGF-b. Like 
nTreg cells, the expression of Foxp3 and CD25 is upregulated on induced Th3 
cells (reviewed in Weiner 2001). Th3 cells can suppress both Th1 and Th2 cells   50 
responses, and the suppressive mechanism is mainly dependent on the production 
of TGF-b (Fantini et al., 2004).  
 
However, TGF-b is a critical factor for Th17 development. In vitro studies have 
shown  that  the  addition  of  IL-6  suppressed  TGF-b  induced  Th3  cells,  while 
reciprocally  promoting  the  generation  of  Th17  cells  (Bettelli  et  al.,  2006). 
Therefore, the cytokine environment may control the development of Th3 cells 
and Th17 cell, thereby balancing the host defence and autoimmunity.  
 
1.1.5.5 Role of Regulatory T cells in rheumatoid arthritis (RA) 
 
Regulatory T cells play a critical role in self-tolerance and autoimmune diseases. 
Autoimmune disorders are characterized by a breakdown in the mechanisms of 
tolerance to self-antigens. It has been shown that depletion of regulatory T cells 
in murine models leads to the spontaneous development of autoimmune diseases, 
such as colitis, gastritis, insulin-dependent autoimmune diabetes, and thyroiditis 
(Sakaguchi et al., 1995; Groux et al., 1997; McHugh & Shevach 2002; Mottet et 
al.,  2003).  In  contrast,  CD4
+CD25
+  T  cells  could  prevent  or  ameliorate  the 
development of experimentally induced autoimmune diseases (Sakaguchi et al., 
1995; Kohm et al., 2002; Dipaolo et al., 2005). Human studies have shown that 
patients  with  autoimmune  diseases  have  lower  regulatory  T  cells  counts  or 
defective regulatory T cells (reviewed in Lan et al., 2005). 
 
The role of regulatory T cells in RA has been analyzed in a series of reports using 
animal models of induced arthritis (Morgan et al., 2003; 2004; 2005; Frey et al.,   51 
2005; Loughry et al., 2005; Kelchtermans et al., 2005; Nguyen et al., 2007). In all 
the cases, depletion of  CD4
+CD25
+ T cells resulted in significantly increased 
incidence  of  arthritis  diseases,  worse  severity  such  as  paw  swelling,  and 
increased  antigen  (CII)-specific  proliferation  of  splenocytes  in  vitro.  These 
effects  were  reversed  by  adoptively  transferring  CD4
+CD25
+  T  cells  isolated 
from syngeneic naïve mice (Morgan et al., 2005; Frey et al., 2005). However, 
there is controversy in human RA studies. One study has shown that there were 
no  significant  difference  in  the  frequency  of  regulatory  T  cells,  between  RA 
patients and normal controls (Ehrenstein et al., 2004). In contrast, another study 
has shown that the percentage of CD4
+CD25
+ T cells in the synovial fluid of RA 
patients was significantly higher than that of normal controls (Van Amelsfort et 
al., 2004). Furthermore, it appears that the number of regulatory T cells present in 
the inflamed synovial tissue of patients with RA is more than the number of 
regulatory T cells in their peripheral circulation (Cao et al., 2004). It has also 
been found that synovial regulatory T cells have the capacity to suppress the 
proliferation of autologous CD4
+CD25
- responder T cells (Cao et al., 2004; Van 
Amelsfort et al., 2004). Of interest, another study has shown that CD4
+CD25high 
T cells isolated from patients with active RA, although anergic, were unable to 
regulate pro-inflammatory cytokines released by effector T cells and monocytes 
in vitro, when compared to cells isolated from healthy individuals (Ehrenstein et 
al., 2004).  
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1.2 Murine Collagen-Induced Arthritis (CIA) as a model for RA  
 
Animal models of RA have provided basic pathogenesis of the disease as well as 
provided valuable research tools for testing new therapies. Among the variety of 
models reported, Collagen-induced arthritis (CIA) is the most commonly studied 
autoimmune  models  of  RA.  CIA  shares  many  pathological  and  clinical 
characteristics of human RA. Like RA, CIA is characterized by mononuclear cell 
infiltration, synovial hyperplasia, and cartilage degradation. 
 
CIA was first observed in rats following the immunization with type II collagen 
(Trentham et al., 1977), and further studies have found that a similar pathology 
could also be induced in primates and susceptible strains of mice (Courtenay et 
al., 1980). Of the susceptible strains of mice, DBA/1 mice are the standard mouse 
strain. The susceptibility of DBA/ 1 mouse to CIA is associated with specific 
major  histocompatiblity  complex  (MHC)  class  II  genes,  especially  H-2
q. 
Interestingly, male mice are more susceptible to CIA than female mice, which 
may be partly related to sex hormone. Another factor affecting the development 
of CIA is the age of mice. Mice are not susceptible to CIA until they reach 6-7 
weeks old, and they become increasingly susceptible to CIA with the increasing 
age (Holmdahl et al., 2002).   
 
CIA is induced in DBA/1 mice after the immunization of heterologous type II 
collagen (C II) with complete Freund’s adjuvant (CFA). CII is a major protein in 
cartilage.  Although  the  precise  mechanisms  how  collagen  II  in  CFA  leads  to 
chronic arthritis are not known, the development of CIA is dependent on both 
cellular and humoral responses in response to collagen II (Holmdahl et al., 2002).   53 
Thus, both B cells and T cells play important roles in CIA. The major role of B 
cells is to produce anti-CII antibodies, which reacts with CII in cartilage and 
induces  arthritis  (Terato  et  al.,  1992).  The  role  of  T  cells  is  to  help  B  cells 
produce  anti-CII  antibodies  (Corthay  et  al.,  1999).  Also,  T  cells  themselves 
probably play a role in joint inflammation. Furthermore, various cytokines are 
found to play crucial roles in the pathogenesis through the activation of immune 
system (Feldmann et al., 1996). 
 
Following  immunization,  a  moderate  inflammatory  reaction  started  at  the 
injection site and lasted 1-2 weeks. The first signs of arthritis development in 
DBA/1  mice  are  visible  around  day  21  after  immunization,  and  the  disease 
became  progressively  worse  for  approximately  2-4  weeks  before  the  slow 
resolution phase (Holmdahl et al., 2002).  
 
Although CIA is widely accepted as an experimental model for RA, there are 
some differences between CIA and human RA. For example, mycobacteria used 
in CIA results in a dominant type I immune response. However, it is unknown 
whether RA is induced by an exogenous pathogen or a spontaneous autoimmune 
disease (Holmdahl et al., 2002).  
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1.3 IL-12 cytokine family  
 
1.3.1 Introduction 
 
Cytokines are small, secreted proteins released by many cells that can regulate an 
array of cellular processes, including altering the behaviour or properties of the 
cells and mediating the immune response to infection or injury (Nicola 1994). 
Cytokine environment present at the earliest stage of T cell priming can control 
the Th cell differentiation program. IL-4 appears to be a predominant early factor 
for determining the development of Th2 effector cells (Paul, 1997). In contrast, 
the  dominant  factor  that  drives  the  development  of  Th1  helper  cells  was 
identified as IL-12 (Murphy, et al., 2000). For many years, IL-12 was the only 
known heterodimeric cytokine before the discovery of IL-23. Later, on the basis 
of the advence of genomics and the development of bioinformatics, IL-27 and IL-
35 (EBI3/p35) have been identified. IL-12 family cytokines started to receive 
attention. 
 
Cytokines play a central role in regulating T cell expansion and differentiation. 
Cytokines also organize the balance between protection and immunopathology 
after infection. The etiology of RA is unknown, but proinflammatory cytokines 
play an important role in the pathogenesis of RA. Neutralizing Abs against the 
proinflammatory cytokines, including TNF-a, IL-1 and IL-6, have been shown to 
successfully suppress the joint inflammation (Kagari et al., 2002). Therefore, an 
understanding of the regulation of new cytokines may lead to novel therapeutic 
strategies.  Initially,  it  was  found  that  IL-12  played  an  important  role  in 
autoimmune diseases. Recently, IL-23 has been found to be more important than   55 
IL-12 in the progression of T-cell dependent autoimmune diseases. However, the 
function of IL-27 and IL-35 remained unclear when I started the project. I was 
interested in how IL-27 and IL-35 can potentially regulate the autoinflammatory 
diseases, particularly in the CIA model.  
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Figure 1.3 The structures of IL-12 family members and their receptors. 
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1.3.2 IL-12 
 
IL-12 is the major cytokine that regulates the differentiation of naïve CD4
+ T 
cells to mature Th1 effector cells. IL-12 is secreted by a variety of cells, but most 
importantly  by  antigen  presenting  cells  such  as  monocytes,  macrophages, 
dendritic cells (DCs) and neutrophils. Numerous pathogenic organisms induce 
IL-12, including bacteria, parasites, viruses, and fungi (Ma & Trinchieri, 2001). 
 
 IL-12 is a heterodimeric 70-kDa glycoprotein composed of two disulfide-linked 
subunits designated p40 and p35. p35 shares homology with IL-6, granulocyte-
specific colony-stimulating factor (GCSF), and is similar to other cytokines in the 
same class (Merberg, et al., 1992). p40 is homologous to the extracellular domain 
of the subunit of  IL-6 receptor (Gearing & Coasman, 1991). The gene encoding 
p35 maps to chromosome 3 in human and chromosome 6 in mice, whereas the 
gene encoding p40 is located on chromosome 5 in human and chromosome 11 in 
mice (Sieburth, et al., 1992; Holscher, 2004). Therefore, the expression of the 
two genes is regulated independently. The p35 subunit is expressed in many cell 
types  at  constitutively  low  levels,  while  the  p40  subunit  expression  is  more 
limited  but  with  higher  levels  (Agnello,  et  al.,  2003).  Also,  free  p35  is  not 
secreted on its own, but p40 can be secreted with free monomer or homodimer 
(p402)  (Watford,  et  al.,  2003).  The  IL-12p40  homodimer  shows  antagonistic 
activity  to  IL-12,  but  does  not  mediate  biological  responses  (Merberg,  et  al., 
1992).  The  bioactive  IL-12p70  is  generated  only  when  the  two  subunits  are 
coexpressed in one cell (Gubler, et al., 1991).  
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The  activities  of  IL-12  are  mediated  by  a  high-affinity  receptor  (IL-12R) 
consisting of two receptor subunits, b1 and b2. Both b1 and b2 are structurally 
related to the class I cytokine receptor superfamily and have strong homology 
with  glycoprotein  gp130  and  leukaemia-inhibitory  factor  receptor  (LIFR) 
(Presky, et al., 1996; Chua et al., 1994). It has been identified that IL-12 receptor 
subunits b1 and b2 have differing affinities for IL-12 in humans and mice. In 
humans, the individual binding affinity of IL-12Rb1 and IL-12Rb2 for IL-12 is 
low, however, the co-expression of b1 and b2 generate high-affinity binding of 
IL-12. In contrast, IL-12Rb1 in mice mediates both high and low affinity binding 
of IL-12 and IL-12Rb2 only has limited capacity for binding to IL-12 (Presky, et 
al., 1996).  
 
The IL-12R b1 and b2 complex is expressed on activated T cells, NK cells, and 
DCs. Resting T cells do not express b1 or b2, but the expression of b1 and b2 are 
induced upon T cell activation. Following differentiation, Th1 cells express b1 
and b2 subunits, but Th2 cells only express b1, not b2 (Rogge, et al., 1999). 
Therefore, IL-12Rb2 expression is highly controlled on Th1 cells, and the control 
of  IL-12Rb2  expression  is  thought  to  regulate  IL-12  response  and  Th1 
phenotype. IFN-g induces the expression of T-bet in Th1 cells, which in turn up-
regulates IL-12R b2 expression. Whereas, IL-4 downregulates the expression of 
IL-12R b2 (Szabo, et al., 1997; Afkarian, et al., 2002).  
 
The biological activity of IL-12 requires the interaction of IL-12p40 with IL-
12Rb1 and the interaction of IL-12p35 with IL-12Rb2. The interaction of IL-12   58 
with the IL-12 receptor complex initiates the signalling pathway through tyrosine 
phosphorylation of the Janus Kinase (JAKs), TYK2 and JAK2 and the activation 
of STATs, 1,3, 4 and 5 (Bacon, et al., 1995). However, STAT4 is the major 
specific mediator for IL-12 signalling (Bacon, et al., 1995; Kaplan, et al., 1996). 
IL-12Rb2  subunit  binds  to  STAT-4  to  initiate  IL-12  signal  transduction.  In 
contrast, IL-12Rb1 has no STAT4 binding site and no reported signalling ability, 
but it is responsible for ligand binding (Wu, et al., 2000).  
 
IL-12  is  an  especially  important  factor  that  plays  a  central  role  in  regulating 
innate and adaptive immune response (reviewed in Trinchieri 2003). It acts on 
naïve CD4
+ T cells to induce their proliferation and differentiation to Th1 cells, 
which produce IFN-g and promote adaptive immune responses. In contrast, IL-12 
combination with IFN-g antagonizes Th2 differentiation and downregulates the 
production of IL-4, IL-5, and IL-13 (Watford, et al., 2003). IL-12 induces IFN- g 
production  in  T  and  NK  cells  (Trinchieri  1994).  The  production  of  IFN- g 
stimulates  bactericidal  activity  to  phagocytic  cells  and  enhances  the  innate 
immune response. Furthermore, IL-12 induces the expression of IL-18 receptor, 
and IL-18 synergizes with IL-12 to enhance the production of IFN- g in a TCR 
independent  pathway  (Trinchieri  1994;  2003).  In  IL-12  deficient  mice,  Th1 
differentiation and IFN- g secretion are impaired. In contrast, Th2 development 
and IL-4 production appear to be enhanced (Mattner, et al., 1996, Magram, et al., 
1996, Wu, et al., 1997; 2000). However, upon antigen stimulation, these deficient 
mice showed Th1 polarization and residual IFN-g production. Therefore, IL-12 is 
not absolutely required for Th1 development. Recently, two new IL-12 family 
members, IL-23 and IL-27 have been discovered, and both IL-23 and IL-27 can   59 
exert immunoregulatory effects on Th1 immune response. (Brombacher, et al., 
2003; Watford, et al., 2003).  
 
Uncontrolled self-reactive effector CD4
+ T cells results in a number of chronic 
inflammatory  diseases.  For  many  years,  the  IL-12-dependent  Th1  cells  were 
considered to be essential for the induction of autoimmune diseases, including 
collagen-induced arthritis (CIA), experimental autoimmune encephalitis (EAE), 
inflammatory  colitis,  and  autoimmune  uveitis  (Leonard  et  al.,  1995; 
Constaninescu et al., 1998; Segal et al., 1998). These opinions have been based 
on a number of studies, in which autoimmune disease was ablated in mice treated 
with neutralizing antibodies specific for IL-12p40 or mice deficient in the IL-
12p40  subunit.  Although  IL-12  inducing  IFN-g  was  characterized  in  these 
autoimmune diseases, the discrepancy was that mice deficient in IFN-g or IFN-
g receptors were found still susceptible to EAE and CIA (Ferber et al., 1996; 
Mattys 1998). Furthermore, a later study found that mice lacking IL-12 receptor 
complex are not resistant to EAE (Zhang et al., 2003). With the discovery of IL-
23 sharing the p40 subunit of  IL-12, it is suggested that  IL-23, not  IL-12, is 
critically associated with autoimmunity in these models.    
 
1.3.3 IL-23 
 
Oppmann  et  al.  (2000)  discovered  that  p40  can  dimerize  with  p19,  a  novel 
protein  identified  by  sequence  database  searching,  to  form  a  disulfide-linked 
herterodimeric cytokine designated IL-23. The structure of IL-23 p19 is closely 
related to IL-12p35 subunit. Like IL-12p35, IL-23p19 is expressed ubiquitously   60 
and constitutively, but is not secreted by itself. Similar to IL-12, coexpression of 
p19 and p40 within the same cell is required to form biologically active IL-23. 
Like IL-12, IL-23 is also produced by activated APC such as DCs and phagocytic 
cells (Oppmann, et al., 2000).   
 
As  IL-23  shares  the  same  IL-12p40  subunit,  IL-23  also  binds  to  IL-12Rb1. 
However, it does not bind to IL-12Rb2, but instead bind to IL-23R, a member of 
the hemopoietin receptor superfamily (Parham, et al., 2002). IL-23R shows 70% 
homology between human and mice, and the structure of IL-23R is very similar 
to IL-12R b2 and gp130. In mice, IL-23R is expressed by memory T cells, bone 
marrow  macrophages,  and  LPS  activated  macrophages.  In  humans,  IL-23R  is 
detected on activated naïve T cells and memory T cells, NK cells, and is also 
expressed  at  low  levels  on  macrophages,  monocytes,  and  DCs.  Only  co-
expression of IL-12R b1 and IL-23R on cells can confer IL-23 responsiveness 
(Parham, et al., 2002). Similar to IL-12 signalling, the binding of IL-23 to IL-23 
receptor complex results in the activation of Tyk2, Jak2 and STAT1, 3, 4, and 5.  
STAT4 activation is much weaker in response to IL-23, when compared to the 
IL-12  response.  Instead,  STAT3  is  dominant  in  the  IL-23  signal-transduction 
cascade (Lankford & Frucht 2003, Watford, et al., 2004).  
 
As a consequence of the structural similarity, IL-23 was predicted to have similar 
functions as IL-12. Initial studies have demonstrated that IL-23 stimulated IFN-g 
production preferentially on memory/effector CD4
+ T cells and maintains Th1 
development; while IL-12 is important for Th1 differentiation of naïve CD4
+ T 
cells (Oppmann, et al., 2000). Surprisingly, emerging studies have shown that IL-  61 
23 plays an important role in Th17 cells, which is distinct from the role of IL-12 
in T cell regulations. Aggarwal, et al. (2003) provided the first evidence that the 
addition of IL-23 in murine memory T cell cultures generated IL-17+ producing 
cells. Subsequent in vivo studies have shown a defect in Th17 subsets in IL-23 
deficient mice (Cua et al., 2003; Langrish et al., 2005). Although it was thought 
that IL-23 was an important cytokine for the differentiation of Th17 cell, IL-23 is 
not  required  for  the  initial  Th17  differentiation  from  naïve  T  cells  in  mice 
(Veldhoen  et  al.,  2006;  Bettelli  et  al.,  2006).  In  fact,  IL-23  is  important  to 
maintain and expand Th17 phenotype (Aggarwal et al., 2003; Langrish et al., 
2005; Veldhoen et al., 2006).  
 
The clear differences between IL-12 and IL-23 have been supported using gene 
disrupted mice models: p19-/-, p40-/- and p35-/- knock out mice (Cua et al. 2003; 
Murphy, et al., 2003). IL-23 p19-/ and p40-/- deficient mice are resistant to EAE 
and CIA, while IL-12p35-/- mice are highly susceptible to EAE and CIA. Thus, 
IL-23  rather  than  IL-12,  is  the  critical  cytokine  in  inflammatory  autoimmune 
responses.  Evidence  of  neutralizing  antibodies  against  IL-23  effectively 
inhibiting the diseases process of EAE has again proved that IL-23 is associated 
with autoimmunity (Chen et al., 2006) 
 
1.3. 4 IL-27 
 
1.3.4.1 Historical perspective 
 
In 1996, Epstein Barr virus-induced gene 3 (EBI3) was identified as an IL-12p40 
homologue induced by EBV infection in B lymphocytes (Devergne et al., 1996).   62 
In 1998, advances in the ability to search sequence databases with structure based 
alignment  tools  had  led  to  the  identification  of  a  gp130-like  protein,  WSX-1 
(named after the WSXWS protein motif that is found in the carboxyl terminus of 
many type I cytokine receptors), also called TCCR, which is described as an 
orphan receptor expressed on NK cells and T cells (Sprecher et al., 1998). In 
2002,  in  search  of  proteins  homologous  to  IL-12p35  and  IL-6,  Pflanz  et  al. 
(2002) group discovered p28 subunit, which can only partner with EBI3 to form 
a stable heterodimeric protein complex. This protein complex was designated IL-
27, as a new member of the IL-12 family. Subsequently, it was established that 
WSX-1 partnered with gp130 to form heterodimeric receptors for IL-27 (Pflanz 
et al., 2004). 
 
1.3.4.2 Characteristics of IL-27 
 
Similar  to  other  members  of  IL-12  family,  IL-27  is  a  heterodimeric  cytokine 
composed of two subunits: EBI3 and p28. EBI3, related to IL-12p40, lacks a 
membrane-anchoring motif and resembles a soluble cytokine receptor (Devergne 
et al., 1996). Human p28 gene is located on chromosome 16p11, and encodes a 
243  amino  acid  polypeptide.  Murine  p28  gene  encodes  a  234  amino  acid 
polypeptide, which is 78% identical to human p28. Like IL-12p35 and IL-23p19, 
IL-27p28 subunit is a member of the long-chain four-helical bundle cytokines. 
Interestingly, IL-27p28 displays a unique stretch of 13 glutamic acid residues, 
which has not been displayed in other helical bundle cytokines (Pflanz et al., 
2002).  EBI3 is secreted by itself; whereas p28 is poorly secreted by itself unless 
co-expressed with the partner EBI3. Although IL-27 shares a similar structural   63 
makeup with IL-12 and IL-23, the subunits of IL-27 are linked by a covalent 
bond not a disulfide bond. Like IL-12 and IL-23, the biological activity IL-27 
requires the expression of both EBI3 and p28 in the same cell (Pflanz, et al., 
2002). The expression of IL-27 has been detected in monocytes, DCs derived 
from monocytes, endothelial cells, and trophoblast cells in human (Pflanz et al., 
2002;  Larousserie  et al., 2004; 2006; Coulomb-L’Herrmine et al., 2007). The 
expression  of  murine  IL-27  has  been  detected  in  activated  macrophages  and 
microglia cells (Pflanz et al., 2002; Sonobe et al., 2005).  
 
1.3.4.3 Regulation of IL-27 
 
Examination of cDNA libraries has indicated that both human and murine IL-27 
are  highly  induced  in  activated  antigen-presenting  cells  (Pflanz,  et  al.,  2002). 
Although there are no sufficient studies in the regulation of IL-27 expression, it 
has been demonstrated that non-pathogenic Gram-negative bacteria, not Gram-
positive bacteria, promotes a strong IL-27 expression. It is clear that LPS is the 
main  immunostimulatory  component  within  the  cell  wall  of  Gram-negative 
bacteria, and the effect of LPS is mediated through toll-like receptor 4 (TLR4). 
Thus,  signalling  via  TLR4  activated  by  LPS  is  the  key  inducer  of  IL-27 
(Schuetze et al., 2005; Schnurr et al., 2005). Besides TLR4, many other microbes 
via other TLRs can trigger the expression of IL-27, such as the engagement of 
TLR3 with polyinosinic-polycytidylic acid [Poly  (I:C)], and ligation of TLR9 
with  double  strand  DNA.  TLR7/8  ligand  is  also  a  strong  inducer  of  IL-27 
(Pirhonen et al., 2007). Furthermore, a variety of host derived factors, including 
CD40L, IL-1b, IFN-a, IFN-b and IFN-g can upregulate the expression of IL-27   64 
(reviewed  in  Villarino  et  al.,  2004;  Pirhonen  et  al.,  2007).  Conversely,  the 
nucleotide  ATP  is  the  negative  regulator  of  IL-27  expression  (Schnurr  et  al., 
2005).  
 
When  LPS  stimulates  monocyte-derived  DCs,  mRNA  levels  of  IL-27p28  are 
induced rapidly and peak after 3 to 6 hr, then decline to the background levels 
after 24hr, whereas mRNA levels of EBI3 are induced more slowly and peak 
after 12 to 24hrs, and then drop but not reach the background levels even after 72 
hr (Pflanz, et al., 2002). These observations indicated that different signalling 
pathways control the expression of EB3  and p28 subunits respectively.  TLRs 
dependent EBI3 expression was shown to be induced in DCs via activation of the 
transcription factors NF-kB and PU-1(Wirtz et al., 2005).Toll/IL-1R-containing 
adaptor inducing IFN-b (TRIF) and its associated IFN regulatory factor (IRF)3 
transcription factor are involved in TLR-inducible expression of human IL-27 
p28 (Molle et al., 2007).   
 
1.3.4.4 IL-27 Receptors 
 
The IL-27 receptor is a heterodimer composed of WSX-1(TCCR, IL-27Ra) and a 
common gp130 chain (Pflanz et al., 2004). WSX-1 is a type I cytokine receptor 
with  four  conserved  cysteine  residues  and  a  WSXWS  protein  motif  in  the 
carboxyl  terminus  (Sprecher  et  al.,  1998;  Chen,  et  al.,  2000).  WSX-1  shows 
homology to members of the IL-6 superfamily receptors, including the IL-12Rb2 
subunit, LIFR and gp130. WSX-1 is expressed mainly in lymphocytes (Pflanz, et 
al., 2004). Interestingly, naïve CD4
+ T cells and NK cells appear to express the   65 
highest  levels  of  WSX-1,  but  differentiated  Th1  and  Th2  cells  show  low 
expression of WSX-1(Pflanz, et al., 2004). gp130 is a shared receptor for IL-6 
and other IL-6 family cytokines, and is widely expressed by a range of immune 
and non-immune cells ( Reviewed in Taga & Kishimoto 1997).  
 
WSX-1 is capable of binding to IL-27 with high affinity in the absence of gp130 
(Pflanz et al., 2002), but WSX-1 requires gp130 to form IL-27 receptor complex 
that is responsible for IL-27 signal transduction (Pflanz, et al., 2004). In addition, 
gp130 does not bind to IL-27 alone (Schellel et al., 2005). WSX-1 and gp130 
appear to be coexpressed on a variety of immune cell types, including CD4
+ T 
cells, CD8
+ T cells, NK cells, monocytes, mast cells, neutrophils and B cells 
(Pflanz, et al., 2004; reviewed in Batten & Ghilardi 2007). 
 
1.3.4.5 Signalling through IL-27 receptors 
 
The engagement of IL-27 with WSX-1/gp130 induces the activation of JAK1 and 
2, Tyrosine kinase-2 (TYK2), STAT1, 2, 3, 4, and 5 in naïve CD4
+ T cells (Lucas 
et al., 2003). Furthermore, the activation of WSX-1 preferentially phosphorylates 
STAT1,  while  gp130  activation  mainly  contributes  to  a  strong  activation  of 
STAT3 (Pflanz, et al., 2004; Kamiya, et al., 2004). Recently, it has been reported 
that IL-27 preferentially induces STAT3 in fully activated CD4
+ T cells, while 
both  STAT1  and  STAT3  are  activated  in  early  activated  T  cells  upon  IL-27 
stimulation (Yoshimura et al., 2006). 
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1.3.4.6 The role of IL-27 in promoting Th1 response 
 
Based  on  sequence  and  structure  homology  between  IL-27  and  IL-12,  the 
function of IL-27 was initially investigated on Th1 immune response. As IL-27 is 
an early product of activated APCs, IL-27 drives rapid clonal expansion of naïve 
CD4
+ T cells and augments the secretion of IFN-g by these CD4
+ T cells under 
non-polarizing  culture  conditions  (Pflanz  et  al.,  2002).  Correspondingly, 
unpolarized naïve CD4
+ T cells from WSX-1 deficient mice produce less IFN-g 
than wild-type counterparts (Chen et al., 2000; Yoshida et al., 2001). Also, IL-27 
synergizes with IL-12 to trigger IFN-g production of naïve CD4
+ T cells and NK 
cells (Pflanz et al., 2002). However, in the presence of high levels of IL-12, IL-27 
is  not  able  to  further  enhance  Th1  development  (Owaki  et  al.,  2005). 
Accordingly, fully differentiated WSX-1-/- Th1 cells produce similiar levels of 
IFN-g upon second stimulation compared to wild-type Th1 cells. Taken together, 
IL-27 is important for early initiation of Th1 response.  
 
In agreement with the expected role of IL-27 in Th1 development in vitro, WSX-
1 deficient mice showed an impaired Th1 response in Listeria monocytogenes 
and the early phase of  Leishmania major (Chen et al., 2000; Yoshida, et al., 
2001). Notably, normal Th1 response and IFN-g production in WSX-1 deficient 
mice have been demonstrated at the late stage of Leishmania major (Yoshida, et 
al., 2001). These data supported that IL-27 is involved in the early phase of Th1 
differentiation. In addition, EBI3 deficient mice display enhanced susceptibility 
to Leishmania major infection with defects in IFN-g production in the early phase   67 
compared to wild-type mice, emphasizing the importance of IL-27 at the initial 
stage of Th1 differentiation (Zahn et al., 2005).   
 
Then, the molecular basis for IL-27 initiating Th1 responses has been elucidated. 
Upon IL-27 stimulation, WSX-1 activates the downstream of STAT1, leading to 
the induction of T-bet. T-bet enhancing the expression of IL-12Rb2 is one of the 
critical events for Th1 differentiation (Lucas et al., 2003; Kamiya et al., 2004). 
Interestingly, it has also been found that IL-27 induces T-bet and IL-12Rb2 at 
mRNA  levels  in  a  STAT-1-  independent  pathway  (Lucas  et  al.,  2003).  More 
recently,  it  has  been  demonstrated  that  IL-27  can  induce  Th1  differentiation 
through  ICAM-1/LFA-1  interaction  in  a  STAT-1-dependent,  but  T-bet 
independent  mechanism.  Furthermore,  IL-27  could  induce  another  pathway, 
which is p38MARK /T-bet –dependent and STAT-1-independent pathway, and 
IL-12Rb2 was shown to be upregulated in both pathways (Owaki et al., 2006).  
 
In contrast to the early characterization of IL-27 as a pro-inflammatory cytokine 
that contributes to Th1 development, recently IL-27 is also recognized as an anti-
inflammatory cytokine that limits immune responses. 
 
1.3.4.7 IL-27 inhibits Th1 responses  
 
Although  IL-27  has  been  described  to  promote  Th1  response,  IL-27  also  has 
effects in suppression of Th1 responses. The anti-inflammatory role of IL-27 has 
been  clearly  shown  in  several  reports.  WSX-1  deficient  mice  infected  with 
Toxoplasma  gondii  remarkably  develop  a  lethal  CD4
+  T  cell-dependent   68 
inflammatory  disease  after  two  weeks  of  infection  that  displays  enhanced 
proliferation  of  CD4
+  and  CD8
+  T  cells  and  excessive  production  of  IFN-g 
(Villarino et al., 2003). The involvement of IL-27 signaling in the induction of 
Th1 immune responses to reduce parasite burden has been further supported by 
WSX-1-/-  mice  infected  with  Trypanosoma  cruzii  or  Leishmania  donovani 
(Hamano  et  al.,  2003;  Rosas  et  al.,  2006).    Infected  WSX-1  deficient  mice 
showed higher sensitivity to infection and led to lethal liver necrosis compared to 
wild-type mice. Immune cells from infected WSX-1 KO mice produced more 
IFN-g  and  other  cytokines  such  as  TNF-a compared  to  immune  cells  from 
infected wild-type mice. Likewise, in Con A-induced hepatitis model, WSX-1 
deficient mice displayed enhanced liver diseases coupled with the elevated levels 
of IFN-g and other inflammatory cytokines (Yamanaka et al., 2004). 
 
Consistent with the observations above from in vivo work, CD4
+ T cells from 
WSX-1  -/-  mice  produce  more  IFN-g  than  wild-type  counterparts  when 
stimulated with low doses of antigen in the presence of IL-12 (Villarino et al., 
2003). IL-27 suppresses IFN-g and other pro-inflammatory cytokine production 
from  activated  CD4
+T  cells  in  vitro  (Yoshimura  et  al.,  2006).  However,  the 
molecular basis for the negative effect of IL-27 on Th1 response remains unclear. 
IL-27 suppresses IL-2 expression on CD4
+ T cells (Villarino et al., 2006). IL-2 is 
a  potent  growth  factor  for  T  cell  development.  The  suppression  of  IL-2 
expression by IL-27 may result in the regulation of excessive Th1 cell activation.  
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1.3.4.8 The role of IL-27 in suppressing Th2 response 
 
It  was  originally  thought  that  IL-27  promotes  IFN-g  production,  which  could 
inhibit the development of Th2 cells. The first study which indicated that IL-27 
has  direct  suppressive  effects  on  Th2  response  has  shown  that  IL-27  inhibits 
CD4
+ T cell expression of GATA3 via STAT1-dependent pathway (Lucas et al., 
2003). Subsequently, there has been increasing evidence of increased Th2 cell 
responses in IL-27 receptor deficient mice models. In particular, studies of WSX-
1 deficient mice infected with the gastrointestinal nematode Trichuris muris, a 
well-characterized  helminth  removed  by  Th2-mediated  immune  responses, 
showed  that  these  mice  are  resistant  to  infection  (Artis  et  al.,  2004).  During 
infection,  WSX-1  deficient  mice  displayed  accelerated  Th2  cell  dependent 
intestinal goblet cell hyperplasia, mastocytosis, and produce more IL-5 and IL-13 
compared to the wild-type counterparts. Furthermore, it has been reported that 
WSX-1-/-  mice  exhibited  exacerbation  of  allergic  asthmatic  phenotypes, 
including  airway  hyper-responsiveness  (AHR),  eosinophilic  infiltration,  and 
mucus overproduction in response to OVA challenge (Miyazaki et al., 2005).   
 
Recent studies have revealed that IL-27 can directly inhibit Th2 cell polarization, 
and simultaneously IL-27 induces Th1 cell differentiation in the absence of IFN-g 
and  IL-12  in  vitro  (Yoshimoto  et  al.,  2007).  Consistent  with  in  vitro  results 
demonstrating  the  ability  of  IL-27  to  suppress  Th2  response,  in  vivo  studies 
showed that daily treatment with IL-27 for the first week after Leishmania major 
infection  significantly  decreased  footpad  swelling  and  parasite  burden  via  the 
inhibition  of  Th2  cell  development  and  induction  of  Th1  cell  development.   70 
Furthermore, IL-27 transgenic mice are not capable of mounting Th2 response 
against  Strongyloides  venezuelensis  infection.    The  molecular  mechanism  has 
been explained that IL-27 downregulates GATA-3 expression and upregulates T-
bet expression.  
 
Remarkably, IL-27 can inhibit already differentiated Th2 cells to produce IL-5 
and IL-13 via the activation of both STAT1 and STAT3 (Yoshimoto et al., 2007). 
In contrast, IFN-g fails to suppress the production of IL-5 and IL-13 from already 
differentiated  Th2  cells.  Consistent  with  these  in  vitro  results,  intranasal 
administration of IL-27 decreases OVA-induced airway hyperresponsiveness and 
inflammation  in  OVA-sensitized  mice  in  vivo.  Therefore,  IL-27  is  a  critical 
cytokine involved in the down-regulation of Th2 responses independently of IL-
12 and IFN-g.    
 
1.3.4.9 The role of IL-27 in suppressing Th17 response 
 
Early  studies  showed  that  IL-27  neutralization  is  beneficial  in  autoimmune 
diseases,  including  adjuvant-induced  arthritis  in  rats  and  experimental 
autoimmune encephalomyelitis (EAE) (Goldberg et al., 2004). However, those 
claims  are  contradicted  with  the  intriguing  evidence  of  IL-27  mediated  Th17 
suppression.  Stumhofer  et  al.  (2006)  showed  that  WSX-1  deficient  mice 
chronically  infected  with  Toxoplasma  gondii  developed  severe  CNS 
inflammation associated with augmented Th17 responses. Batten et al. (2006) 
showed that WSX-1 deficient mice were hypersusceptible to EAE induced by 
immunization  with  myelin  oligodendrocyte  glycoprotein  (MOG)  in  CFA,  and   71 
generated  more  Th17  cells.  Consistent  with  the  in  vivo  results,  both  groups 
demonstrated that IL-27 suppresses the development of Th17 driven by IL-6 and 
TGF-b in vitro. Furthermore, IL-27 inhibits IL-23-induced IL-17 on activated 
CD4
+ T cells (Yoshimura et al., 2006). Thus, IL-27 may be a potential target for 
treating  inflammatory  diseases  and  autoimmune  diseases  mediated  by  Th17. 
More recent studies have found the enhanced expression of IL-27 in the target 
tissues  of  autoimmune  diseases,  including  CNS  at  the  effector  phases  of 
relapsing-remitting  EAE  (Fitzgerald  et  al.,  2007),  and  retinal  ganglion  and 
photoreceptor cells of uveitis and scleritis (Amadi-Obi et al., 2007). Mice treated 
with exogenous IL-27 had reduced CNS inflammatory infiltration and a lower 
proportion of Th17 cells (Fitzgerald et al., 2007).     
 
The molecular mechanism for IL-27-mediated Th17 inhibition is still not clear. 
Considering IL-6 as an important factor for the development of Th17 cells, and 
the fact that IL-6 and IL-27 share the common receptor gp130, it was speculated 
that IL-27 may compete with IL-6 for receptor binding, which may result in the 
inhibition  of  Th17  cells.  However,  IL-27  appears  to  further  reduce  IL-17 
production in the absence of IL-6, which indicated that IL-27 exerts its inhibitory 
effects beyond simply antagonizing IL-6-mediated signalling (Stumhofer et al., 
2006). Based on STAT-1 deficient mice, it was established that the suppression 
of Th17 development by IL-27 is dependent on STAT1 pathway. T-bet has been 
found to be a negative regulator of Th17 cells, but IL-27 does not reduce the 
inhibition of Th17 cells in T-bet deficient cells. These data indicated that T-bet is 
not  required  for  IL-27  mediated  Th17  inhibition  (Stumhofer  et  al.,  2006).  In 
addition, SOCS-3, an important regulator of Th17 generation, can be induced by   72 
IL-27. Although it has been proposed that SOCS-3 may mediate the inhibitory 
effects of IL-27 in Th17 cells, studies have shown that Th17 generation using 
SOCS-3 deficient T cells was still suppressed by IL-27(Stumhofer et al., 2006). 
Therefore, IL-27 is an effective suppressor of Th17 development via a STAT1 
dependent process, and the exact pathways remain to be identified.     
 
1.3.4.10 IL-27 inhibits the development of TGF-b b b b-induced Foxp3+ Treg cells 
(Th3), but induces IL-10-producing Tr1 cells 
 
TGF-b can induce naïve T cells to Treg cells with the high expression of Foxp3.  
Recent  studies  have  found  that  IL-27  inhibited  the  development  of  Tregs 
generated by TGF-b (Neufert et al., 2007; Huber et al., 2008). In contrast to these 
inducible  Treg  cells,  IL-27  has  not  been  found  to  have  effect  on  naturally 
occurring Foxp3+ Tregs (Neufert et al., 2007).IL-27 suppressed TGF-b mediated 
Treg  cells  phenotype  at  the  levels  of  Foxp3,  CD25  and  CTLA-4  expression 
(Huber et al., 2007). This inhibitory effect of IL-27 on the inducible Treg cells is 
dependent of STAT3 signaling, but independent of STAT1 signaling (Neufert et 
al., 2007; Huber et al., 2007). 
 
Tr1  cells  are  another  type  of  induced  Treg  that  regulate  T  cell  function  by 
producing IL-10, but lack the expression of Foxp3. Although IL-27 inhibits the 
development of TGF-b-induced Foxp3+ Treg cells, recent studies have shown 
that IL-27 induced naïve CD4
+ T cells into IL-10-producing cells, and TGF-b 
further enhanced the generation of induced IL-10+ Tr1 cells by IL-27 (Awasthi et 
al.,  2007;  Fitzgerald  et  al.,  2007  (2);  Stumhofer  et  al.,  2007).  These  IL-10-  73 
producing cells are Foxp3 negative. Furthermore, it was found that IL-27 induces 
IL-10 in Th1 and Th2 but not Th17 conditions. Notably, the ability of IL-27 to 
induce IL-10 requires both STAT1 and STAT3 (Stumhofer et al., 2007).  
 
1.3.4.11 The role of IL-27 on other cells 
 
Besides the effects of IL-27 on CD4
+ T cells, the immunosuppressive effects of 
IL-27  also  extend  to  other  lymphocytes.  IL-27  stimulates  CD8
+  T  cells  and 
enhances cytotoxic activity, which plays an important role for protection against 
viral infection and cancer (Salcedo et al., 2004; reviewed in Shimizu et al., 2006). 
IL-27 enhances the proliferation of B cells and induces IgG2a class switching in 
vitro (Yamanaka et al., 2004). Although IL-27 acts synergistically with IL-2 and 
IL-12 to promote proliferation of NK cells and enhances the production of IFN-g 
from these cells in vitro (Pflanz et al., 2002), NK cells from WSX-1-/- mice 
produced more IFN-g and IL-4 compared to wild-type mice in response to con A 
stimulation  (Yamanaka  et  al.,  2004).  These  data  suggested  that  IL-27  has  a 
regulatory role in NK cell function. IL-27 also inhibits macrophages to produce 
cytokines, including IL-12 and TNF-a (Holscher et al., 2005). Furthermore, IL-
27 can suppress endotoxin-induced production of reactive oxygen mediated by 
granulocytes  and  macrophages  (Wirtz  et  al.,  2006).  In  turn,  lethal  septic 
peritonitis  was  protected  by  the  neutralization  of  IL-27.  IL-27  also  induces 
STAT1 and STAT3 in osteoblasts, but its effects have not been identified. This 
indicated that IL-27 may protect against bone destructive autoimmune diseases 
(Kamiya  et  al.,  2007).  Thus,  IL-27  has  broad  immunosuppressive  effects  in   74 
immune  responses,  although  the  underlying  mechanisms  for  this 
immunosuppressive function are not fully understood.   
 
1.3.4.12  The  studies  of  IL-27  signaling  deficient  mice  to  immunological 
challenge  
Mouse 
genotype  Challenge  T helper 
response  Outcome  Reference    
EBI3
−/−   Leishmania 
major  
Early Th1 
defect 
Delayed but 
effective response 
Zahn et al., 
2005 
WSX-1
−/−   Leishmania 
major  
Early Th1 
defect 
Delayed but 
effective response 
Yoshida et 
al., 2001 
Artis et al., 
2004 
WSX-1
−/−  Mycobacteria 
bovis BCG  
Early Th1 
defect 
Delayed but 
effective response, 
increased 
granuloma number 
and size 
Yoshida et 
al., 2001 
  
WSX-1
−/− 
Mycobacteriu
m 
tuberculosis  
Th1 
reduced 
Enhanced 
bacterial clearance 
Pearl et al., 
2004 
WSX-1
−/− 
Mycobacteriu
m 
tuberculosis  
Th1 
enhanced 
Enhanced 
bacterial 
clearance, lung 
immunopathology 
Holscher et 
al., 2005 
WSX-1
−/−  Trypanosoma 
cruzi  
Th2 
enhanced 
Increased 
parasitemia, 
hepatic 
immunopathology 
Hamano et 
al., 2003  
WSX-1
−/−  Leishmania 
donovani  
Th1 
enhanced 
Enhanced 
bacterial 
clearance, hepatic 
immunopathology 
Rosas et al., 
2006 
WSX-1
−/− 
Acute 
Toxoplasma 
gondii  
No defect 
Highly effective 
response, hepatic 
immunopathology 
Villarino et 
al., 2003 
WSX-1
−/− 
Chronic 
toxoplasmic 
encephalitis 
Th17 
enhanced 
Exacerbated 
encephalitis 
Stumhofer et 
al., 2006  
WSX-1
−/−   Trichuris 
muris  
Th2 
enhanced 
Enhanced 
helminth clearance 
Artis et al., 
2004; 
Bancroft et 
al., 2004    75 
Mouse 
genotype  Challenge  T helper 
response  Outcome  Reference    
WSX-1
−/−  
 
Concanavalin 
A-induced 
hepatitis 
 
Th1,Th2 
enhanced 
 
Exacerbated 
hepatitis 
 
Yamanaka 
et al., 2004  
EBI3
−/− 
ConA-
induced 
hepatitis 
Th1 
reduced 
Resistant to 
hepatitis 
 
Siebler et 
al., 2007 
WSX-1
−/−  DSS-induced 
colitis 
Th1 
reduced 
Resistance to 
colitis 
Honda et al., 
2005 
EBI3
−/−  
Oxazolone-
induced 
colitis 
Th2 
reduced 
Resistance to Th2-
mediated colitis 
Nieuwenhui
s et al., 2002 
EBI3
−/−  
Trinitrobenze
ne sulfonic 
acid-induced 
colitis 
Th1 
unaffected 
Normal 
development of 
Th1-mediated 
colitis 
Nieuwenhui
s et al., 2002  
EBI3
−/−  
Caecal 
ligation and 
puncture 
(CLP) 
induced 
septic 
peritonitis 
Not 
known 
Enhanced 
granulocytes 
ability to bacterial 
clearance, 
resistance to sepsis 
Wirtz et al., 
2006 
 
WSX-1
−/−  EAE  Th17 
enhanced 
Exacerbated 
encephalitis 
Batten et al., 
2006  
WSX-1
−/−  Allergic 
asthma 
Th2 
enhanced 
Exacerbated 
disease 
Miyazaki et 
al., 2005  
WSX-1
−/− 
Proteoglycan-
induced 
arthritis 
(PGIA)  
Th1 
reduced 
Delayed in 
arthritis 
development and 
reduced diseases 
severity 
Cao et al., 
2007) 
 
Table 1.1 List  of  the  studies  with  IL-27  signaling  deficient  mice  (adapted  from 
Batten & Chilardi 2007) 
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1.3. 5 IL-35 (EBI3/p35) 
 
EBI3 was originally identified as a transcriptionally activated gene in Epstein-
Barr virus-infected human B lymphocytes. EBI3 encodes a 34-Da glycoprotein 
that lacks a membrane anchored motif. Structurally, EBI3 bears 27% homology 
to the subunit IL-12p40 at the amino acid sequence level (Devergne, et al., 1996). 
EBI3  can  form  heterodimers  with  IL-27  p28  subunit.  However,  EBI3  is 
expressed  much  more  widely  than  p28.  EBI3  is  expressed  by  human  B 
lymphoblast cell lines, macrophage like cells in the lamina propria of the human 
colon in patients with ulterative colitis (Christ 1998), human colon epithelial cell 
lines, and by placental syncytiotrophoblasts at very high levels (Devergne, et al., 
2001). It raises possibility that EBI3 might associate with other partners and have 
functions  other  than  IL-27.  IL-12  was  identified  and  purified  from  culture 
supernatant  of  EBV-transformed  B  cell  lines  and  is  expected  to  be  closely 
associated with EBI3. IL-12 p35 is ubiquitously expressed whereas IL-12 p40 
expression is inducible. The dissociation between p35 and p40 gene regulation 
suggests that either subunit may be associated with other partners. p40 associates 
with  p19  to  form  IL-23.  It  has  been  demonstrated  that  EBI3  associates  non-
covalently with IL-12p35 to form a novel heterodimeric cytokine (Devergne, et 
al.,  1997).  Notably,  coexpression  of  EBI3  and  p35  facilitates  their  secretion, 
where they are not efficiently secreted when expressed alone. The expression of 
p35 was detected in the entire cell types positive for the expression of EBI3 in 
placental tissues (Devergne 2001) Additionally, intestinal epithelial cells were 
also shown to express EBI3 and p35 together (Masser, et al., 2004). Thus, EBI3-
p35  heterodimer  may  represent  a  novel  cytokine  of  the  IL-12  family.  This 
heterodimeric  cytokine  has  been  called  IL-35  by  the  International  Union  of   77 
Immunological Societies (IUIS) subcommittee on Interleukin Nomenclature and 
the HUGO Gene Nomenclature Committee (Schrader 2002).  
 
IL-12p40 can form homodimers to compete with IL-12 and through binding to 
IL-12  receptors,  and  IL-23  receptors  shares  b1 subunit  of  IL-12  receptors. 
However, unlike IL-12p40 homodimer and  IL-23, IL-35 does not bind to IL-
12 b1 and  b2 receptor  (Devergne,  et  al.,  1997).  Therefore,  IL-35  might  have 
different  receptor  complex.  It  is  known  that  EBI3  binds  to  gp130,  but  it  is 
uncertain whether IL-35 interacts with gp130 to date.  
 
As the survival of EBV-infected B lymphocytes and syncytial trophoblasts needs 
an effective NK and T cells response, it is likely that IL-35 might have an effect 
on  NK  and  T  cells,  and  downregulate  the  biological  effects  of  IL-12.  It  was 
speculated that the association of EBI3 with p35 might inhibit the expression of 
IL-12 (Devergne, et al., 1997). However, little was known about the biological 
role of IL-35 in immune responses since this cytokine has been found. Although 
neither EBI3-/- or IL-12p35-/- mice displayed overt autoimmune diseases, EBI3-
/- mice are more susceptible to leishmaniasis (Zahn et al., 2005), and IL-12p35-/- 
mice are more susceptible to Leishmania major infection (Mattner et al., 1996), 
EAE and CIA (Gran et al., 2002; Murphy et al., 2003). These phenomenon were 
always interpreted as a lack of IL-27 and IL-12. It is possible that the lack of IL-
35 function was involved in the EBI3-/- and IL-12p35-/- mice. A very recent 
study  has  demonstrated  that  both  EBI3  and  IL-12p35  genes  were  highly 
expressed by mouse Foxp3+Treg cells, but not by resting or activated effector 
CD4
+  T  cells  (Collison  et  al.,  2007).  IL-35  heterodimer  is  preferentially   78 
constitutively secreted by Treg cells but not effector T cells. It also has been 
shown  that  EBI3  is  a  downstream  target  of  Foxp3,  indicating  IL-35  might 
regulate  function  of  Treg.  EBI3-/-  and  IL-12p35-/-  Treg  cells  showed 
significantly reduced abilities to suppress the proliferation of effector T cells in 
vitro compared to wild-type Treg cells. Furthermore, EBI3-/- and  IL-12p35-/- 
Treg  cells  failed  to  cure  inflammatory  bowel  diseases  compared  to  wild-type 
Treg cells in vivo (Collison et al., 2007). Therefore, IL-35 is required by Treg 
cells for maximal regulatory function.   
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 1.4  Specific aims of this thesis 
 
Cytokines play a central role in regulating T cell expansion and differentiation, 
and an understanding of cytokines may lead to novel therapeutic strategies. 
 
IL-27  initially  has  been  characterized  as  a  cytokine  in  the  initiation  of  Th1 
responses; however, subsequent work has provided evidence that IL-27 has broad 
anti-inflammatory effects on Th1, Th2, and Th17 subsets. My hypothesis was 
that  IL-27  might  play  an  anti-inflammatory  role  in  RA  since  Th17  has  been 
shown to be involved in the pathogenesis of RA. Thus, one part of this project 
was designed to elucidate the function of IL-27 in CIA, a model that closely 
resembles human RA.  
 
IL-35  (EBI3/p35)  is  a  naturally  occurring  herterodimeric  cytokine,  but  the 
biological role of IL-35 was unknown when I started the project. The expression 
of  EBI3  and  p35  has  been  highly  detected  in  placental  tissues  and  intestinal 
epithelial cells. This indicated that IL-35 may be important in immune regulation. 
A very recent study has demonstrated that IL-35 is required for the regulatory 
function of Treg cells, which highlighted that IL-35 may be a inhibitory cytokine. 
Thereby, one part of this project was designed to elucidate the biological role of 
IL-35 in immune responses, and the possibility of using IL-35 as a therapeutic 
agent in inflammatory diseases, like CIA. 
 
The objectives of this project were to solve these questions:   80 
1.  To clone and express murine IL-27 and IL-35 in order to provide enough 
materials  for  murine  in  vitro  and  in  vivo  study.  In  addition,  to  clone  and 
express human recombinant IL-35 for the future human studies. 
2.  To investigate the potential role for recombinant IL-27 in murine model of 
inflammatory arthritis, CIA. 
3.  To characterize the role of recombinant IL-35 in different subsets of CD4
+ T 
cells in vitro, and study the effects of IL-35 in inflammatory response in vivo, 
using murine CIA model. 
 
I will employ a range of in vitro and in vivo techniques to address the above 
questions. The project will not only provide dynamic and advanced training in 
immunology for a PhD program, but the results should also provide important 
information on the crucial area of immune regulation by cytokines, leading to 
potential cytokine therapeutic approaches to a range of inflammatory diseases. 
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Chapter 2 
Material & Methods 
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2.1  Molecular Cloning 
 
2.1.1 Generation and culture of Dendritic cells (DCs) 
 
Human  EBI3  mRNA  and  p35  mRNA  were  expressed  by  DC.  DCs  were 
generated  from  isolated  Peripheral  blood  mononuclear  cells  (PBMC)  from 
healthy  volunteers.  PBMC  were  incubated  with  RPMI1640  complete  medium 
(supplemented 2mM L-glutamine, 100U/ml penicillin & 100 mg/ml streptomycin, 
10% foetal calf serum (FCS), and 50 mM b-Mercaptoethanol) (Invitrogen) in 25 
cm
2 flasks at 37
oC in a humidified incubator with 5% CO2 for 2 h to adhere to the 
flask.  Then the supernatant including non-adherent cells was removed, and the 
remaining adherent cells were cultured with RPMI1640 complete medium in the 
presence of 10 ng/ml  IL-4 (R  & D Systems)  and 5 ng/ml GM-CSF  (R & D 
Systems)  for  6  days  (Ranieri  1999),  thus,  monocytes  were  differentiated  into 
mature DCs. The DCs were stimulated with 100 ng/ml lipopolysaccharide (LPS) 
(Sigma)  and  100  ng/ml  of  interferon  (IFN)-g  (R&D  Systems).  After  7  h 
incubation, the DCs were harvested (Johansson 2002) and the pelleted cells were 
lysed in buffer RLT (Qiagen) with 1% b-Mercaptoethanol (b-ME) (Sigma).  The 
lysates were stored at –70
oC until required. 
 
2.1.2 RNA purification 
 
Total  cellular  RNA  was  extracted  from  the  lysates  that  were  prepared  as 
described  above  using  the  RNeasy  Mini  Kit  (Qiagen)  following  the 
manufacturer’s protocol. In brief, the lysate samples were homogenized using 
QIAshredder  spin  columns.  1  volume  of  70%  ethanol  was  added  to  the 
homogenized lysate and transferred to an RNeasy spin column and centrifuged   83 
for 15 seconds at 10,000 rpm and the flow through the column was discarded. 
RW1 buffer (700 ml) was added to the column and spun for 15 seconds at 10,000 
rpm. The column was washed twice with 550 ml RPE buffer. Finally, RNA was 
eluted in 40 ml of Rnase-free water. The amount and quality of purified RNA was 
determined  by  measuring  the  OD260  and  OD280  in  GeneQuant  (Amersham 
pharmacia biotech). 
 
2.1.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
Cloned DNA (cDNA) was generated from the RNA prepared as described above 
using the superscript II RT system (Invitrogen). 1-5 mg of RNA in a volume of 
<11 ml was added to 1 ml of Random Primer (RP) (50 ng/ml) (Roche), and the 
total  volume  was  made  up  to  12  ml  with  Rnase-free  water.  The  mixture  was 
heated at 70
oC for 10 minutes and then placed on ice for at least 1 minute. During 
this time, a mixture of 4 ml 5 x first strand buffer, 2 ml 0.1M DTT, and 1 ul 10 
mM dNTP was prepared. This mixture (7 ml) was added into the tube containing 
the RNA and RP mixture. 1 ml of Superscript II (200 u /ml) was added to the 
sample  and  reverse  transcribed  using  the  following  conditions:  25
oC  for  10 
minutes,  42
oC  for  50  minutes,  and  70
oC  for  15  minutes  in  the  Mastercycler 
gradient (Eppendorf).   
 
2.1.4 Polymerase Chain Reaction (PCR)  
 
The cDNA obtained above was used as a template in subsequent PCR reactions. 
All the primer- oligonucleotides (listed in table 2.1 below) were designed using 
Primer Express
TMv1.0 program (PE biosystems) and purchased from Sigma. 1 ml   84 
cDNA was mixed with 5 ml 10 x Pfu Buffer (Invitrogen), 1 ml 10 mM dNTP, and 
2.5 ml specific 5’ and 3’ primer- oligonucleotides (0.04 mg/ml). 1ml of Pfu DNA 
polymerase (5 unit/ ml) (Invitrogen) was added and the volume adjusted to 50 ml 
with DEPC H2O. The mixed sample was amplified in a thermo-cycler (Sigma) 
under  following  reaction  conditions:  35  cycles  of  denaturating  at  95
oC  for  1 
minute, annealing at 56
oC for 2 minutes, and extending at 72
oC for 3 minutes, 
followed by a final extension step of 72
oC for 10 minutes. After the reaction, the 
PCR samples were cooled at 4
oC. 
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Table 2.1  List of  PCR Primer- oligonucleotides used for cloning 
 
  
Oligonucleotide  DNA sequences (5’-3’)  Location 
hEBI3-5’  ATGACCCCGCAGCTTCT
CCTGGCCCTTGTCCT 
Human EBI3-cDNA 
hEBI3-3’  TTGCTACTTGCCCAGGC
TCATTGTGGCAGTGG 
Human EBI3-cDNA 
hEBI3-SMP-1  GAAATCTTCTCACTGAA
GTACTGGATCC 
Human EBI3-cDNA 
in TA vector 
hEBI3-SMP-2  GATTTCTGGGAAGGGC
CAGGACCCGGGA 
Human EBI3-cDNA 
in TA vector 
hEBI3-5’-Bgl II  TCTGAGATCTCTGCCCG
CCCTGCAGTGGAAGG 
Human EBI3-cDNA 
hEBI3-3’-Bgl II  CTTGAGATCTGCCCAGG
CTCATTGTGGCAGTG 
Human EBI3-cDNA 
Hp35-5’-NP1  AGCAAGAGACCAGAGT
CCCGGGAAAGTCCT 
Human p35-cDNA 
Hp35-3’-NP2  CCTAGTTCTTAATCCAC
ATCCTATCAAAGT 
Human p35-cDNA 
Hp35-5’  CCTCGGGACAATTATA
AAAATGTGGCCCCCTG 
Human p35-cDNA 
Hp35-3’  GACAACGGTTTGGAGG
GACCTCGCTTTTTAGG 
Human p35-cDNA 
Hp35-SMP-P1  CAAATCTTTCTAGATCA
AAACATGCTGG 
Human  p35-cDNA 
in TA vector 
Hp35-SMP-P2  GATTTGCCTCTTAGGAT
CCATCAGAAGC 
Human  p35-cDNA 
in TA vector 
Hp35-Not I-P1  TTTGCGGCCGCACCTCC
CCGTGGCCACTCCAG 
Human p35-cDNA 
Hp35-Not I-P2  TTTTGCGGCCGCATTCA
GATAGCTCATCACTCT 
Human p35-cDNA 
McsP1-Bgl II  AGCTTAGATCTG  pEE14.4 vector  
McsP2 -Bgl II  AATTCAGATCTA  pEE14.4 vector 
Psec-P1-Bgl II 
 
GCTAAGATCTATGGAG
ACAGACACACTCCTGC 
pSec-Linker-Fc 
vector 
PFc-P2-Bgl II  CAAGATCTCTATTATTT
ACCCGGGGACAGGAA 
pSec-Linker-Fc 
vector 
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2.1.5 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was used to analyse or confirm the size of DNA 
fragments from PCR or restriction endonuclease digestion. Agarose gel (1%) was 
made with 1 g agarose (Sigma) into 100 ml 0.5 x TBE buffer (100 mM Tris.HCl, 
pH  8.0,  450  mM  boric  acid,  and  12.5  mM  EDTA),  and  Ethidium  bromide 
(Sigma) was added at a final concentration of 10 ng/ml. The DNA products were 
mixed 1:5 with 5 x loading buffer (0.25% Bromophenol Blue, 80% Glycerol, 10 
mM Tris.HCl pH 7.4, and 1 mM EDTA) and loaded onto the gel which was then 
electrophoresed at 1-5 V/cm and visualised under ultra-violet (UV) light.  
 
2.1.6 PCR Fragment Purification 
 
PCR products were purified using the Qiagen Gel extraction kit (Giagen). The 
bands of interest visualized under UV light were cut from the gel with a sterile 
scalpel  blade,  and  purified  from  the  agarose  following  the  Gel  extraction  kit 
protocol. The concentration of the purified DNA fragment was measured with 
GeneQuant. 
 
2.1.7 Addition of 3’ A-overhangs on PCR products by Pfu polymerases 
 
DNA  amplified  products  by  Pfu  polymerases  were  blunt  ended  fragments.  In 
order to ligate into the pCR 2.1 vector (Invitrogen), the purified DNA products 
were incubated with Taq polymerase (Invitrogen). 40 ml of the purified DNA 
fragments were mixed with 1 ml dNTP, 5 ml PCR buffer (10 x) (200 mM Tris 
HCl  pH  8.4  and  500  mM  KCl),  1ml  50  mM  MgCl,  1  ml  Taq  polymerase 
(Invitrogen) and 2 ml DEPC H2O. The reaction mixture was incubated at 72
oC for   87 
10 minutes, and placed on ice for at least 1 minute. Then the DNA product was 
gel purified as described in section 2.1.6.  
 
 
2.1.8 Restriction Endonuclease Digestion 
 
Most  of  the  enzymes  used  were  purchased  from  Roche  Biochemicals  unless 
specified.  Restriction  endonuclease  digestion  was  set  up  according  to  the 
manufacturer’s protocols. Typically, 1 mg of DNA was digested using 20 units of 
enzyme and adjusted to a total volume of 20 ml in a recommended salt condition. 
The digests were incubated at 37
oC for at least 1 h and analysed by agarose gel 
electrophoresis (see section 2.1.5). 
 
2.1.9 Dephosphorylation of linearised plasmid DNA 
 
To clone the DNA fragments into a selected plasmid vector, the vector DNA was 
cut by restriction endonuclease (see section 2.1.8). To prevent self-ligation of the 
plasmid,  the  digested  vector  was  incubated  with  calf  alkaline  phosphatase 
(Roche) following the manufacturer’s instruction, and then gel purified.  
 
2.1.10 Ligation of DNA fragments into plasmid DNA vector 
 
Before ligation, the amount of vector DNA and the DNA fragment to be inserted 
were  analyzed.  Equal  molar  ratio  of  the  insert  DNA  and  vector  DNA,  were 
ligated with T4 ligase (Invitrogen) (50 ng DNA vector: 5 units ligase) according 
to  the  manufacturer’s  protocol.  The  ligation  reaction  was  incubated  at  room 
temperature for a minimum of 30 minutes, and then incubated at 15
oC overnight.  
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2.1.11 Transformation of DH5a a a a competent cells  
 
An  aliquot  of  50  ml  DH5a  competent  cells  (Invitrogen)  was  thawed  on  ice, 
before adding 5 ml of ligation reaction or 1/1000 diluted plasmid. The competent 
cells were incubated on ice for 30 minutes, and heat shock treated at 37
oC for 40 
seconds before cooling on ice for another 2 minutes. 1 ml of sterile 2-YT broth 
without ampiciline was added and the cells were incubated at 37
oC for 1 h in a 
shaking incubator. The cells were spun down at 13,000 rpm for 15 seconds, and 
the supernatant was removed. The cells were re-suspended before being plated on 
an LB-agar plate containing 100 mg/ml ampiciline. The agar plate was incubated 
in 37
oC oven overnight to obtain single colonies. 
 
2.1.12 Purification of plasmid DNA 
 
Individual colonies from LB-agar plates were picked using 100 ml size tips, and 
cultured in 3 ml of sterile 2-YT broth containing 100 mg/ml ampiciline overnight 
at 37
oC with vigorous shaking. Plasmid DNA was purified using QIAprep spin 
Miniprep  Kit  (Qiagen)  according  to  the  instructions.  Positive  clones  were 
identified by restriction endonuclease digestion (see section 2.1.8). If necessary, 
10  ml  of  DNA  from  a  positive  clone  was  sent  to  DNASHEF  Company  for 
sequencing. The rest was stored in -20
oC until required. 
 
2.2  Expression  of  recombinant  proteins  with  Glutamine  Synthetase  (GS) 
system  
 
The  Lonza  Biologics’  Glutamine  Synthetase  (GS)  gene  expression  system 
produces  high  protein  expression  levels  from  Chinese  Hamster  Ovary  cells   89 
(CHO).  The  following  procedures  were  carried  out  according  to  the  Lonza 
Biologics’ operating procedures for use with the CHO-K1 cell line. In brief:  
 
2.2.1 Preparation of constructs 
 
The constructs were prepared using methods described in above sections. The 
pEE 14.4 vector was obtained from Lonza Biologics. 
 
2.2.2 Cell culture 
 
CHO-K1 (Lonza Biologics) were grown in glutamine-free Dulbecco’s Modified 
Eagle’s Medium (DME) (JRH Biosciences) which contained 10% dialysed Foetal 
Bovine  Serum  (dFCS)  (Invitrogen),  100  U/ml  penicillin  &  100  mg/ml 
streptomycin, and 10 ml GS supplement (JRH Biosciences ),  called GS medium. 
The cells were sub-cultured every 3-4 days.  
 
2.2.3 Transfection 
 
The construct was transfected into CHO-K1 cells using Genejuice Transfection 
Reagent (Novagen). The day before transfection, 8 x10
5 CHO-K1 cells per 10 cm 
Petri dish in GS medium were incubated at 37
oC and 5% CO2 overnight to reach 
50-80% confluency before transfection. Genejuice (9 ml) was added to 100 ml of 
serum free medium Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) 
and mixed thoroughly by vortexing. The mixture was then incubated at room 
temperature for 5 minutes. Then, 3 mg DNA was added to the Genejuice / serum 
free medium mixture, and shaken gently before incubating at room temperature 
for 10 minutes. The entire volume of the mixture was added onto the surface of   90 
dish in a drop-wise manner. The cells were incubated for 5 h at 37
oC before 
replacing the medium with fresh GS medium.  
 
2.2.4 Selection of GS-CHO transfectants 
 
The high expressing cell lines were selected by Methionine sulphoximine (MSX) 
(Sigma). 24 h following transfection, a 25 mM final concentration of MSX was 
added to the dish. Colonies appeared about two weeks after transfection, and 
individual colonies were picked and grown in 96-well plates. The colonies with 
high protein expression levels were identified using ELISA (see section 2.4.1) 
and expanded with increasing concentrations of MSX from 50 mM to 500 mM to 
generate a cell line with a high protein expression level.  
 
2.3  Purification of recombinant Fc-fusion proteins 
 
2.3.1 Production of recombinant Fc- fusion proteins 
 
The  recombinant  Fc  proteins  were  expressed  by  the  transfected  cells.  The 
established transfected cells were expanded from one 25 cm
2 flask to ten 75 cm
2 
flasks  with  DMEM  medium  containing  10%  FCS  (Invitrogen)  and  100  U 
Penicillin & 100 mg/ml streptomycin, and 2 mM L-glutamine culture medium. 
Then, the cells were passaged into ten 175 cm
2 flasks and cultured with DMEM 
medium containing 10% low IgG FCS (Invitrogen), 100 U/ml penicillin & 100 
mg/ml streptomycin, and 2 mM L-glutamine. The supernatants were harvested 
after the cells were grown for 2 weeks.  
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2.3.2 Purification of recombinant Fc fusion proteins 
 
The recombinant Fc fusion proteins were purified using Econo-Pac protein A 
cartridge (Bio-RAD) following the manufacturer’s guidelines. The supernatants 
were spun down at 5000 rpm for 30 minutes at 4
oC to remove cell debris before 
being loaded onto an Econo-Pac protein A cartridge at 4
oC. The cartridge was 
washed with 20-30 ml Binding Buffer (20 mM Sodium Phosphate Buffer PH7.0) 
at room temperature to remove non-specific proteins. The recombinant Fc fusion 
protein was eluted with Elution buffer (0.1 M Glycine HCl pH 3.0) and 1 ml was 
collected  for  each  fraction  and  neutralised  immediately  with  25  ml  of 
Neutralisation  Buffer  (1  M  Tris.  HCl  pH  9.0).  The  fractions  containing  the 
proteins required were identified using LP Data View program (Bio-RAD), and 
the purified recombinant protein was dialysed in dialysis buffer (2% Nacl, 0.02% 
KCl,  0.024%  KH2PO4,  and  0.144%  Na2HPO4)  overnight  at  4
oC.  The  protein 
concentration of each aliquot was estimated using the Coomassie Protein Assay 
(Pierce). 
 
2.4  Protein Analysis and Detection 
 
2.4.1 Enzyme linked immunosorbent assay (ELISA) 
 
The  Fc  fusion  protein  expression  levels  of  the  transfected  CHO  cells  were 
identified using the human IgG Fc antibody (CALTAC). 96 well plates (Dynex 
Technologies) were coated overnight at 4 
oC with the appropriate concentrations 
of  capture  antibody,  anti-HIgG  purified  antibody  (1:1000  dilution)  in  0.1  M 
NaHCO3, pH 8.2. The working volume was 50 ml per well. The plates were 
washed twice with 1 x PBS containing 0.05% Tween 20 (washing buffer), and   92 
blocked for 2 h at 37
oC with 100 ml/well of 10% FCS in PBS (ELISA buffer). 
After  washing  four  times  with  washing  buffer,  50  ml  samples  were  added  in 
triplicate to the plate. Serial double dilutions of hIgG in triplicate were also added 
as standards. The plates were then incubated for 2 h at 37
oC to allow binding 
between cytokine and antibody. 50 ml of detection antibody (biotin anti-hIgGFc 
1:1000 dilution) (CALTAC) in ELISA buffer was added after six washes, and the 
plate was incubated at 37
oC. After 1 h incubation, the plate was washed 6 times 
before adding 50 ml of 1:1000 dilution of ExtrAvidin (Sigma) in ELISA buffer in 
each well. The plate was incubated for another hour at 37
oC and washed 8 times.   
Finally,  100  ml/well  of  Microwell  Peroxidase  Substrate   was  added  and  the 
reaction was allowed to develop at room temperature in the dark until a sufficient 
colour product was visible (TMB, Gaitherburg). The plate was then read at 630 
nm on a  MRX II microplate reader (Dynex Technologies) reader. 
 
2.4.2 SDS- PAGE 
 
The purity of the recombinant protein was analyzed by SDS-PAGE following the 
manufacturer’s protocol. In brief, the protein was denatured by heating to 70
oC 
for 10 minutes and loaded onto a NuPAGE 4-12% Bis-Tris Gel (Invitrogen). The 
gel was electrophoresed at 200 V, 400 mA until the dye front was close to the 
bottom, and the gel was rinsed in sterilized water before staining with Bio-safe 
Coomassie staining (BIO-RAD). After 1 h staining, the gel was destained with 
sterilized water until the band of the interest was clearly visible. 
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2.4.3 Western blot analysis of proteins 
 
After running the SDS-PAGE (see section 2.4.2), instead of staining, the gel was 
transferred  to  a  nitrocellulose  membrane  (Trans-Blot,  BIO-RAD)  in  transfer 
buffer (20 mM Tris, 40 mM glycine, and 20% v/v methanol) for 1 h at 30V, 400 
mA. The transferred membrane was incubated in blocking buffer (5% non-fat 
milk  in  PBS)  for  2  h  with  shaking  at  room  temperature  before  the  primary 
antibody  a-HIgG  purified  antibody  (1:2000  dilution  in  blocking  buffer)  was 
added.  After  1  h  incubation  with  the  primary  antibody,  the  membrane  was 
washed 3 times in washing buffer, and was incubated in blocking buffer with the 
DONKEY  anti-goat  IgG-HRP  conjugate  (1:4000  dilution  in  Blocking  buffer) 
(Sigma) for 1 h. The membrane was washed 3 times with washing buffer before 
being  developed  by  enhanced  chemiluminescence  (Amsersham  Pharmacia 
Biotech) and visualised by exposing to X-ray film (Kodak).  
 
2.5 In vitro studies  
 
2.5.1  Cells  
 
In all the in vitro studies described below, the mouse cells were harvested from 
female BALB/c (H-2
d-d, IgM
a) mice, which were purchased from Harlan Olac. 
All  mice  were  housed  and  treated  in  the  Biological  Service  facilities  in  the 
University of Glasgow according to the local UK home office guidelines under 
specific pathogens free condition. 
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2.5.2  Regents  
 
Table 2.2 List of cytokines used for in vitro culture 
 
 
Cytokines  Source  Source  Concentration  Usage 
IL-27  R&D Systems 
 
murine  10 ng/ml 
to 
100 ng/ml 
cell 
culture 
IL-23  R&D Systems  murine  20 ng/ml  cell 
culture 
IL-6  R&D Systems  murine  20 ng/ml  cell 
culture 
TGF-b  R&D Systems  murine  1 ng/ml  cell 
culture 
IL-1b  BD Bioscience 
 
murine  10 ng/ml  cell 
culture 
IL-2  GlaxoSmithKline 
 
human  10 ng/ml  cell 
culture 
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Table2.3 List of antibodies used for in vitro culture and FACS analysis 
 
 
Antibodies 
(Clone No.) 
Source  Isotype  Concentration  Usage 
CD3(145-2C11)  BD 
Bioscience 
Hamster 
IgG1 
1 mg/ml (soluble) 
2.5 mg/ml (plate-
bound) 
T cells 
activations 
CD28 
(37.51) 
BD 
Bioscience 
Syrian 
Hamster 
IgG2 
1 mg/ml 
 
Co-stimulatory 
signal for T cell 
activations 
IL-4 
(30340.11) 
R&D 
Systems 
Rat IgG1  10 mg/ml  Cell culture 
IL-2  R&D 
Systems 
Rat IgG2a  10 mg/ml  Cell culture 
IFN-g 
(XMG1.2) 
BD 
Bioscience 
Rat IgG1  10 mg/ml  Cell culture 
CD16/32 
(2.4G2) 
BD 
Bioscience 
Rat IgG2b  0.5 mg/100ml  Fc receptor 
blocking 
FITC  CD4 
(RM4-4/5) 
BD 
Bioscience 
Rat IgG2a  0.5 mg/100ml  FACS 
PE-CD25 
(PC61/7D4) 
BD 
Bioscience 
Rat IgG2b  3.6 mg/10
8 cells  T cell 
separation 
FACS 
Alexa  Fluor-
IL-17 
e Bioscience  Rat IgG1  0.5 mg/10
6cells  FACS 
PE-IL-17A  e Bioscience  Rat IgG2a  0.5 mg/10
6cells  FACS 
PE-Foxp3  e Bioscience  Rat IgG2a  1 mg/10
6cells  FACS 
PE-IFN-g  BD 
Bioscience 
Rat IgG1  0.5 mg/10
6cells  FACS 
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Antibodies 
(Clone No.) 
 
Source  Isotype   Concentration  Usage 
FITC  
Rat IgG2a 
BD 
Bioscience 
Rat IgG2a  0.5 mg/100ml  FACS 
PE 
Rat IgG2b 
BD 
Bioscience 
Rat IgG2b  3.6 mg/10
8 cells  FACS 
Alexa  Fluor- 
Rat IgG1 
e Bioscience  Rat IgG1  0.5 mg/10
6cells  FACS 
PE 
 Rat IgG2a 
e Bioscience  Rat IgG2a  0.5 mg/10
6cells  FACS 
PE 
Rat IgG1 
BD 
Bioscience 
Rat IgG1  0.5 mg/10
6cells  FACS 
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2.5.3  Preparation of Lymphocytes  
 
Single  cell  suspensions  were  obtained  by  forcing  murine  lymph  nodes  and 
spleens  that  were  prepared  in  cold  RPMI1640  medium  through  sterile  Nitex 
(Cadisch & Sons). The cell suspensions were centrifugated at 400 g for 5 minutes 
and resuspended in 1 ml red cell lysis buffer (Sigma) for exactly 1 minute, 20 ml 
cold RPMI 1640 containing 100 U/ml penicillin & 100 mg/ml streptomycin was 
added  to  inhibit  the  lysis.  The  cell  suspensions  were  washed  3  times  with 
centrifugation, before being resuspended in RPMI 1640 Complete Medium.   
 
2.5.4 T cell separation –autoMACS (Miltenyi Biotech) 
 
2.5.4.1 Negative selection of CD4
+ T cells 
 
The cell suspensions (see section 2.5.3) in RPMI 1640 Complete Medium were 
incubated in 75 cm
2 flasks at 37
oC in a humidified incubator with 5% CO2 for 1 
h, which allowed adherent cells to adhere to the flask. Then, non-adherent cells 
including the supernatant were collected and centrifuged at 400 g for 5 minutes 
and  re-suspended  in  20  ml  cold  MACS  Buffer  (1  x  PBS  without  Calcium, 
Magnesium,  Invitrogen,  2%  FCS,  100  U/ml  penicillin  &  100  mg/ml 
streptomycin).  10  ml  of  cells  were  counted  with  a  Neubauer  haemocytometer 
(Weber Scientific International) by diluting in 10 ml of a cell counting fluid (0.01 
M acetic acid, 0.1% trypan blue in PBS). The remaining cells were centrifuged at 
400g  for  5  minutes  and  incubated  with  the  cocktail  of  biotin-conjugated 
monoclonal antibodies [against CD8a (Ly-2, Rat  IgG2a), CD11b (Mac-1, Rat 
IgG2b), CD45R (B220, Rat IgG2a), DX5 (Rat IgM) and Ter-119 (Rat IgG2b)]   98 
(Miltenyi Biotech), at a concentration of 10 ml antibody per 10
7 total cells in 40 
ml MACS Buffer for 15 minutes at 4
 oC. Anti-biotin microbeads (20 ml per 10
7 
cells in 80 ml MACS Buffer) were added to the cells and incubated for another 15 
minutes. The cells were then washed with 40 ml MACS Buffer, centrifuged at 
300g for 10 minutes, and re-suspend in 6 ml MACS Buffer. CD4
+ T cells were 
then negatively selected by an AutoMACS machine according to Manufacture’s 
protocol. The purity of CD4
+ T cells was determined by Flow Cytometry (see 
section 2.5. 6). Routinely the purity of CD4
+ T cells was ≥95%. 
 
2.5.4.2  Positive  selection  of  CD4
+CD25
+ T  cells  and  negative  selection  of 
CD4
+CD25
- T cells 
 
The  selected  CD4
+  T  (see  section  2.5.4.1)  were  incubated  with  PE-CD25 
antibody (3.6 mg per 10
8 cells) in 1 ml MACS Buffer at 4
oC in the dark for 15 
minutes, and then washed twice with 20 ml MACS Buffer. The cells were then 
incubated with anti-PE microbeads (36 ml per 10
8 cells) in 1 ml MACS buffer at 
4
oC in the dark for another 15 minutes. Cells were washed by centrifugation at 
300g for 10minutes and re-suspend in 4 ml MACS Buffer. Magnetically labelled 
CD4
+CD25
+ T cells were sorted on AutoMACS by positive selection according 
to  Manufacture’s  protocol.  The  depleted  cells  were  CD4
+CD25
-  T  cells.  The 
purity of CD4
+CD25
+ T cells were analysed by Flow Cytometry (see section 2.5. 
6), routinely ≥ 90%. 
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2.5.5 Culture and stimulation of murine CD4
+, CD4
+CD25
+ and CD4
+CD25
- 
T cells 
 
2.5.5.1 T cells were cultured in two culture conditions 
 
1).  In  U-bottom  96  well  plates  (Nunc),  3  x  10
4  of  CD4
+,  CD4
+CD25
+  or 
CD4
+CD25
- T cells per well were cultured in triplicate with an equivalent number 
of  mitomycin C (50 mg/ml Sigma) treated APC in 200 ml of RPMI1640 complete 
medium  in  the  presence  of  1  mg/ml  of  anti-CD3.  Various  concentrations  of 
murine cytokines were added to cell culture as indicated in the text.  
 
2). 1 x10
5 CD4
+, CD4
+CD25
+ or CD4
+CD25
- T cells per well were cultured in 
triplicate in anti-CD3 (2.5 mg/ml) coated 96-well flat bottom plates in 200 ml of 
RPMI1640 complete medium in the presence of 1 mg/ml of anti-CD28. Various 
concentrations of murine cytokines were added to cell culture as indicated in the 
text.  
 
2.5.5.2 Established Th17 cell culture 
 
CD4
+CD25
- T cells (3x 10
4 cells/well) were cultured with anti-CD3 (1 mg/ml) 
and mitomycin C (50 mg/ml)-treated APC (3x 10
4 cells/well) under optimal Th17 
culture conditions: IL-6 (20 ng/ml), IL-1b (10 ng/ml) and TGF-b (1 ng/ml), and 
the neutralizing antibodies anti-IL-4 (10 mg/ml), anti-IFN-g (10 mg/ml) and anti-
IL-2 (10 mg/ml). After 4 days, activated cells were washed and re-stimulated with 
anti-CD3 (1 mg/ml) and APC (3x 10
4 cells/well) in the presence of IL-23 (20   100 
ng/ml) for another 3 days. Various concentrations of IL-27 were added to cell 
culture as indicated in the text. 
 
2.5.5. 3 Regulatory T cell suppressive function assay  
 
Regulatory T cell suppressive function assays were set up in 96-well U-bottom 
plates. In brief, CD4
+CD25
- T cells (3x 10
4 cells/well used as responders) were 
co-cultured  with  an  equivalent  number  of  freshly  purified  or  activated 
CD4
+CD25
+ T cells as regulatory T cells in the presence of anti-CD3 (1 mg/ml) 
and APC (3x 10
4 cells/well) in 200 ml of RPMI1640 complete medium. 
 
2.5.6 Proliferation Assay 
 
Proliferation assay was performed in 96-well U-bottom or 96-well flat bottom 
plates. Generally, after 3- 4 days cell culture, 100 ml/well of supernatant was 
harvested and 100  ml/ well of 1  mCi of [
3H]-thymidin (Amersham Pharmacia 
Biotech) was added and cultured for 8-12 hours. Plates were harvested onto a 
glass fibre filter mat (Packard) using a Micromate 196 Harvester (Packard) and 
3H -TdR uptake was counted on a Betaplate counter (Wallac). 
 
2.5.7 Flow Cytometry 
 
 
2.5.7.1 CFSE staining  
 
Before  setting  up  cell  culture,  CD4
+CD25
-  T  cells  were  incubated  in  PBS 
containing 2 mM CFSE (Sigma) for 15 minutes at 37
oC in the dark. The cells   101 
were  then  washed  twice  with  RPMI1640  complete  medium  and  pelleted  by 
centrifugation at 400 x g for 5 minutes and re-suspended in a volume of 200 ml 1 
x PBS Buffer (Invitrogen) containing 2% FCS and100 U Penicillin & 100 mg/ml 
streptomycin.  The  cells  were  checked  for  cell  cycles  by  Flow  Cytometry 
(FACScan,  BD  Bioscience)  and  analyzed  using  Cellquest  software  (BD 
Bioscience).  
 
2.5.7.2 Surface staining  
 
Cell  surface  markers  were  performed  by  surface  staining.  The  cells  were 
transferred to FACS Tube (BD Bioscience) and washed by MACS Buffer. After 
centrifugation (300 g, 5 minutes), the cells were incubated with anti-CD16/CD32 
antibody (0.5 mg/100 ml) for 15 minutes to block Fc receptors and non-specific 
binding. Then, the appropriate antibodies were added as indicated in the text and 
incubated for 20 minutes at 4
oC in the dark. The cells were then washed twice 
with MACS Buffer, re-suspended in 200 ml of MACS buffer and analyzed by 
Flow Cytometry.  
 
2.5.7.3 Intracelluar Cytokine Staining 
 
IL-17-producing cells, IFN-g-producing cells and Foxp3 expressing cells were 
determined by intracellular sytokine staining. In general, cells were stimulated 
for 5 hours with phorbol myistate acetate (BD Bioscience) and ionomycin (BD 
Bioscience) with Golgistop (BD Bioscience) added after 1hr. Cell stimulation 
was terminated by fixing in freshly prepared Fixation/Permeadbilization working   102 
solution (BD Bioscience). Fixed cells were stained with fluorescent-conjugated 
antibodies  in  Permeabilization  Buffer  for  20minutes  (4
oC,  Dark),  and  then 
washed, and analyzed with Flow Cytometry. 
 
2.5.8  Measurement of Cytokine Production 
 
Cytokine production was measured by ELISA as described in section 2.4.1. Most 
of the paired capture and biotinylated detection antibodies were purchased from 
BD Bioscience unless specified. Details of the concentrations of antibody used 
and the lower limit of detection for each assay are given in Table 2.4. IL-1Ra 
production  was  measured  using  Quantikine  IL-1Ra  Immunoassay  Kit  (R&D 
Systems) according to the manufacturer’s protocol.  
 
Table 2.4 List of cytokine antibodies used for ELISA 
 
 
Cytokine  Capture 
Antibody 
(m m m mg/ml) 
Detection 
Antibody 
(m m m mg/ml) 
Lower Limit of 
Detection of 
Assay (pg/ml) 
IL-2  1  1  10 
IFN-g  1  0.5  40 
IL-17  0.5  0.5  10 
IL-6  0.5  0.5  10 
IL-4  1  1  10 
IL-10 
(Biosource) 
1.25  0.06  10 
IL-12  2  0.5  20 
TNF-a  1:250 
(Volume) 
1:250 
(Volume) 
5 
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2.5.9 Real-Time PCR 
 
To quantify message levels, Real-time PCR was performed using an ABI prism 
7700 sequence detector (Applied Biosystems) according to the manufacturer’s 
instruction. All the primers and probes were purchased from Applied Biosystems 
(Listed in the table 2.5). 
 
1 ml cDNA template converted from mRNA was mixed with 12.5 ml Master mix 
(10 mM dNTP mix, 5 mM MgCl2, 0.625 U AmpliTaqGold
TM, 0.25 U AmErase 
N-Glycosylase, 10 x qPCR
TM buffers), 1 ml probe, and 0.75 ml of each of the 
primers. The total volume of each sample was adjusted to 25 ml with DEPC H2O. 
The mixed sample was loaded to a Thermo-Fast 96 semi-skirt plate (ABgene) 
and amplified on an ABI prism 7700 sequence detector under following reaction 
cycles:  the  first  cycle  was  50
oC  for  2  minutes  and  followed  at  95
oC  for  10 
minutes, and the remaining 45 cycles were 95
 oC for 15 seconds and 60
 oC for 1 
minute. Data analysis was performed using Sequence Detector Software (Applied 
Biosystems).  The  cDNA  levels  during  the  liner  phase  of  amplification  were 
normalized with respect to the levels of ‘housekeeping’ gene encoding HPRT 
(hypoxanthine phosphorbosyltransferase). The results were presented as relative 
mRNA expression level.   
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Table 2.5  List of Primers and Probes used for Real time PCR 
 
 
Gene  Forward Primer  Reverse Primer  Probe ( 5’-FAM&3’-
TAMRA) 
Foxp3  5’-CCCAGGAAAG 
ACAGCAACCTT-3’ 
5’-TTCTCACAAC 
CAGGCCACTTG-3’ 
5’-ATCCTACCCACTGC 
TGGCAAATGGAGT-3’ 
HPRT  5’-GCAGTACAGC 
CCCAAAATGG-3’ 
5’-AACAAAGTCTGG 
CCTGTATCCAA-3’ 
5’- TAAGTTGCAAGCT 
TGCTGGTGAAAAGGA
-3’ 
T-bet  5’-GCCAGGGAACC 
GCTTATATG-3’ 
5’-AACTTCCTGGCG 
CATCCA-3’ 
5’-CCCAGACTCCCCC 
AACACCGGA-3’ 
GATA-3  5’-TCCTCCTCTACG 
CTCCTTGCTA-3’ 
5’-ACACTGATTCCT 
TGGCGCTC-3’ 
5’-TCGTGATCGGAAG 
AGCAACCGTCTC-3’ 
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2. 6  In Vivo studies: Collagen- induced Arthritis (CIA) 
  
2.6.1 Animal 
 
All the in vivo studies described below were carried out under a project licence 
provided by UK home office and was performed to address scientific questions 
that could not be investigated by in vitro studies alone. The mice used were male 
DBA/1 mice purchased from Harlan Olac. All mice were kept in the Biological 
Service facilities in the University of Glasgow according to the local UK home 
office guidelines under specific pathogens free condition. 
 
2.6.2 Induction and treatment of CIA  
 
CIA was induced in mice as previously described (Ruchatz 1998). Briefly, male 
DBA/1  mice  (6-8  weeks)  were  immunised  with   100 mg  of  Bovine  type  II 
collagen (MD Bioscience) in Freund’s complete adjuvant (MD Bioscience) by 
intradermal injection (day 0), and boosted intraperitoneally (i.p.) on day 21 with 
collagen II (100 mg in PBS). Daily injections of IL-27-Fc (2 mg/mouse/day), IL-
35-Fc  (2  or  1  mg/mouse/day),  IL-23-Fc  (2  mg/mouse/day),  EBI3-Fc  (2 
mg/mouse/day) or PBS were administered i.p. for 10 days starting at different 
time points (day 21 or 27) as indicated in the text. 
 
2.6.3 Clinical assessment of CIA 
 
Mice  were  monitored  every  other  day  for  signs  of  arthritis,  and  the  disease 
severity was recorded following a scoring system for each limb: 0 = normal, 1 =   106 
erythema, 2 = erythema plus swelling,
 3 = extension/loss function and total score 
= sum of four limbs. Paw thickness was measured with a dial-caliper (Kroeplin). 
 
2.6.4 Histological assessment 
 
Mice were sacrificed and the hind limbs removed, fixed in 10% formalin for 3 
weeks, and decalcified with 35% (v/v) formic acid and 13% (w/v) sodium citrate 
for another 2-3 weeks. Then, the tissues were fixed in wax and cut in to 5 mm 
sections and stained with haematoxylin and eosin. Quantification of arthritis in 
each joint were scored blindly, based on the degree of inflammation, synovial 
hyperplasia and erosion as described previously (Joosten 1997).   
 
2.6.5 Ex Vivo cell culture 
 
Splenocyte were harvested from immunized mice at the indicated time-points, 
and single suspension of spleen cells were prepared as described in section 2.5.3). 
Spleen cells were cultured at 2 x10
6 cells per ml for up to 96 hours in RPMI 1640 
Complete Medium with graded concentrations of type II collagen at 37°C in 5% 
CO2.  Proliferation assays were performed in triplicate in
 U-bottom 96-well plates 
as  previously  described  in  section  2.5.6.  Supernatants
  from  parallel  triplicate 
cultures were estimated for cytokine contents by ELISA. 
 
2.6.6 Serum anti-Collagen Antibodies ELISA 
 
Anti-collagen Abs titers in serum obtained at the end of treatment of immunized 
mice were measured by ELISA. Briefly, 96-well plates (Dynex Technologies) 
were  coated  overnight  at  4
oC  with  4  µg/ml  bovine  type  II  collagen  in  0.1M   107 
NaHCO3, pH8.2, blocked, and serially-diluted serum were added. Total IgG was 
detected  with  horseradish
  peroxidase-conjugated  goat  anti-mouse  IgG 
(Genzyme), and biotin-conjugated
 anti-mouse IgG1 and IgG2a (BD Bioscience). 
The plates were developed as described in section 2.4.1 and read at 630nm. 
 
2.6.7 Multiplex Bead Assay-10 plex luminex 
 
Serum  cytokine  production  was  also  analysed  by  Multiplex  Bead  Assay 
(Biosource) according to the manufacturer’s instructions. The Assay contained 
10 cytokines: GM-CSF, IFN-g, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40 
and  TNF-a.  The  principle  of  this  method  is  a  sandwich  immunoassay  where 
specific  antibodies  have  already  been  coated  to  the  surface  of  fluorescently 
encoded  microspheres.  Each  microsphere  is  labelled  with  a  distinguishable 
fluorphore that allows it to be assigned or gated to a particular region by the 
scanner. Briefly, cytokine capture microspheres were first incubated with serum 
samples and followed by biotinylated detection antibodies. Relevant standards 
used for quantitative analysis were added at the same time as serum samples. 
Finally,  streptavidin-RPE  was  added  and  the  fluorescence  bound  to  the 
microspheres was analysed using Luminex XMAP
TM system. The fluorescence 
intensity  was  proportional  to  the  concentration  of  cytokines  present  in  the 
samples. 
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2.7 Statistical analysis 
 
Data are presented as the mean ± standard error of the mean (SEM). Statistical 
analysis  was  performed  using  Student’s  Test,  or  Mann-Whitney  U  test  as 
indicated  in  the  text.  Statistical  significance  was  defined  as  *p<0.05,  or 
**p<0.01.  
 
2.8 List of plasmid vectors 
 
Plasmid  vectors  used  for  cloning,  transfection  or  expression  of  recombinant 
proteins are listed in Figure 2.1. 
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Figure 2.1 List of Plasmid vectors 
 
pCR2.1 vector 
 
 
 
 
 
 
 
pSecTag2A 
 
 
 
 
 
 
 
 
pEE14.4-1 
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Table 2.6 List of suppliers’ details 
 
Company  Address 
ABgene Ltd  Abgene  House,  Blenheim  Road,  Epsom 
KT19 9AP, UK 
Amsersham Pharmacia Biotech Ltd  Amersham  Place,  Little  Chalfont,  
Buckinghamsire HP7 9NA, UK 
Applied Biosystems  850 Lincoln Centre Drive, Foster City, CA 
94404, USA 
BD Bioscience Ltd  21  Between  Town  Road,  Cowley,  Oxford 
OX4 3LY,UK 
BioSource 
TM  Rue  de  L'industrie,  8B-1400  Nivelles,  
Belgium 
Bio-RAD Labtoratories  Bio-Rad  House,  Maxted  Road,  Hemel 
Hempstead, Hertfordshire HP2 7DX 
Carisch & Sons company  745 High Rd, London, N12 0BP  UK 
Chondrex Inc 
C/o MD Biosciences 
Morwell  Diagnostics  GmbH, 
Gewerbestrasse  9,  Postfach  8132,  Zuriich 
Switzerland 
DNASHEF Technologies  Edinburgh  Royal  Infirmary,  1  Lauriston 
Place, Edinburgh EH3 9YW, UK 
Dynex Technologies  Columbia  House,  Columbia  Drive, 
Worthing, West Sussex, BN13 3HD, UK 
eBiosciences C/o Insight Biotechnology Ltd  Wembley  Commercial  Centre,  East  Lane, 
Wembley HA9 7XX 
Eppendorf UK Ltd 
c/o Helena Biosciences Europe Ltd 
Queensway  South,  Team  Valley  Trading 
Estate, Gateshead, Tyne & Wear NE11 0ZF, 
UK 
Genzyme ltd  12 Rookwood Way, Haverhill, Suffolk, CB9 
8PU, UK   111 
Company  Address 
Harlan Olac  Shaw’s  Farm,  Bicester,  Oxon  Ox25  1TP, 
UK 
Invitrogen Life Technologies  3 Fountain Drive, Inchinnan Business Park, 
Paisley, UK 
JRH Biosciences  West  Portway  Industrial  Estate,  Andover, 
Hempshire, SP10 3LF 
 
Kodak Ltd  Kodak  House,  Sation  Road,  Hemel 
Hempstead, Hertfordshire, HP 1 1JU,UK 
Lonza Biologics Ltd  228  Bath  Road,  Slough,  Berkshire  SL1 
4DX, UK 
Miltenyi Biotec Ltd  Almac House, Church Lane, Bisley, Surrey 
GU24 9DR 
Novagen 
Merck Biosciences Ltd 
Boulevard  Industrial  Park,  Padge  Road, 
Beeston, Nottingham, NG9 2JR 
Packard Instrument Company  800 Research Parkway Meriden, CT 06450 
USA 
Pierce 
c/o Perbio Science UK Ltd 
Unit 9, Atley Way, North Nelson Industrial 
Estate Cramlington, Northumberland NE231 
WA 
Qiagen Ltd  QIAGEN  House,  Fleming  Way,  Crawley, 
West Sussex, RH10 9NQ, UK 
Roche Diagnostics Ltd  Bell  Lane,  Lewes,  East  Sussex  BN7  1LG, 
UK 
R&D Systems Europe Ltd  19  Barton  Lane,  Abingdon  Science  Park, 
Abingdon, Oxon OX14 3NB   112 
Company  Address 
Sigma-Aldrich Company Ltd  Fancy Road, Poole, Dorset BH12 4QH 
VWR International Ltd  Haasrode  Researchpark  Zone  3, 
Geldenaaksebaan 464 Leuven B309 
Wallac Oy  Mustionkatu 6, 20101 Turku, Finland 
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Chapter 3 
Cloning and expression of murine IL-27-Fc, IL-35-Fc and human 
IL-35-Fc with GS system 
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3.1 Cloning and expression of murine IL-27-Fc and IL-35-Fc with GS system 
 
3.1.1 Introduction 
 
The murine cDNA encoding IL-27-Fc and IL-35-Fc were successfully cloned in 
our  lab  and  constructed  into  pSecTag2A  vector  (Invitrogen).  Schematic 
representation of recombinant murine IL-27-Fc and IL-35-Fc are shown in Figure 
3.1. However, the production of these recombinant proteins expressed from that 
vector was low. In order to produce large quantities of IL-27-Fc and IL-35-Fc for 
in vivo studies, it was necessary to choose a new mammalian expression system. 
GS system, as described in previous material and method, is a highly efficient 
mammalian  expression  system,  and  provides  a  way  to  produce  recombinant 
proteins  in  high  quantities.  Therefore,  the  general  approach  underlying  the 
cloning of IL-27-Fc and IL-35-Fc from the previous expression vector into GS 
vector was to get the higher amount of the expression of recombinant proteins 
with GS system. As a comparison, IL-12-Fc and IL-23-Fc previously constructed 
in pSecTag2A vector were also transferred into GS system. 
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Figure 3.1 Schematic representation of recombinant murine IL-27-Fc, IL-35-Fc, 
IL-12-Fc, and IL-23-Fc.  
 
The  fusion  protein  includes  the  leader  sequence,  Pro/Thr  rich  regions  of  the 
native IL-12p40, IL-27 EBI3, linker, Pro/Thr region of IL-12p35, IL-23p19, IL-
27p28, and the Fc part of human IgG1 at their C-terminus. 
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3.1.2 Cloning of the cDNA insert encoding IL-27-Fc, IL-35-Fc, IL-12-Fc, and 
IL-23-Fc  
 
PCR amplification, using the pSecTag2A vectors encoding IL-27-Fc, IL-35-Fc, 
IL-12-Fc  and  IL-23-Fc  as  templates  respectively,  resulted  in  around  2200  bp 
PCR  fragments  containing  the  cDNA  encoding  IL-35-Fc,  IL-12-Fc,  IL-27-Fc, 
and IL-23-Fc with the Bgl II site insertion on both ends (Figure 3.2 A). These 
above 2200 bp PCR fragments were cloned into the PEE14.4-1 GS vector via the 
Bgl II site in the polylinker respectively. The sequence identities of these cloned 
products were confirmed by restriction enzyme mapping respectively (Figure 3.2 
B, C, D).  
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A. 
                                                                                                                                                           
                                                              
                     
 
      
 
B.                                         C.                                         D. 
                                                                                
 
 
 
 
 
Figure 3.2 Cloning of the cDNA insert encoding murine IL-12-Fc, IL-23-Fc, IL-
27-Fc and IL-35-Fc. 
 (A) PCR was performed on pSecTag2A vector with interest inserts to obtain  
PCR fragments encoding murine  IL-12-Fc,  IL-23-Fc,  IL-27-Fc, and  IL-35-Fc, 
and  a  Bgl  II  site  was  inserted  at  both  ends  of  these  fragments.  (B)  BamH  I 
digestion of mIL-12-pEE14.4 cDNA resulted in 2035 bp, 943 bp, and 273 bp 
fragments, but 273 bp fragment was too small to be visualized on gel. (C) BamH 
I digested mIL-23-pEE14.4 cDNA (1) and mIL-27-pEE14.4 cDNA (2) to obtain 
2035 bp and 943 bp, 2063 bp and 630 bp fragments. (D) BamH I digestion of m 
IL-35-Fc-pEE14.4 DNA resulted in 2035 bp and 630 bp fragments. (The ladder 
used is 1kb+ DNA ladder) 
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3.1.3  Expression  of  IL-27-Fc,  IL-35-Fc,  IL-12-Fc  and  IL-23-Fc  with  GS 
system 
 
These constructs of IL-27-Fc, IL-35-Fc, IL-12-Fc and IL-23-Fc within GS vector 
were transfected into CHO-K1 cells, expression colonies were selected out by 
detecting the Fc fusion part from the cell culture supernatants using hIgG Fc 
ELISA,  which  is  described  in  material  and  methods.  With  the  increasing 
concentrations of MSX, the expressing cell lines were educated to produce higher 
and stable recombinant protein production. The expression level in the culture 
supernatants from GS system was 10 times higher compared to the expression 
level from the previous cloning (Figure 3.3).  However, the protein expression 
from IL-27-Fc and IL-35-Fc colonies was still much lower than the expression 
from  IL-12-Fc  and  IL-23-Fc  colonies.  The  expressing  cells  were  washed  and 
lysated, and the lysates proteins were checked for levels of recombinant proteins 
which were maintained inside the cells by western blot. As shown in Figure 3.4, 
there were no proteins recognized by human IgG antibody. This indicated that the 
recombinant proteins with Fc fusion part were all secreted outside CHO-K1 cells. 
 
The  recombinant  fusion  proteins  IL-23-Fc,  IL-27-Fc,  IL-35-Fc  were  purified 
using  Econo-Pac  protein  A  cartridge.  The  purity  of  the  recombinant  proteins 
were analysed by SDS-PAGE (Figure 3.5).  The recombinant proteins were also 
analysed  by  western  blot.  Monoclonal  antibody  directed  against  human  IgG 
resulted in IL-23-Fc band of 87.3 kd, IL-27-Fc of 78.8 kd, IL-35-Fc band of 80 
kd, and IL-12 band of 88.9 kd (Figure 3.6). Monoclonal antibody against murine 
IL-12 p40 recognized the same protein bands of IL-12-Fc and IL-23-Fc, but not   119 
IL-27-Fc and IL-35-Fc (Figure 3.6). No additional bands were visible using these 
two detection systems.  
 
 
 
 
       
 
 
 
 
 
Figure  3.3  Comparison  of  the  levels  of  Fc  fusion  proteins  expression  from 
pSecTag2A vector and pEE14.4-1 vector. 
 
The selected stable high-yielding IL-12-Fc, IL-23-Fc, IL-27-Fc and IL-35-Fc cell 
lines from pSecTag2A vector and pEE14.4-1 vector were cultured in the 175 cm
2 
size of flasks for 5 days, and 150 ml of supernatants were removed and analyzed 
for  Fc  fusion  protein  expression  by  human  IgG  Fc  ELISA.  The  cell  line 
transfected with pEE14.4-1 vector encoding the insert genes  yielded 10 times 
high  levels  of  Fc  fusion  protein  compared  with  the  cell  line  transfected  with 
pSecTag2A vector encoding the insert genes. 
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Figure 3.4 Western Blot analysis of cell lysates.  
 
CHO-K1 cells respectively expressing  IL-27-Fc and IL-35-Fc were harvested, 
washed and lysated. Cell lysates were detected by human IgG-Fc antibody. There 
were  no  proteins  recognized  by  human  IgG  antibody.  This  indicated  that  the 
recombinant proteins with Fc fusion part were all secreted outside CHO-K1 cells. 
IL-27-Fc protein was used as a positive control. 
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Figure 3.5 SDS-PAGE analysis of purified recombinant proteins.  
 
Various amounts of purified recombinant proteins IL-12-Fc, IL-27-Fc, IL-35-Fc 
and  IL-23-Fc  were  run  on  SDS-PAGE,  and  stained  with  Coomassie  blue  to 
demonstrate  their  purities.  The  molecular  weights  of  these  products  were  the 
same as they were designed (The ladder used is SeeBlue Plus2 from Invitrogen).   
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Figure 3.6 Western blot analyses of purified recombinant proteins.  
 
The purified recombinant proteins mIL-12-Fc, m IL-35-Fc, mIL-27-Fc and mIL-
23-Fc were demonstrated in western blot by two detecting antibodies: anti-hIgG 
and anti-IL-12p40. Both antibodies detected the same protein bands of 88.9 kd of 
mIL-12-Fc and 87.3 kd of mIL-23-Fc. 78.8 kd size of m IL-27-Fc and 80 kd size 
of IL-35-Fc were only detected by anti-hIgG.  
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3.1.4 Bioactivity of the recombinant proteins IL-27-Fc, IL-35-Fc, IL-12-Fc 
and IL-23-Fc 
 
The  recombinant  proteins  IL-27-Fc,  IL-35-Fc,  IL-12-Fc  and  IL-23-Fc  were 
assessed  for  their  biological  activities  in  vitro.  CD4
+  T  cells  isolated  from 
BALB/c  mice  were  stimulated  with  plate-bound  anti-CD3  and  soluble  anti-
CD28, and the increasing concentrations of recombinant proteins IL-35-Fc, IL-
27-Fc, IL-12-Fc and IL-23-Fc were added to the beginning cell culture. After 72 
h, the culture supernatants were harvested and analyzed for IFN-g by ELISA. As 
expected, IL-12-Fc and IL-27-Fc stimulated the production of IFN-g from CD4
+ 
T  cells  in  a  dose  dependent  manner  (Figure  3.  7).  Also,  IL-35-Fc  stimulated 
CD4
+ T cells to produce IFN-g in a dose dependent manner (Figure 3.7), which 
will be discussed in chapter 5. IgG Fc did not induce IFN-g on CD4
+ T cells, 
which indicated that the Fc part on the recombinant proteins did not play any role 
to affect the biological function of these recombinant proteins. As expected, IL-
23-Fc did not enhance the production of IFN-g, because IL-23 does not act on 
naïve murine CD4
+ T cells to induce IFN-g  (Figure 3.7 A). To further test the 
activity of IL-23, the culture supernatants were analyzed for IL-17 by ELISA. IL-
23 enhanced the secretion of IL-17 （ Figure 3.7 B）. 
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A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 3.7 Effect of purified recombinant proteins on CD4
+ T cells. 
 
1 x10
5 CD4
+ T cells isolated from BALB/c mice were stimulated with plated-
bound anti-CD3 (2 mg/ml) and soluble anti-CD28 (1 mg/ml), and the increasing 
concentrations of recombinant proteins IL-35-Fc, IL-12-Fc, IL-27-Fc, and IL-23-
Fc (0.05, 0.5, 5, 50 ng/ml) were added to the cell culture. After 72 h, the culture 
supernatants  were  harvested  and  analyzed  for  IFN-g  (A)  and  IL-17  (B)  by 
ELISA. Data are Mean ± SD, ** p< 0.01, *p< 0.05 compared to control, by 
student’s t test. 
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3.2 Cloning and expression of human IL-35-Fc 
 
3.2.1 Introduction 
 
The biological role in mice might be different from the biological role in humans. 
The human recombinant IL-35-Fc fusion protein was designed to investigate the 
biological effects of the human IL-35 heterodimer in humans. The cloning and 
construction of the IL-35-Fc gene was to express the two soluble fragments of 
EBI3 and p35 fused with a flexible linker and tagged with human IgG-hinge Fc 
(Figure 3.8).  
 
 
 
 
 
Figure 3.8 Schematic representation of recombinant human IL-35-Fc.  
 
This  recombinant  protein  includes  the  leading  sequence,  encoding  the  protein 
rich region of EBI3 and p35 linked with a flexible linker sequence, and the Fc 
part of human IgG at the C-terminus.  
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3.2.2 Cloning of the cDNA insert encoding human IL-35-Fc 
 
Human cDNA encoding EBI3 was prepared by RT-PCR from mRNA that was 
extracted from LPS and IFN-g stimulated human DCs. Using specific primers, 
PCR amplification resulted in a PCR product of 690 bp (Figure 3.9 A). This band 
was extracted from the gel and subsequently cloned into the pCR2.1 TA vector 
(Figure 3.9 B). A Bgl II site silent mutation was introduced into the TA vector 
carrying the EBI3 insert by PCR. The template vector without the silent mutation 
site  was  digested  by  Dpn  I,  and  the  remaining  amplified  DNA  vector  was 
sequenced  using  M13R  and  T7  primers  to  confirm  the  sequence  with  silent 
mutation (Figure 3.10). Then, using this DNA vector as a template, another round 
of PCR amplification was performed to yield a 665 bp fragment with a Bgl II site 
insertion on both ends (Figure 3.9 C).  This product encoding EBI3 with the Bgl 
II  enzyme  site  on  both  ends  was  transfered  into  the  BamH  I  site  of  vector 
pSecTag2A containing the insert of Fc and a flexible linker (named as vector 
pSec-Linker-Fc). This was confirmed by restriction enzymes mapping (Figure 
3.9 D, E).  
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Figure 3.9 Cloning of the cDNA encoding human EBI3. 
 
cDNA encoding EBI3 derived from DC was obtained by RT-PCR (A). The PCR 
fragment encoding EBI3 was cloned into the TA pCR2.1 vector (B). The PCR 
fragment  was  amplified  from  cloned  EBI3  TA  vector  containing  the  silent 
mutation, and a Bgl II site was introduced at both ends (C). Pst I digested vector 
pSec-Linker-Fc inserted with EBI3-Fc to obtain a 502 bp fragment (D). Bam HI 
and  Hind  III  digested  pSec-Linker-Fc  vector  inserted  with  DNA  fragment 
encoding EBI3 to obtain a 479 bp fragment, and Not I and Hind III together 
digested pSecTag2A vector inserted with EBI3 to obtain a 774 bp fragment (E). 
(The ladder used is 1kb+ DNA ladder). 
 
 
 
 
690bp-
690bp- 665bp- 502bp-
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Cloning 
ATGACCCCGCAGCTTCTCCTGGCCCTTGTCCTCTGGGCCAGCTGCCCGCCCTGCAGTG 
ATGACCCCGCAGCTTCTCCTGGCCCTTGTCCTCTGGGCCAGCTGCCCGCCCTGCAGTG 
Genebank 
GAAGGAAAGGGCCCCCAGCAGCTCTGACACTGCCCCGGGTGCAATGCCGAGCCTCTC 
GAAGGAAAGGGCCCCCAGCAGCTCTGACACTGCCCCGGGTGCAATGCCGAGCCTCTC 
 
GGTACCCGATCGCCGTGGATTGCTCCTGGACCCTGCCGCCTGCTCCAAACTCCACCA 
GGTACCCGATCGCCGTGGATTGCTCCTGGACCCTGCCGCCTGCTCCAAACTCCACCA 
 
GCCCCGTGTCCTTCATTGCCACGTACAGGCTCGGCATGGCTGCCCGGGGCCACAGCT 
GCCCCGTGTCCTTCATTGCCACGTACAGGCTCGGCATGGCTGCCCGGGGCCACAGCT 
 
GGCCCTGCCTGCAGCAGACGCCAACGTCCACCAGCTGCACCATCACGGATGTCCAGC 
GGCCCTGCCTGCAGCAGACGCCAACGTCCACCAGCTGCACCATCACGGATGTCCAGC 
 
TGTTCTCCATGGCTCCCTACGTGCTCAATGTCACCGCCGTCCACCCCTGGGGCTCCAG 
TGTTCTCCATGGCTCCCTACGTGCTCAATGTCACCGCCGTCCACCCCTGGGGCTCCAG 
 
CAGCAGCTTCGTGCCTTTCATAACAGAGCACATCATCAAGCCCGACCCTCCAGAAGG 
CAGCAGCTTCGTGCCTTTCATAACAGAGCACATCATCAAGCCCGACCCTCCAGAAGG 
 
CGTGCGCCTAAGCCCCCTCGCTGAGCGCCAGCTACAGGTGCAGTGGGAGCCTCCCGG 
CGTGCGCCTAAGCCCCCTCGCTGAGCGCCAGCTACAGGTGCAGTGGGAGCCTCCCGG 
 
GTCCTGGCCCTTCCCAGAAATCTTCTCACTGAAGTACTGGATCCGTTACAAGCGTCAG 
GTCCTGGCCCTTCCCAGAGATCTTCTCACTGAAGTACTGGATCCGTTACAAGCGTCAG 
 
GGAGCTGCGCGCTTCCACCGGGTGGGGCCCATTGAAGCCACGTCCTTCATCCTCAGG 
GGAGCTGCGCGCTTCCACCGGGTGGGGCCCATTGAAGCCACGTCCTTCATCCTCAGG 
 
GCTGTGCGGCCCCGAGCCAGGTACTACGTCCAAGTGGCGGCTCAGGACCTCACAGAC 
GCTGTGCGGCCCCGAGCCAGGTACTACGTCCAAGTGGCGGCTCAGGACCTCACAGAC 
 
TACGGGGAACTGAGTGACTGGAGTCTCCCCGCCACTGCCACAATGAGCCTGGGCAAG 
TACGGGGAACTGAGTGACTGGAGTCTCCCCGCCACTGCCACAATGAGCCTGGGCAAG 
 
TAG 
TAG 
 
Figure 3.10 Comparison of Nucleotide sequence of EBI3 from cloning and gene 
bank. 
 
The  upper  sequence  was  obtained  from  cloning,  and  the  lower  sequence  was 
from genebank. The highlighted point indicates the silent mutation.  
 
 
   129 
The cDNA encoding human p35 fragment was cloned using a nested PCR. The 
first  amplification  round  products  were  used  as  a  template  in  a  second  PCR 
reaction, which resulted in a PCR product of 762 bp (Figure 3.11 A). This PCR 
fragment was cloned into the pCR2.1 TA vector (figure 3.11 B), and site directed 
mutagenesis was performed to insert the Bgl II site silent mutation into TA vector 
carrying p35 fragment part. The template vector without the silent mutation site 
was  digested  by  Dpn  I,  and  the  remaining  amplified  DNA  vector  with  silent 
mutation  was  confirmed  by  sequencing  using  M13R  and  T7  primers  (Figure 
3.12). Then, using this DNA vector as a template, another round of amplification 
was performed with the insertion of a Not I site at both ends of the PCR fragment 
(Figure 3.11 C). This PCR product encoding p35 with the Not I on both ends 
were transfered into the Not I site of vector pSec-Linker-Fc, already containing 
the cDNA encoding EBI3 (Figure 3.11 D, E).  
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Figure 3.11 Cloning of the cDNA encoding human p35. 
 
cDNA encoding p35 derived from DC was obtained by RT-PCR (A). The PCR 
fragments encoding p35 was cloned into the TA pCR2.1 vector (B). The PCR 
fragment was amplified from cloned p35 TA vector containing silent mutation, 
and a Not I site was introduced at both ends (C). 606 bp fragment encoding p35 
was cloned into the vector pSec-L-Fc containing the EBI3 fragment (D). Hind III 
digestion of this construct resulted in an 1110 bp fragment, and BamH I digestion 
of this construct resulted in a 642 bp fragment (E). (The ladder used is 1kb+ 
DNA ladder). 
 
 
 
 
 
 
M                      M                         M             M                                M  
762bp- 710bp-
606bp-
606bp-
1110bp-
642bp-  131 
Cloning 
 
ATGTGGCCCCCTGGGTCAGCCTCCCAGCCACCGCCCTCACCTGCCGCGGCCACAGGT  
ATGTGGCCCCCTGGGTCAGCCTCCCAGCCACCGCCCTCACCTGCCGCGGCCACAGGT  
Genebank 
 
CTGCATCCAGCGGCTCGCCCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGC  
CTGCATCCAGCGGCTCGCCCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGC  
 
 
GCAGCCTCCTCCTTGTGGCTACCCTGGTCCTCCTGGACCACCTCAGTTTGGCCAGAAA  
GCAGCCTCCTCCTTGTGGCTACCCTGGTCCTCCTGGACCACCTCAGTTTGGCCAGAAA  
 
CCTCCCCGTGGCCACTCCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAAAAC  
CCTCCCCGTGGCCACTCCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAAAAC  
 
CTGCTGAGGGCCGTCAGCAACATGCTCCAGAAGGCCAGACAAACTCTAGAATTTTAC  
CTGCTGAGGGCCGTCAGCAACATGCTCCAGAAGGCCAGACAAACTCTAGAATTTTAC  
 
CCTTGCACTTCTGAAGAGATTGATCATGAAGATATCACAAAAGATAAAACCAGCAC 
CCTTGCACTTCTGAAGAGATTGATCATGAAGATATCACAAAAGATAAAACCAGCAC 
 
 
AGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAATGAGAGTTGCCTAAATTCCAG  
AGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAATGAGAGTTGCCTAAATTCCAG 
 
AGAGACCTCTTTCATAACTAATGGGAGTTGCCTGGCCTC CAGAAAGACCTCTTTTAT  
AGAGACCTCTTTCATAACTAATGGGAGTTGCCTGGCCTC CAGAAAGACCTCTTTTAT  
 
GATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGTGGAGTT  
GATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGTGGAGTT  
 
CAAGACCATGAATGCAAAGCTTCTGATGGATCCTAAGAAGCAGATCTTTCTAGATCA  
CAAGACCATGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTCTAGATCA  
 
AAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGA 
AAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGA  
 
CTGTGCCACAAAAATCCTCCCTTGAAGAACCGGATTTTTATAAAACTAAAATCAAGC  
CTGTGCCACAAAAATCCTCCCTTGAAGAACCGGATTTTTATAAAACTAAAATCAAGC  
 
TCTGCATACTTCTTCATGCTTTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAG  
TCTGCATACTTCTTCATGCTTTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAG 
 
CTATCTGAATGCT TCCT AA 
CTATCTGAATGCT TCCT AA 
 
Figure 3.12 Comparison of Nucleotide sequence of p35 from cloning and gene 
bank. 
 
The  upper  sequence  was  obtained  from  cloning,  and  the  lower  sequence  was 
from genebank. The highlighted point indicates the silent mutation.  
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PCR amplification, using the pSec- EBI3-linker-p35-Fc as a template, resulted in 
a 2270 bp PCR fragment containing the cDNA encoding EBI3, p35 and the hinge 
IgG Fc with the Bgl II site insertion on both ends (Figure 3.13 A). This PCR 
product  was  cloned  into  the  PEE14.4  GS  vector  via  the  Bgl  II  site  in  the 
polylinker  (Figure  3.13  B).  The  reading  frame  of  EBI3-p35-Fc  was  sent  for 
sequenceing to confirm the correct identity. Also, the sequence identity of the 
cloned product was confirmed by restriction enzyme mapping (Figure 3.13 C, D).  
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            A.                            B.                               C.                             D. 
                                    
 
 
 
 
 
 
Figure 3.13 Cloning of human EBI3-L-p35-Fc cDNA into pEE14.4 vector. 
 
PCR  was  performed  on  the  pSec-EBI3-L-p35-Fc  construct  to  obtain  a  PCR 
fragment encoding EBI3-Linker-p35-Fc, with a Bgl II site inserted at both ends 
of the fragment (A). This 2270bp PCR fragment was cloned into pEE14.4 vector 
(B). The enzyme digest was to confirm the correct insertion. Hind III digestion of 
the pEE14.4 vector construct confirmed the presence of an 1110 bp fragment (C).  
BamH I digestion of this construct resulted in two fragments: 642 bp and 1607 bp 
(D). (The ladder used is 1kb+ DNA ladder). 
 
 
 
 
 
 
 
2270bp- 2270bp-
1110bp- 1607bp-
642bp-
M                              M                              M                     M           134 
3.2.3 Expression of human IL-35-Fc in CHO-K1 cells 
 
The PEE14.4 vector carrying the cDNA insert encoding EBI3-linker-p35-Fc was 
transfected  into  CHO-K1  cells,  and  the  expressing  colonies  were  detected  by 
hIgG Fc ELISA. With the gradually increasing concentration of MSX from 50 
mM  to  500  mM,  the  highest  stable  expressing  colonies  were  selected  out  and 
analyzed by hIgG Fc ELISA (3.14 A)，and confirmed by IL-12 p35/ IgG Fc 
ELISA (3.14 B) which is described in material and method. Then, a large-scale 
of  cell  colonies  with  the  highest  protein  expression  were  cultured,  and  the 
supernatants  were  harvested.  Using  Protein  A  affinity  purification,  the 
recombinant fusion proteins of human IL-35-Fc were purified. The purity of the 
recombinant proteins were analysed by SDS-PAGE (Figure 3.15) and detected by 
western blot with anti-human IgG (Figure 3.16) 
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A.                                                                 B. 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.14 The levels of recombinant human IL-35-Fc protein expression.  
 
Two highest stable expressing colonies were selected out, cultured in 24 well 
plates for 48 hours,  and the supernatants were harvested, analyzed by hIgG Fc 
ELISA ( A)，and confirmed by IL-12 p35/ IgG Fc ELISA (B). 
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                                              20 mg   10 mg   5 mg   2.5 mg 
 
80 kd- 
 
 
Figure 3.15 SDS-PAGE analysis of purified recombinant protein human IL-35-
Fc. 
 
Various amounts of purified recombinant protein human IL-35-Fc were run on 
SDS-PAGE, and stained with Coomassie blue to demonstrate their purities. The 
molecular weight was the same as it was designed. (The marker used is SeeBlue 
Plus2 protein marker).  
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Figure 3.16 Western blot analyses of purified recombinant protein human IL-35-
Fc.  
 
The purified recombinant protein human IL-35-Fc was demonstrated in western 
blot by anti-hIgG. 
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3.3 Summary 
 
The murine cDNA encoding IL-27-FC, IL-35-Fc, IL-12-Fc and IL-23-Fc were 
constructed from pSecTag2A vector to PEE14.4-1 GS vector, and expressed in 
GS  system.  Using  elevated  levels  of  MSX,  GS  vector  copy  numbers  were 
amplified multiple numbers, which resulted in a 10 times higher production of 
recombinant proteins than the previous vector pSecTag2A. Also, the recombinant 
proteins retained the expected bioactivities.  
 
The human cDNA fragments encoding EBI3 and p35 were cloned from human 
DC by RT-PCR. The cloned cDNA EBI3 and p35 have been joined together by a 
flexible linker, and linked to the cDNA fragment encoding human IgG Fc. The 
resulting  cDNA  construct  was  cloned  into  PEE14.4-1GS  vector  and  used  to 
express human IL-35-Fc in CHO cells. The recombinant protein has a molecular 
weight of 80 kd and could be detected by antibody against human IgG, and the 
purity could be found in SDS-PAGE coomassie blue staining. 
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Chapter 4 
IL-27 and Collagen-induced arthritis 
(Some of results in this chapter already have been in publication as shown in 
Appendix 1)  
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4.1 Introduction 
 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized 
by  chronic  inflammation  of  the  synovial  tissues  in  multiple  joints  and  by 
subsequent progressive destruction of articular joints (Firestein & Zvaifler, 1991; 
Kouskoff, et al., 1996). Although it has been well described that synoviocytes, 
macrophages,  DCs,  and  B  cells  contributed  to  RA,  the  prominent  T  cells 
infiltration suggested that RA is a T cell mediated disease (Van Boxel & Paget 
1975;  Yocum  1999).  During  the  previous  decade,  RA  was  considered  as  a 
systemic Th1-driven disease with a relative predominance of IFN-g production 
and  a  lack  of  Th2  cytokines  (Miltenburg  et  al.,  1992;  Dolhain  et  al.,  1996; 
Feldmann et al., 1996). However, recent studies demonstrated that Th17 cells 
played a predominant pathogenic role in RA (Lubberts et al., 2005, Chu et al., 
2006). CD4
+ T cell- produced IL-17 promotes inflammation through enhancing 
the expression of TNF-a and IL-1b by monocytes. IL-17 has a synergistic effect 
on TNF-a inducing IL-1, IL-6, and IL-8 in the skin and synovial fibroblasts. IL-
17 also enhances the IL-1-induced synthesis of IL-6 and LIF by RA synoviocytes 
(Jovanovic et al., 1998, Katz et al., 2001). Furthermore, IL-17 has a direct role in 
joint inflammation, cartilage damage, and bone erosion (Lubberts et al., 2001, 
Cai  et  al.,  2001).  It  has  been  demonstrated  that  IL-17  neutralization  could 
suppress  arthritis  in  several  experimental  animal  models  (Nakae  et  al.,  2003, 
Lubberts et al., 2005).   
 
Although  the  etiology  and  pathogenesis  of  RA  has  not  been  completely 
elucidated, neutralizing Abs against the inflammatory components, particularly 
TNF-a,  IL-1,  and  IL-6  have  been  shown  to  successfully  suppress  joint   141 
inflammation,  reduce  the  relapse  rate  and  delay  disease  onset  in  RA  patients 
(Kagari et al., 2002). Therefore, the expression and regulation of cytokines that 
are  produced  during  the  disease  progression  have  been  the  major  interest  in 
therapeutic studies. 
 
To understand the immune mediated events in RA, various disease models have 
been established. Collagen induced arthritis (CIA) is one of the well-developed 
models and closely resembles the features of human RA (Trentham et al., 1977). 
The progression of CIA is relatively dependent on both cellular and humoral 
immune response to collagen type II (CII), and various cytokines are involved in 
the pathogenesis of the disease development (Feldmann et al., 1996).   
 
The heterodimeric cytokine IL-27，a member of the IL-12 family, is comprised 
of an IL-12p40 related protein, EBI3 and a unique IL-12p35 like protein p28 
(Pflanz et al., 2002). Currently, the role of IL-27 in the regulation of immune 
responses  is  quite  controversial.  Some  studies  have  demonstrated  that  IL-27 
promotes naive T cells proliferation and initiates Th1 immune responses (Pflanz 
et al., 2002; Chen et al., 2000). However, other studies have shown that IL-27 
suppresses the expansion of effector and memory T cells and inhibits several 
different  cytokines  including  IL-2,  IL-4,  IFN-g  and  IL-17  suggesting  anti-
inflammatory functions of IL-27 (Artis et al., 2004; Batten et al., 2006; Villarino 
et al., 2006). The dual role of IL-27 in vitro has also been demonstrated on in 
vivo  infectious  and  autoimmune  inflammatory  models.  IL-27  neutralization 
suppressed inflammation in rodent adjuvant arthritis (Goldberg et al., 2004). In 
contrast,  IL-27R  knockout  mice  displayed  enhance  CNS  inflammation  when   142 
infected with Toxoplasma gondii, or are hypersusceptible to EAE (Batten et al., 
2006,  Stumhofer  et  al.,  2006).  However,  at  the  present  moment,  our 
understanding of the role of IL-27 in RA is limited. It was therefore the objective 
of this chapter to explore the role of IL-27 in RA.  
 
In this study, we found that IL-27 was able to attenuate CIA when administrated 
at the onset of disease. Reduced disease development was associated with down 
regulation  of  IL-17  and  IL-6  productions.  In  contrast,  when  IL-27  was 
administered  late  in  disease  development,  it  exacerbated  disease  progression. 
Disease exacerbation was accompanied by elevated IFN-γ and IL-6 production. 
Consistent with this, we observed that in vitro IL-27 was able to inhibit Th17 
differentiation  from  naïve  CD4
+  T  cells,  but  had  little  or  no  effect  on  IL-17 
production by polarised Th17 cells. 
 
4.2 Results 
 
4.2.1 Administration of IL-27 prevents the development of CIA at the early 
stage of disease 
 
Since the immunopathogensis of CIA closely resembles RA, the effect of IL-27 
administration  on CIA  in  susceptible  male  DBA/I  mice  was  monitored.  Mice 
immunized  by  intradermal  injection  of  type  II  collagen  in  Freund’s  complete 
adjuvant began to show clinical sign of arthritis after challenge i.p. with collagen 
II on day 21. Mice were given 10 daily i.p. injections of IL-27 (2 mg/dose), IL-23 
(2 mg/dose) or PBS starting on day 21 (Figure 4.1). As expected, IL-23 group and 
PBS control group developed severe arthritis. In contrast, mice treated with IL-27 
developed significantly attenuated disease in the mean number of arthritic paws   143 
(Figure 4.2A) and mean clinical score (Figure 4.2B). Also, mice treated with IL-
27 had much reduced incidence of developing arthritic diseases compared to PBS 
control goup and IL-23 treated mice group (Figure 4.2C). Mean paw thickness of 
mice treated with IL-27 was lower compared to PBS control group (Figure 4.2D). 
In contrast, IL-23 treated mice developed significant higher mean paw thickness 
compared to PBS control mice and IL-27 treated mice (Figure 4.2D). To examine 
whether IL-27 administration modified articular destruction, cartilage and bone 
integrity were evaluated histologically. Histology examination of the hind limb 
joints from IL-23 and PBS control treated mice revealed massive cell infiltration 
of  the  joint  compartment  with  synovial  hyperplasia  and  bone  erosion  (Figure 
4.3A, Figure 4.3B). Administration of IL-27 markedly suppressed each of these 
parameters (Figure 4.3 C). The histological scores were summarized in Figure 
4.3D. Together these data clearly indicated that IL-27 potently suppressed the 
development of CIA. 
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B. 
 
Normal paws                   Arthritic paws     
Figure 4.1 The schedule of Collagen-induced arthritis.  
DBA/1 mice were primed intraermally with 100 mg of bovine collagen type II 
(CII)  in  complete  Freund’s  adjuvant  (CFA)  at  the  base  of  tail  on  day  0,  and 
boosted intraperitoneally with 100 mg of CII in PBS on day 21. 10 times of 200 
ml PBS, 2 mg/ 200 ml of IL-27, 2 mg/ 200 ml of IL-23 were given i.p. starting on 
day 21 (A). The mice were observed for clinical sign of arthritis (B), and the 
footpads were measured by callipers every other day. Mice were culled on day 
33. 
Day 0                                   Day 21                   Day 33
Prime                                Boost                       Cull
Intradermal Intraperitoneal
CII + CFA                       CII in PBS
Day   21  22   23  24  25  26  27  28  29  30 
IP  injection
1.PBS
2. IL-27 2 m m m mg/mouse/time
3. IL-23 2 m m m mg/mouse/time - m m m m
Day 0                                   Day 21                   Day 33
Prime                                Boost                       Cull
Intradermal Intraperitoneal
CII + CFA                       CII in PBS
Day   21  22   23  24  25  26  27  28  29  30 
IP  injection
1.PBS
2. IL-27 2 m m m mg/mouse/time
3. IL-23 2 m m m mg/mouse/time - m m m m  145 
 
A.                                                                          B.    
 
 
 
 
 
 
C.                                                                          D.  
 
 
 
 
 
 
 
Figure 4.2 IL-27 inhibited the development of CIA.  
Collagen-primed  DBA/I  mice  were  randomly  divided  into  groups  of  10, 
challenged on day 21, and given 10 daily i.p. injections of 2 mg/200 ml of IL-27, 
2 mg /200 ml of IL-23, or 200 ml of PBS starting on day 21. Mice were monitored 
for disease progression as indicated by (A) Mean number of arthritic paws, (B) 
Mean clinical score, (C) incidence, and (D) Mean Paw Thickness (mm). Values 
are  mean  ±  SEM.*,  p<  0.05.  IL-27  treated  mice  developed  significantly  less 
severe disease compared with IL-23 treated mice and control PBS group.  
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Figure 4.3 Administration of IL-27 significantly reduced joint pathology.  
On day 33, mice were administrated with 10 times of IL-27, IL-23, or PBS were 
culled.  Hind limbs (five mice /group) were removed, formalin-fixed, decalcified, 
and  stained  with  H&E.  Profound  cartilage  and  bone  erosion,  hyperplasia  and 
cellular infiltration were observed in the control PBS group (A) and IL-23-treated 
mice  goup  (B).  IL-27-treated  mice  exhibited  reduced  histological  evidence  of 
destruction (C). Histological appearances were scored (0-3) for the presence of 
bone erosion, synovial hyperplasia, and cellular infiltration (D). Data are mean ± 
SEM.*, p< 0.05, compared to PBS control group, and original magnification (A, 
B, and C) is x 50.    147 
4.2.2  Serum cytokines in vivo 
 
To  gain  insight  into  the  mechanism  of  how  IL-27  could  suppress  articular 
inflammation, serum samples in the arthritic mice were taken on day 33 when 
they were culled, and serum cytokines were analyzed by multiple bead assay-10 
plex  luminex  or  ELISA.  Since  the  role  of  IL-23  in  CIA  has  been  published 
(Murphy et al., 2003), the following studies were focused on the mice treated 
with IL-27 comparing with control mice treated with PBS. Although IL-1b, IL-4, 
IL-5, and GM-CSF were undetectable in serum from both PBS treatment group 
and IL-27 treatment group, TNF-a, IL-10, IL-2 and IFN-g levels were similarly 
low  in  both  groups  (Figure  4.4.A).  There  was  no  difference  in  IL-12  level 
between  PBS  treatment  group  and  IL-27  treatment  group  (Figure  4.4  A); 
however, IL-6 (Figure 4.4 B) and IL-17 (Figure 4.4 C) levels were significantly 
reduced in the mice treated with IL-27 when compared with mice treated with 
PBS. Interestingly, sera from mice treated with IL-27 contained slightly higher 
IL-1Ra than those from control mice (Figure 4.4 A). 
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A. 
 
 
 
 
 
B.                                    C.      
 
 
 
 
 
 
Figure 4.4 Serum cytokines levels of IL-27 and PBS treated mice. 
  
DBA/1 mice treated with either IL-27 or PBS control mice were sacrificed on 
day 33 and serum was collected from seven mice in each group. Levels of TNF-
a,  IL-10,  IL-2,  IFN-g,  IL-12,  IL-1Ra  (A),  IL-6  (B),  and  IL-17  (C)  were 
determined  by  ELISA  of  individual  samples.  Data  are  mean  ±  SEM. 
representative of 2 experiments. There was no significant difference in TNF-a, 
IL-10, IL-2, IFN-g, IL-12, and IL-1Ra between two groups, but IL-6 and IL-17 
were  significantly  reduced  in  the  IL-27-treated  mice.  Each  dot  represents  an 
individual mouse, and representative of 2 experiments; *, p< 0.05, **, p< 0.01 
compared to PBS control group. 
0
200
400
600
TNF-a IL-10 IL-2 IFN-g IL-12 IL-1Ra
p
g
/
m
l
PBS
IL-27
0
200
400
600
TNF-a IL-10 IL-2 IFN-g IL-12 IL-1Ra
p
g
/
m
l
PBS
IL-27
0
100
200
300
400
I
L
-
1
7
 
(
p
g
/
m
l
)
PBS IL-27
0
100
200
300
400
I
L
-
1
7
 
(
p
g
/
m
l
)
PBS IL-27
*
0
50
100
150
200
PBS IL-27
I
L
-
6
 
(
p
g
/
m
l
)
**
0
50
100
150
200
PBS IL-27
I
L
-
6
 
(
p
g
/
m
l
)
**  149 
4.2.3  IL-27 treated mice showed reduced anti-collagen Ab production 
 
Because Ab levels against Collagen II correlate well with the development of 
arthritis, CII specific antibodies IgG1 and IgG2a levels were measured by ELISA 
(Figure 4.5). Collagen-specific IgG2a levels in sera from the mice receiving IL-
27  were  significantly  lower  than  control  mice,  but  IgG1  antibody  was  not 
different between two groups.  
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A.                                                                    B.   
 
 
 
 
 
 
 
Figure 4.5 Assessment of serum anti-collagen Ab responses in IL-27 and PBS 
treated mice.  
 
At the end of treatment with IL-27 or PBS, serums were collected on day 33 and 
collagen specific antibodies IgG1 (A) and IgG2a (B) in serum were determined 
by ELISA. IL-27-treated mice produced significantly lower IgG2a but not IgG1 
antibody.  Serum  samples  were  diluted  4000-fold.  Each  dot  represents  an 
individual mouse, and data are expressed as mean absorbance (OD 630). n=7 and 
are representative of 2 experiments; **, p< 0.01, compared to PBS control group. 
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4.2.4  IL-27 suppresses CII-specific proinflammatory immune response ex 
vivo  
 
To  further  explore  the  effect  of  IL-27  mediated  suppression  during  CIA 
development, CIA was induced in mice and the administration of PBS or IL-27 
was exactly the same as previously described in Figure 4.1. However, mice were 
culled  at  two  different  time  points  (as  shown  in  Figure  4.6)  to  examine  CII-
specific T cell immune responses.  
 
Spleen cells from mice that had been treated with IL-27 or control PBS were 
harvested after 6 times of treatment (day 27) and they were cultured with type II 
collagen in vitro. Cells from the IL-27 treated mice produced significantly less 
IL-17  (Figure  4.7)  compared  with  parallel  cultures  from  control  PBS  group, 
which indicated a suppression of Th-17 response. However, T cell proliferation, 
IL-6, TNF-a, IFN-g, and IL-1Ra production remained similar between the two 
groups (Figure 4.7).  
 
The above observations from the first time point (day 27) were supported by the 
second time point, in which inguinal lymph nodes and spleen cells from mice that 
had  been  treated  with  IL-27  or  control  PBS  were  harvested  after  10  times 
treatment (day 33). Inguinal lymph nodes and spleen cells were stimulated with 
PMA and ionomycin and analysed by intracellular staining. Control mice induced 
higher proportion of IL-17 and IFN-g -producing spleen cells and lymph nodes 
cells compared with IL-27 treated mice (Figure 4.8). The remaining spleen cells 
were cultured with type II collagen in vitro. Cells from the IL-27 treated mice   152 
produced significantly less IL-17 than cells from control PBS group (Figure 4.9), 
while  other  cytokines  production  showed  no  difference  between  two  groups 
(Figure 4.9). Furthermore, the T cell mitogen,  ConA, stimulated equally  high 
levels of IL-17, IL-6, TNF-a, and IFN-g by spleen cells from both groups of 
mice, indicating that IL-17 suppression of the immune response was Ag-specific 
(Figure 4.10). 
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Figure 4.6 The schedule of Collagen-induced arthritis.  
DBA/1 mice were primed intraermally with 100 mg of bovine collagen type II 
(CII)  in  complete  Freund’s  adjuvant  (CFA)  at  the  base  of  tail  on  day  0,  and 
boosted intraperitoneally with 100 mg of CII in PBS on day 21. 10 times of 200 
ml PBS, 2 mg/ 200 ml of IL-27 were given i.p. starting on day 21. The mice were 
observed  for  clinical  sign  of  arthritis,  and  the  footpads  were  measured  by 
callipers every other day. Mice were culled at two time points on day 27 and day 
33. 
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Figure 4.7 Assessment of in vitro responses against collagen from mice treated 
with IL-27 or PBS. 
Spleen cells (pooled from 4 mice per group) were collected from IL-27 treated or 
PBS treated mice after 6 times of injections (day 27) and cultured with titrated 
concentrations of collagen for 96 h. T cell proliferation (A) was determined by 
[
3H] thymidine uptake. Supernatants from parallel cultures were collected after 
72 h. IL-17, IL-6, TNF-a, IL-1Ra, and IFN-g levels were measure by ELISA. 
There was no significant difference in T cell proliferation, IL-6, TNF-a, IL-1Ra, 
and IFN-g concentrations between two groups, but cells from the IL-27- treated 
mice produced significantly less IL-17. Data are expressed as mean ± SEM of 
triplicate cultures. **, p< 0.01, compared to PBS control group. 
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Figure 4.8 Intracelluar cytokine analysis of IFN-g and IL-17 secretion.  
 
Spleen cells and LN cells were harvested (n=6) from mice treated with IL-27 or 
PBS on day 33, stimulated with PMA and ionomycin and stained intracellularly 
for IL-17 and INF-g. The percent of IL-17
+ and IFN-g
+ cells were reduced by IL-
27 treatment. The number in quadrants represent the percentage of IL-17- or IFN-
g expressing cells.  
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Figure 4.9 Assessment of in vitro responses against collagen from mice treated 
with IL-27 or PBS. 
 
 Spleen cells (pooled from 6 mice per group) were collected from IL-27 treated 
or PBS treated mice after 10 times injections (day 33) and cultured with collagen 
as described before. Supernatants from parallel cultures were collected after 72 h. 
IL-17, IL-6, TNF-a, IL-1Ra, and IFN-g levels were measure by ELISA. Cells 
from the IL-27- treated mice produced significantly less IL-17, but there was no 
significant difference in IL-6, TNF-a, IL-1Ra, and IFN-g concentrations between 
two groups. Data are expressed as mean ± SEM and pooled of triplicate cultures. 
*, p< 0.05, compared to PBS control group. 
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Figure 4.10 Stimulation of spleen cells with ConA from IL-27 treated or PBS 
treated mice.  
 
Spleen cells (pooled from 6 mice per group) from IL-27 treated mice or PBS 
treated mice were cultured with  con A (1mg/ml) for 96 h. Supernatants from 
cultures were collected, and IL-17, IL-6, TNF-a, and IFN-g levels were measure 
by ELISA. Equally high levels of  IL-17,  IL-6, TNF-a, and  IFN-g  production 
were produced between two groups. Data are expressed as mean ± SEM. There is 
no statistical difference between PBS control mice and IL-27 treated mice. 
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4.2.5 Administration of IL-27 at the later stage of CIA enhances the disease 
expression 
 
To determine the role of IL-27 during joint inflammation and tissue destruction at 
a later stage of CIA, administration of IL-27 was started on day 27 after CII 
immunization. On day 27, about 50% of CIA mice paws began to show clinical 
sign of arthritis. Mice were injected i.p. daily with IL-27 (2 mg/dose) or PBS 
from days 27 to 36, for a total of ten administrations. Surprisingly, mice treated 
with  IL-27  developed  significantly  more  severe  diseases  in  the  mean  paw 
thickness compared to PBS control CIA mice (Figure 4.11A). However, there 
was no difference in the mean number of arthritic paws; arthritic incidence and 
mean  clinical  score  (Figure  4.11  B  C).  Similarly,  there  was  no  difference  in 
serum  cytokines  between  PBS  and  IL-27  treated  group  (Figure  4.12).  This 
observation was also reflected in immune responses in vitro (Figure 4.13). Spleen 
cells from IL-27 recipients produced slightly higher concentrations of IL-6 and 
IFN-g, and slightly lower concentrations of TNF-a  and  IL-17,  in response to 
collagen  compared  to  spleen  cells  from  control  group,  while  there  is  no 
significant difference between the two groups. 
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A.                                                                  B.  
 
 
 
 
 
 
C.                                                                         D. 
                                                                              
 
 
 
 
 
 
Figure 4.11 IL-27 enhanced the development of CIA at the later stage.  
 
Collagen-primed  DBA/1  mice  were  randomly  divided  into  groups  of  10, 
challenged on day 21, and given 10 daily i.p. injections of 2 mg/200 ml of IL-27, 
or  200  ml  of  PBS  starting  on  day  27.  Mice  were  monitored  for  disease 
progression as indicated by (A) Mean paw thickness, and (B) Mean Number of 
Arthritic Paws, (C) incidence and (D) Mean Clinical Score. Values are mean ± 
SEM.*, p< 0.05. IL-27 treated mice developed more severe disease compared to 
control PBS group. 
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Figure 4.12 Serum cytokine levels of IL-27 and PBS treated mice. 
 
DBA/1 mice treated with either IL-27 or PBS control mice (n=5 in each group) 
were sacrificed on day 36 and serum was collected. Levels of IL-6 and IL-17 
were determined by ELISA of individual samples. There was no difference in 
serum  cytokines  between  two  groups.  Data  are  mean  ±  SEM.  There  is  no 
statistical difference between two groups. 
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Figure 4.13 Assessment of in vitro responses against collagen from mice treated 
with IL-27 or PBS.  
 
Spleen cells (pooled from 5 mice per group) were collected from IL-27 treated or 
PBS treated mice after 10 times injections (day 36) and cultured with collagen as 
described  before.  T  cell  proliferation  (A),  which  was  determined  by  [3H] 
thymidine uptake, is expressed as mean stimulation index ± SEM of triplicate 
cultures. Supernatants from parallel cultures were collected after 72 h. IL-17, IL-
6, TNF-a, and IFN-g levels were measure by ELISA and expressed as mean ± 
SEM. There were no significant differences in cell proliferations, IL-17, IL-6, 
TNF-a, and IFN-g concentrations between two groups. 
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4.2.6 IL-27 suppresses the development of Th17 cells 
 
Because of the critical importance of IL-17 in the pathogenesis of CIA, and the 
above data suggested that IL-27 down-regulated IL-17 in vivo, it is important to 
determine the direct effect of IL-27 in the Th-17 cell differentiation pathway in 
vitro. When CD4
+ T cells isolated from the spleens of wild-type DBA/1 mice 
were activated with immobilized anti-CD3 plus anti-CD28, moderate amount of 
IL-17 were produced; and the addition of IL-27 inhibited the production of IL-17 
(Figure 4.14 A). Also, according to Figure 4.14A, it was found that 25 ng/ml of 
IL-27 was the optimal concentration to inhibit IL-17 production. Therefore, the 
following  experiments  were  done  using  25  ng/ml  of  IL-27.  According  to  the 
published reports (Veldhoen et al., 2006, Mangan et al., 2006), the efficiency of 
in vitro IL-17 production requires the combination of TGF-b, IL-1b and IL-6. 
When the cell culture medium was supplemented with TGF-b, IL-1b and IL-6, 
robust secretion of IL-17 occurred, but IL-27 still efficiently suppressed IL-17 
production  (Figure  4.14  B).  Furthermore,  to  exclude  artificially  skewed 
development towards Th1 or Th2 helper lineage, the neutralizing antibodies anti-
IL-4, anti-IFN-g, and anti-IL-2 were added to the above cell culture, high amount 
of IL-17 was produced. The presence of IL-27 still efficiently suppresses Th17 
cells differentiation (Figure 4.14 C).  
 
Similar results were obtained with CD4
+ T cells isolated from BALB/c mice. 
CD4
+ T cells from BALB/c mice, labelled with CFSE, were cultured with APC, 
anti-CD3, and the combination of TGF-b, IL-1b and IL-6. In the presence of IL-
27, CD4
+ T cells stained much less positive for IL-17 compared with the CD4
+ T 
cells  without  the  presence  of  IL-27  (Figure  4.15  Aa).  This  reduction  was   163 
supported  by  the  paralleled  ELISA  results  (Figure  4.15  Ab).  This  generally 
confirmed those results in the published reports (Stumhofer et al., 2006). IL-27 
can trigger signalling in a variety of cell types, therefore, the experiments were 
repeated using CD4
+CD25
+ T cells and CD4
+CD25
- T cell from BALB/c mice, 
treatment with IL-27 markedly reduced Th17 cells development (Figure 4.15 B, 
C). Meanwhile, IL-27 had no effect on T cell proliferation (Figure Figure 4.15 
Aa) or the percent of Foxp3
+ Treg cells (Figure 4.15 Ca). 
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                A                                            B                                                 C 
 
 
 
 
 
 
 
Figure 4.14 IL-27 suppression of IL-17 production by CD4
+ T cells.  
 
CD4
+ T cells from DBA/I mice were stimulated with plate-bound anti-CD3 Ab 
plus soluble anti-CD28 Ab in the presence of graded concentrations of IL-27 for 
3 days, and then the culture supernatants were analyzed for IL-17 by ELISA (A). 
CD4
+ T cells from DBA/I mice were stimulated with plate-bound anti-CD3 Ab 
plus  soluble  anti-CD28  Ab,  and  TGF-b,  IL-1b  and  IL-6,  in  the  absence  or 
presence of IL-27 (25 ng/ml) for 3 days, and then the culture supernatants were 
analyzed  for  IL-17  by  ELISA  (B).  CD4
+  T  cells  from  DBA/I  mice  were 
stimulated with plate-bound anti-CD3 Ab plus soluble anti-CD28 Ab, and TGF-
b, IL-1b, IL-6, anti- IL-4, anti- IFN-g, and anti-IL-2, in the absence or presence 
of IL-27 (25 ng/ml) for 3 days, and then the culture supernatants were analyzed 
for IL-17 by ELISA (C). IL-27 efficiently suppresses Th-17 cells differentiation 
in all A, B and C conditions. Data are expressed as mean ± SEM, representative 
of 3 experiments, *, p< 0.05 compared to control. 
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Figure 4.15 IL-27 mediated the inhibition of Th-17 development. 
CD4
+  T  cells  (A),  CD4
+CD25
+  T  cells  (B)  and  CD4
+CD25
-  T  cell  (C)  were 
isolated from BALB/c mice, and the CD4
+ T cells were labeled with CFSE, then 
the three groups of cells respectively were activated with APC, anti-CD3, and 
TGF-b, IL-1b and IL-6, in the absence or presence of IL-27 (25 ng/ml) for 3 
days. After that, the cells, respectively, were stimulated with 4 h with PMA and 
ionomycin, stained for intracellular IL-17 (Aa, Ba, Ca), or Foxp3 ( Ba, Ca) and 
analyzed on flow cytometry. The parallel culture supernatants were analyzed for 
IL-17  by  ELISA  (Ab,  Bb,  and  Cb).  IL-27  had  no  effect  on  cell  proliferation 
(CFSE) or Foxp3 expression but significantly reduced the expression of IL-17. 
Data are representative of three independent experiments. Plots are gated on T 
cells; numbers in quadrants indicate the frequency of cells each. ELISA data are 
expressed as mean ± SEM, *, p< 0.05 compared to control group.   166 
4.2.7 IL-27 does not suppress IL-17 production on established Th-17 cells 
 
Those above data presented has demonstrated that IL-27 negatively regulates Th-
17  cell  development.  It  is  also  important  to  examine  the  effect  of  IL-27  on 
established  Th-17  producing  cells.  CD4
+  T  cells  isolated  from  BALB/c  mice 
were cultured with APC, anti-CD3, the combination of TGF-b, IL-1b and IL-6, 
and  the  neutralizing  antibodies  anti-IL-4,  anti-IFN-g  and  anti-IL-2.  Under  the 
optimal Th-17 inducing condition, naïve CD4
+ T cells were polarized to Th-17 
cells. After 4 days of cell culture, cells were washed and re-stimulated with APC 
and anti-CD3, in the presence of IL-23 which is an important factor to maintain 
established Th-17 cells. The established Th-17 cells produced high amount of IL-
17
+ cells, but the addition of IL-27 showed no suppressive effect on IL-17
+ cells 
(Figure 4.16A). It was further confirmed by the parallel ELISA result (Figure 
4.16B).  Similar  results  were  also  observed  on  CD4
+CD25
+  T  cells  and 
CD4
+CD25
- T cell by ELISA (Figure 4.16C, D). 
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B.                                              C.                                       D. 
 
 
 
 
 
Figure 4.16 IL-27 does not suppress IL-17 production on established Th17 cells.  
CD4
+ T cells, CD4
+CD25
+ T cells and CD4
+CD25
- T cell isolated from BAB/c 
mice  were  respectively  cultured  for  4  days  under  the  optimal  Th17  inducing 
condition, washed and restimulated with APC, anti-CD3 and IL-23, in the graded 
concentrations of IL-27 for 3 days. The re-stimulated Th17 cells generated from 
CD4
+ T cells were analyzed for intracellular IL-17 staining by flow cytometry 
(A). The established Th17 cells produced high amount of IL-17
+ cells, but IL-27 
showed  no  suppressive  effect  on  IL-17
+  cells.  The  culture  supernatants  from 
restimulated Th17 cells generated from CD4
+ T cells, CD4
+CD25
+ T cells and 
CD4
+CD25
- T cell, respectively were analyzed for IL-17 production by ELISA 
(B, C, and D). Again, IL-27 showed no effect on IL-17 production. Data are 
representative  of  three  independent  experiments.  Plots  are  gated  on  T  cells; 
numbers  in  quadrants  indicate  the  frequency  of  cells  each.  ELISA  data  are 
expressed as mean ± SEM, and there is no statistical significance among them. 
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4.3 Conclusion and discussion 
 
The data presented in this chapter demonstrate that IL-27 can play a dual role in 
murine  model  of  CIA.  The  administration  of  IL-27  at  the  onset  of  CIA 
dramatically attenuated disease severity, but the administration of IL-27 at the 
later stage of CIA did not inhibit the disease development, but even exacerbated 
the disease severity. 
 
A  short  term  administration  of  IL-27  at  the  onset  of  the  disease  markedly 
suppressed  the  disease  development  compared  with  untreated  PBS  controls 
(Figure  4.2).  Histological  examination  revealed  that  while  untreated  mice 
developed severe cellular infiltration in the joints, synovial hyperplasia and joint 
erosion, this pathology was profoundly reduced in IL-27-treated animals (Figure 
4.3). Treatment of mice with IL-27 also decreased the amounts of serum IL-17, 
IL-6 and collagen-specific IgG2a (Figure 4.4B, 4.5). There were lower frequency 
of IFN-g
+ and IL-17
+ expressing cells from spleen and lymph nodes of the IL-27-
treated mice compared with the control mice (Figure 4.8). Also, the spleen and 
lymph node cells from the IL-27-treated mice produced less IL-17 compared with 
cells from the control mice when cultured with collagen in vitro (Figure 4.7, 4.9). 
These results indicated  that the effect of  IL-27-mediated inhibition of disease 
development  was  probably  mainly  due  to  the  inhibition  of  IL-17  production. 
Consistent with the in vivo finding, in vitro data presented that IL-27 markedly 
inhibited  the  differentiation  of  Th-17  from  naïve  CD4
+,  CD4
+CD25
-  and 
CD4
+CD25
+ three T cells populations under different Th-17 inducing conditions 
(Figure 4.14, 4.15). These results confirmed previous observations that IL-27 can 
suppress  the  development  of  Th-17,  thus  attenuating  the  development  of   169 
autoimmune inflammation, such as experimental autoimmune encephalomyelitis, 
chronic neuroinflammation, and human uveitis and scleritis (Yoshimura et al., 
2006; Batten et al., 2006; Stumhofer et al., 2006; Amadi-Obi et al., 2007). The 
mechanism  in  which  IL-27  inhibits  the  generation  of  Th17  has  been  mainly 
implicated through a STAT-1-dependent pathway (Batten et al., 2006; Stumhofer 
et al., 2006), and STAT-3 signalling has  also been considered to be partially 
involved (Yoshimura et al., 2006). However, it is unclear whether STAT-1 and 
STAT-3 signalling are involved in IL-27 inhibited the production of IL-17 in 
CIA here. Further investigations would elucidate the potential pathways involved 
in  the  regulatory  role  of  IL-27  on  Th-17  development  during  CIA  diseases 
process. 
 
Currently, the role of IL-27 in various models of inflammatory diseases is still 
controversial.  In  some  disease  models  IL-27  had  been  found  to  suppress  the 
inflammation as mentioned above, but in other disease models, IL-27 was found 
to exacerbate inflammation (Goldberg et al., 2004; 2004 (2)). This controversy 
was also shown in the results in this chapter. In contrast to the inhibitory role of 
IL-27 administrated at the early stage of CIA, IL-27 did not inhibit the disease 
development,  but  in  fact  exacerbated  the  disease  severity  when  administered 
during the late phase of CIA (Figure 4.11). There were no difference in serum IL-
17 and IL-17 synthesis by the lymphoid cells between IL-27-treated mice and 
control mice (Figure 4.12, 4.13). This indicated that Th-17 cells were not affected 
by the IL-27 at the later phase of CIA. This can probably be explained by the fact 
that  the  CIA  disease  already  progressed  and  Th17  cells  were  already 
differentiated one week after CII challenge. The data here showed that IL-27 had   170 
little or no effect on pre-polarised Th17 cells in vitro (Figure 4.16). Furthermore, 
at the advanced disease stage of CIA, the lymph node and spleen cells from the 
mice  with  the  administration  of  IL-27  produced  elevated  IFN-γ  and  IL-6 
production  when  cultured  with  collagen  in  vitro,  compared  to  the  cells  from 
untreated  mice.  The  elevated  pro-inflammatory  cytokines  IL-6  and  IFN-γ 
induced  by  Il-27  may  be  a  consequence  of  the  disease  exacerbation.  The 
inhibitory effect on IL-6 and IFN-g synthesis by IL-27 administrated at the early 
phase of CIA, and the accelerated effect on these cytokines synthesis when IL-27 
administrated at the later phase of CIA, demonstrated that IL-27 might have the 
opposite  effect  on  the  inflammatory  process  depending  on  the  timing  of 
administration.   
 
Together, these results demonstrated that IL-27 had both pro-inflammatory and 
anti-inflammatory effects. Any potential therapeutic use of IL-27 in modulating 
inflammatory diseases has to be approached with careful analysis. 
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Chapter 5 
The role of a novel cytokine IL-35 
(Some of results in this chapter already have been in publication as shown in 
Appendix 2)  
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5.1  Introduction 
 
Cytokines  play  pivotal  roles  in  the  regulation  of  immune  response  and 
inflammation.  Epstein-Barr  virus-induced  gene  3  (EBI3),  first  identified  in  B 
lymphoblastoid cell lines during EBV infection, encodes a 34-kDa glycoprotein 
with 27% amino acid identity to the IL-12 p40 subunit (Devergne, 1996). Both 
EBI3  and  p40  are  encoded  by  mRNAs  with  a  3’  untranslated  Alu  repeat 
sequence, lacking a membrane anchoring motif, and are predicted to be secreted 
(Devergne, 1996).  IL-12, composed of p40 and p35 subunits, was identified and 
purified from culture supernatant of EBV-transformed B cell lines and would be 
expected to be closely associated with EBI3 (Schoenhaut et al., 1992). IL-12 p35 
is ubiquitously expressed whereas IL-12 p40 expression is inducible (Schoenhaut 
et al., 1992). The dissociation between p35 and p40 gene regulation suggests that 
either subunit may be associated with other partners.  It has been known that p40 
associates with p19 to form IL-23 (Oppmann et al., 2000). Recently discovered 
IL-27 is made with EBI3 and p28 protein (Pflanz et al., 2002). The association of 
EBI3 with IL-12 p35 to form a heterodimeric hematopoietin was discovered by 
Devergne’s group in 1997, and this EBI3-p35 heterodimer may represent a novel 
cytokine of the IL-6 family which includes IL-12, IL-23 and IL-27. This novel 
heterodimeric cytokine EBI3-p35 has been officially designated interleukin-35 
(IL-35) in 2002 (Schrader, 2002).  
 
EBI3 is expressed at a high level in human B lymphoblast cells, tonsil and spleen 
(Devergne,  1996).  Notably  co-expression  of  EBI3  and  p35  facilitates  their 
secretion. They are not efficiently secreted when expressed alone. It has been 
demonstrated  that  p35  was  detected  in  the  entire  EBI3  positive  cell  types,   173 
especially in placental tissue throughout pregnancy and intestinal epithelial cells 
(Devergne, 2001; Masser, 2004). More importantly, a very recent paper found a 
high expression of EBI3 and IL-12p35 mRNA in mouse Foxp3
+ Treg cells, but 
not in resting or activated effector CD4
+ T cells (Collison et al., 2007).  
 
When the project was designed, there has no report to suggest that IL-35 had any 
biological  functions.  To  investigate  the  biological  effects  of  IL-35,  we 
constructed a soluble Fc fusion protein by flexibly linking the EBI3 chain to the 
p35 polypeptide, as described in the chapter 3. In this chapter, I will present data 
from the characterisation of this IL-35-Fc fusion protein in the murine model. 
 
5.2   Results 
 
5.2.1 IL-35 induces the proliferation of naïve CD4
+CD25
- T cells with plate-
bound anti-CD3 and soluble anti-CD28 stimulation 
 
Naïve  CD4
+CD25
-  T  cells  were  purified  from  spleen  and  lymph  nodes  of 
BALB/c mice, and the cells were stimulated with immobilized anti-CD3 for 4 
days, and IL-35 was titrated into the beginning culture. T cells proliferation was 
dose dependent in response to IL-35 (Figure 5.1). However, in the absence of 
CD3 activation, there was no cell proliferation observed. This indicated that IL-
35-induced  proliferation  was  dependent  on  CD3/TCR  stimulation.  In  similar 
experiments, naïve CD4
+CD25
- T cells were activated with immobilized anti-
CD3 and soluble anti-CD28 for 4 days, the graded concentrations of IL-35 or 
EBI3-Fc were added in the beginning of the culture. The proliferation of naïve 
CD4
+CD25
-  T  cells  driven  by  IL-35  was  profoundly  enhanced.  Thus,  IL-35-  174 
mediated  proliferation  was  improved  by  co-stimulatory  signal  through  CD28. 
(Figure 5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 IL-35 induces CD4
+CD25
- T cells proliferation under polyclonal TCR 
activation and costimulation. 
 
CD4
+CD25
-  T  cells  purified  from  spleen  and  lymph  nodes  of  BALB/c  were 
stimulated for 4 days in the medium alone, with plate-coated anti-CD3 alone, or 
plate-coated  anti-CD3  plus  soluble  anti-CD28,  in  the  presence  of  graded 
concentrations  of  IL-35  or  EBI3-Fc  (100ng/ml)  or  medium  alone.  Cell 
proliferation was determined by [
3H] thymidine uptake. Data are shown as mean 
± SEM. n=4, and are representative of at least three independent experiments. **, 
p< 0.01 compared to control. 
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5.2.2  IL-35 triggers naïve CD4
+CD25
- T cells to produce IFN-g, g, g, g, but not  
IL-4 
 
The structure of IL-35 is closely tied to Th1 cytokine family, IL-12 and IL-27. 
Therefore, it was of interest to investigate the effect of IL-35 in IFN-g synthesis. 
Naïve CD4
+CD25
- T cells isolated from BALB/c spleen and lymph nodes were 
stimulated for 4 days with plate-coated anti-CD3 alone or plate-coated anti-CD3 
plus soluble anti-CD28. IL-35 itself induced low levels of IFN-g production in 
anti-CD3  activated  assay.  With  costimulation  of  anti-CD28,  IL-35  alone  was 
capable of inducing significant amount of IFN-g (Figure 5.2A). EBI3-Fc had no 
effect on IFN-g synthesis. In contrast, IL-35 had little effect on IL-4 synthesis, 
and the slightly enhanced production of IL-4 compared to control was due to the 
higher proliferation from IL-35 cultured CD4
+CD25
- T cells (Figure 5.2B).Thus, 
IL-35 appeared to trigger naïve CD4
+CD25
- T cells to produce IFN-g, but not  
IL-4.  
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B. 
 
 
 
 
 
 
 
Figure 5.2 IL-35 induces CD4
+CD25
- T cells to produce IFN-g, but little IL-4. 
 
Purified  CD4
+CD25
-  T  cells  from  BALB/c  spleen  and  lymph  nodes  were 
stimulated for 4 days with plate-coated anti-CD3 alone or plate-coated anti-CD3 
plus soluble anti-CD28, in the presence of graded concentrations of IL-35, or 
EBI3-Fc (100ng/ml), or medium alone. IFN-g (A) and IL-4 (B) concentrations in 
the parallel culture supernatants were measured by ELISA. Data are shown as 
mean  ±  SEM.  n=4,  and  are  representative  of  at  least  three  independent 
experiments. *, p< 0.05 compared to control by student’s t test. 
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5.2.3 IL-35 induces the expression of T-bet  
 
Th1  differentiation  requires  the  expression  of  T-bet,  a  master  transcription 
regulator, by directly activating Th1 associated genetic process and repressing the 
production of Th2 cytokines (Hibbert et al., 2003). Therefore, these  activated 
CD4
+CD25
-  T  cells  from  the  above  costimulation  culture  conditions  were 
analysed  for  T-bet  expression  by  RT-PCR.  IL-35  greatly  enhanced  T-bet 
expression compared to control (Figure 5.3 A). As a comparison, the effect of IL-
35 on the expression of GATA-3, which is a master transcription factor for Th2 
development, was also examined. As shown in Figure 5.3B, GATA-3 mRNA 
expression was not affected, but even slightly repressed by IL-35.  
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A. 
 
 
 
 
B.  
 
 
 
 
 
 
Figure 5.3 IL-35 induces the expression of T-bet, but not GATA-3.  
 
Purified  CD4
+CD25
-  T  cells  from  BALB/c  mice  were  stimulated  with  plate-
bound anti-CD3 and soluble anti-CD28 in the graded concentrations of IL-35 or 
human Fc (100ng/ml).  After  culture  for 48 h,  total mRNA were isolated and 
analyzed by Taqman-PCR for the mRNA expression of transcription factors T-
bet  (A)  and  GATA-3  (B).  Data  are  represented  as  the  percentage  of  HPRT 
expression, n=4, and are representative of at least three independent experiments. 
*, p< 0.05 compared to control. 
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5.2.4 IL-35 induces expression of STAT-1 phosphorylation 
 
As is known that T-bet is induced early in T cell development by a STAT-1 
dependent mechanism (Hibbert et al., 2003), the next experiment was to check 
whether  IL-35  was  responsible  for  the  induction  of  STAT1.  Purified  naïve 
CD4
+CD25
- T cells were activated with plate-coated anti-CD3 plus soluble anti-
CD28 for 24 h, in the presence or absence of IL-35. As shown in the Figure 5.4, 
STAT1 was strongly phosphorylated in response to IL-35. This data indicated 
that IL-35 might exert its effect on the up-regulation of T-Bet expression through 
STAT-1 activation. 
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                                               Control  IL-35  
 
 
 
Figure 5.4 IL-35 induces the expression of STAT-1 phosphorylation. 
 
Purified naïve CD4
+CD25
- T cells from BALB/c mice were activated with plate-
coated anti-CD3 plus soluble anti-CD28 for 24 h, in the absence or presence of 
IL-35 (100ng/ml). The  cells were then washed and lysated. Total cell lysates 
were  prepared  and  subjected  to  Western  Blotting  with  antiphosphotyrosine 
antibodies. 
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5.2.5 IL-35 inhibits the proliferation of naïve CD4
+CD25
- T cells with APC 
and soluble anti-CD3 
 
The  next  studies  were  performed  to  determine  whether  IL-35  regulates  the 
proliferation of naïve T cells under different culture condition using mitomycin 
C- treated antigen-presenting cells (APCs) from spleen cells and soluble anti-
CD3 antibody. Upon encounter between mitomycin C- treated APC and soluble 
anti-CD3,  purified  CD4
+CD25
- T  cells  became  activated  and  proliferated  at  a 
similar level as when they were activated with plate bound anti-CD3 and anti-
CD28. It was surprising that IL-35 significantly suppressed the proliferation of 
CD4
+CD25
- T cells in a dose dependent manner (Figure 5.5 A).  
 
Furthermore, the supernatants were harvested and the cytokines were analysed. 
IFN-g (Figure 5.5 B) and IL-4 (Figure 5.5 C) production were markedly inhibited 
in the cell culture in the presence of IL-35 compared to the control culture with 
human IgGFc. These results therefore demonstrated that IL-35 is an inhibitory 
cytokine under more “physiological” conditions. 
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B.                                                                       C.   
 
     
 
 
 
             
 
Figure 5.5 IL-35 suppresses the proliferation of CD4
+CD25
- T cells and inhibited 
the cytokine productions of CD4
+CD25
- T cells. 
 
CD4
+CD25
- T cells were purified from spleen and lymph nodes of BALB/c mice 
and cultured for 4 days with mitomycin C- treated APCs and soluble anti-CD3 
antibody in the presence of graded concentrations of IL-35 or human Fc. IL-35 
markedly suppressed the proliferation (A), IFN-g (B) and IL-4 (C) production of 
CD4
+CD25
- T cells. Cell proliferation was determined by [
3H] thymidine uptake. 
Data  are  mean  ±  SEM.  n=4,  and  are  representative  of  three  independent 
experiments, *, p< 0.05, **, p< 0.01 compared to Fc control by student’s t test.  
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5.2.6 IL-35 expands CD4
+CD25
+ T cells with co-stimulation  
 
Regulatory T cells mediate significant protection against autoimmune diseases by 
suppressing the proliferation of auto-reactive T cells (Sakaguchi et al., 2004). To 
determine whether IL-35 have effects on Treg cell, CD4
+CD25
+ T cells were 
purified from spleen and lymph nodes of BALB/c mice and cultured in vitro with 
IL-35  in  the  presence  of  plate-bound  anti-CD3  for  3  days,  and  anti-CD28 
antibody plus IL-2 were added at 24 h interval after the start of the culture. Under 
these culture conditions, IL-35 markedly induced proliferation of CD4
+CD25
+ T 
cells  (Figure  5.6  A),  with  a  significant  elevated  level  of  IL-10  in  the  culture 
supernatants compared to Fc control (Figure 5.6 B).To further identify the effect 
of IL-35 on Treg cells, the characteristics of Treg cells were examined when they 
were expanded by IL-35. The expression of Foxp3, a transcript factor specifically 
expressed in Tregs cells, was detected by Taqman and intracellular staining. The 
majority of CD4
+CD25
+ T cells from wild- type BALB/c mice expressed high 
levels of Foxp3. Although there are slightly higher levels of Foxp3 mRNA in 
CD4
+CD25
+  T  cells  expanded  in  the  presence  of  IL-35  compared  to  control 
(Figure  5.6.C),  no  significant  difference  for  Foxp3  expression  was  observed 
intracelluarly  (Figure  5.6.  D).  Thus,  these  data  showed  that  IL-35  expanded 
CD4
+CD25
+  T  cells,  but  did  not  induce  additional  Foxp3  expression  of  Treg 
cells.  
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A.                                                                     B.   
 
 
 
C.                                                                     D.                                                                                                                                    
                                                
 
Figure 5.6 IL-35 expands CD4
+CD25
+ T cells under polyclonal TCR activation 
and co-stimulation.  
CD4
+CD25
+ T cells were purified from spleen and lymph nodes of BALB/c mice 
and  cultured  with  the  different  concentrations  of  IL-35  or  human  Fc  in  the 
presence of plate-bound anti-CD3 for 3 days, and anti-CD28 antibody and IL-2 
were  added  at  24  h  interval  after  the  start  of  the  culture.  IL-35  induced 
CD4
+CD25
+ T cells to proliferate (A), and to produce IL-10 (B). There was no 
difference in Foxp3 expression (C and D). Cell proliferation was determined by 
[
3H]  thymidine  uptake.  IL-10  concentrations  in  the  culture  supernatants  were 
measured by ELISA. Total mRNA was isolated and analyzed by taqman for the 
mRNA expression of transcription factor Foxp3. Data are representative as the 
percentage  of  HPRT  expression.  For  intracelluarlly  staining,  the  cells  were 
stained for Foxp3 and analyzed on a flow cytometer. The number in quadrants 
represent the percentage of Foxp3
+ expressing cells. Data are shown as mean ± 
SEM. n=4, and are representative of three independent experiments, *, p< 0.05; 
**, p< 0.01 compared to Fc control. 
0
70
140
210
280
350
0
C
P
M
 
X
1
0
3
*
*
0
70
140
210
280
350
0
C
P
M
 
X
1
0
3
*
*
0
300
600
900
1200
0 Fc 10 100
0
300
600
900
1200
0 Fc 10 100
IL-35 (ng/ml)
I
L
-
1
0
 
(
p
g
/
m
l
) **
0
300
600
900
1200
0 Fc 10 100
0
300
600
900
1200
0 Fc 10 100
IL-35 (ng/ml)
I
L
-
1
0
 
(
p
g
/
m
l
) **
0
100
200
300
400
0
100
200
300
400
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
F
o
x
p
3
/
H
P
R
T
0 Fc 10 100 0 Fc 10 100
IL-35 (ng/ml)
0
100
200
300
400
0
100
200
300
400
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
F
o
x
p
3
/
H
P
R
T
0
100
200
300
400
0
100
200
300
400
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
F
o
x
p
3
/
H
P
R
T
0 Fc 10 100 0 Fc 10 100
IL-35 (ng/ml)  185 
5.2.7  The  IL-35-  expanded  CD4
+CD25
+  T  cells  maintain  the  suppressive 
function against the effector CD4
+CD25
- T cells 
 
Regulatory  CD4
+CD25
+  T  cells  have  the  capability  to  suppress  effector 
CD4
+CD25
- T cells in vitro (Sakaguchi et al., 2004). In the presence of IL-35, the 
capability of Treg to suppress the proliferation of effector T cells was enhanced 
compared to the culture in the absence of IL-35 (Figure 5.7A). Notably, under 
mitomycin C- treated APC and soluble anti-CD3 antibody culture condition, IL-
35  had  little  or  no  effect  on  CD4
+CD25
+  T  cells  (Figure  5.7.A).  However, 
consistent  with  data  presented  in  Figure  5.5  A,  IL-35  directly  suppressed  the 
proliferation of effector CD4
+CD25
- T cells in the absence of Treg cells (Figure 
5.7.A). To rule out the direct suppressive effect of  IL-35 on effector T cells, 
purified CD4
+CD25
+ T cells ware expanded with plate-bound anti-CD3 in the 
presence  of  IL-35  for  4  days,  and  soluble  anti-CD28  plus  IL-2  were 
supplemented after 24 hours interval at the beginning of cell culture. Then, the 
IL-35- expanded CD4
+CD25
+ T cells were washed and the suppressive function 
was checked. Expanded CD4
+CD25
+ T cells by  IL-35 maintained the  normal 
capacity to suppress CD4
+CD25
- effector T cells (Figure 5.7.B).  
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A.                                                                      B. 
 
 
 
 
 
 
 
Figure  5.7  The  IL-35-  expanded  CD4
+CD25
+  T  cells  maintain  suppressive 
function against the effector CD4
+CD25
- T cells. 
A.  Under  mitomycin  C-  treated  APCs  and  soluble  anti-CD3  antibody  culture 
condition,  CD4
+CD25
+  T  cells  and  CD4
+CD25
-  T  cells  were  separated  from 
spleen  and  lymph  nodes  of  BALB/c  mice,  and  were  cultured  individually  or 
mixed together (1:1 ratio). IL-35 (100 ng/ml) were added in some culture. After 3 
days culture, cell proliferation was determined by [
3H] thymidine uptake. Data 
are  shown  as  mean  ±  SEM.  n=4,  and  are  representative  of  at  least  three 
independent experiments,*, p< 0.05 compared to control.       
B. Purified CD4
+CD25
+ T cells was expanded with plate-bound anti-CD3 in the 
presence of IL-35 (100ng/ml) for 4 days, and soluble anti-CD28 plus IL-2 were 
supplemented after 24 hours interval at the beginning of cell culture. Then, the 
IL-35  -expanded  CD4
+CD25
+  T  cells  were  washed  and  cultured  with  freshly 
purified CD4
+CD25
- T cells for 3 days. Cell proliferation was determined by 
[3H]  thymidine  uptake.  Data  are  shown  as  mean  ±  SEM.  n=4,  and  are 
representative  of  three  independent  experiments,  **,  p<  0.01  compared  with 
CD4
+CD25
- T cells proliferation alone.        
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5.2.8  IL-35 inhibits Th-17 development 
 
As  described  in  chapter  4,  IL-27  is  found  to  inhibit  IL-17  production,  which 
raises  the  question  about  the  effect  of  IL-35  on  Th-17  development.  Purified 
CD4
+CD25
- and CD4
+CD25
+ T cells from BALB/c mice were stimulated for 4 
days with plate-coated anti-CD3 and anti-CD28 in the absence or presence of IL-
35 or EBI3-Fc, and additional IL-2 was added after 24 h in the CD4
+CD25
+ T 
cell culture. Activated CD4
+CD25
- and CD4
+CD25
+ T cells acquired the ability 
to produce IL-17, in the absence of exogenous IL-35. Activated CD4
+CD25
+ T 
cells spontaneously induced nearly 3 times more IL-17 compared to activated 
CD4
+CD25
- T cells. IL-35 strongly suppressed the production of IL-17 in both 
activated  T  cells  (Figure  5.8  A).  In  contrast,  EBI3-Fc  failed  to  reduce  IL-17 
production.  
 
IL-1, TGF-b, and IL-6 are essential for Th-17 differentiation, whereas blockade 
of  IFN-g,  IL-2,  and  IL-4  amplifies  their  development  (Veldhoen  et  al.,  2006, 
Mangan et al., 2006). Therefore, we tested the ability of IL-35 to directly affect 
Th17 cells. Purified CD4
+ T cells isolated from the spleens and lymph nodes of 
BALB/c mice were stimulated with anti-CD3 plus anti-CD28 for 4 days. Some 
cultures received IL-1, TGF-b, and IL-6 (a Th-17 cytokine mixture), and others 
received  the  Th-17  cytokine  mixture  with  the  combination  of  blocking 
antibodies: IFN-g, IL-2, and IL-4 (an optimal Th-17- inducing conditions). In 
both culture conditions, analysis of supernatants showed that IL-35 significantly 
suppressed  the  production  of  IL-17  (Figure  5.8B).  In  a  parallel  study,  these 
cultured cells were restimulated with PMA and ionomycin, then analysed for IL-
17 by flow cytometry. Consistent with the supernatants data presented above, the   188 
addition of IL-35 efficiently inhibited the differentiation of Th17 producing cells 
(Figure  5.8C).  Notably,  IL-35  seemed  less  effective  in  inhibiting  Th-17 
production in the culture supplemented with blocking antibodies compared to the 
culture without blocking antibodies. Thus, IFN-g production was analyzed from 
the  Th-17  cytokine  mixture  culture  only.  IL-35  significantly  enhanced  the 
production of IFN-g compared to the control culture (Figure 5.8D). These results 
collectively suggested that IL-35 is a potent antagonist of Th-17 activity, and the 
inhibitory ability of IL-35 might be partly through enhancing IFN-g synthesis.    
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Figure  5.8  IL-35  inhibits  Th-17  development,  but  promotes  Th1  cell 
differentiation. 
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(A.) Highly purified CD4
+CD25
- and CD4
+CD25
+ T cells from BALB/c mice 
were  stimulated  for  4  days  with  plate-coated  anti-CD3  and  anti-CD28  in  the 
absence  or  presence  of  IL-35  (100  ng/ml),  or  EBI3-Fc  (100  ng/ml),  and 
additional IL-2 was added after 24 h later in the CD4
+CD25
+ T cell culture. After 
3  days  culture,  the  supernatants  were  harvested  and  analyzed  for  IL-17  by 
ELISA. Data are shown as mean ± SEM. n=4, and are representative of three 
independent experiments. *, p< 0.05.    
 
(B, C.D) Purified CD4
+ T cells isolated from the spleens and lymph nodes of 
BALB/c mice were stimulated with anti-CD3 plus anti-CD28 for 4 days, under 
two culture conditions:  a Th-17 cytokine mixture condition (IL-1, TGF-b, and 
IL-6),  and  a  optimal  Th-17-  inducing  condition  (IL-1,  TGF-b,  and  IL-6,  and 
blocking antibodies IFN-g, IL-2, and IL-4). IL-35 or EBI3-Fc was added to some 
samples. After 3 days culture, the supernatants were harvested and analyzed for 
IL-17 (B) and IFN-g (D) by ELISA. Data are shown as mean ± SEM. n=4, and 
are representative of three independent experiments. *, p< 0.05;  **, p< 0.01 
compared to control. Then, the cultured cells were restimulated with PMA and 
ionomycin, after that the cells were stained for intracellular IL-17, and analyzed 
by flow cytometry. The numbers in quadrants represent the percentage of IL-17- 
expressing CD4
+ T cells. 
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5.2.9 Treatment with IL-35 reduced the severity of CIA 
 
In the previous sections I have shown that IL-35 played certain roles in vitro. 
This raises the question about the in vivo biological function of IL-35. CIA, as 
described before, is an animal model for RA. IL-12 and IL-35 share the same p35 
subunit,  and  studies  have  defined  that  IL-12  regulates  the  inflammatory 
progression  of  CIA  (Joosten  1997).  These  raised  our  interest  to  examine  the 
process of CIA administrated with IL-35。 
 
CIA was induced as described in the material and methods. As expected, the 
mice began to develop the clinical sign of arthritis on day 24. From then, the 
mice were given 10 daily i.p. injections of IL-35 (2 mg/dose) or PBS. The mice 
were culled after IL-35 administration (day 34) to investigate the kinetics of the 
response (Figure 5.9). 
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Figure 5.9 The schedule of Collagen-induced arthritis. 
 
DBA/1 mice (7 week old) were primed intradermally with 100  mg of  bovine 
collagen type II (CII) in complete Freund’s adjuvant (CFA) at the base of tail on 
day 0, and boosted intraperitoneally with 100 mg of CII in PBS on day 21. 10 
times of 200 ml PBS, 2 mg/ 200 ml of IL-35 were given i.p. starting on day 24. 
The  mice  were  observed  for  clinical  sign  of  arthritis,  and  the  footpads  were 
measured by callipers every other day. Mice were culled on day 34. 
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Control mice treated with PBS developed the expected disease progression. In 
contrast, mice treated with  IL-35 displayed a significant reduction in arthritic 
incidence (Figure 5.10A) and in the number of arthritic paws (Figure 5.10B). 
Likewise, the thicknesses of the paw swelling and mean clinical score in IL-35 
treated mice were also milder, relative to PBS treated mice (Figure 5.10C, D). 
Histological analysis of joints revealed that mice treated with PBS exhibited cell 
infiltration into joint compartment, synovial hyperplasia and bone erosion (Figure 
5.11A). Each of these parameters was markedly suppressed in the mice treated 
with  IL-35  (Figure  5.11B).  The  histological  scores  are  summarized  in  Figure 
5.11C.  These  results  indicated  that  IL-35  potently  down-regulate  the 
development of CIA and prevent the progression of articular damage. 
 
To gain insight into the mechanism of IL-35- mediated suppression, serum levels 
of certain cytokines were measured at the end of the treatment. TNF-a, IFN-g, 
IL-1Ra, and IL-6 were similar, IL-17 and IL-12 were slightly reduced, whereas 
IL-10 was greatly enhanced in the mice treated with IL-35 compared with control 
mice (Figure 5.12A). In addition, serum anti-CII Ab was analyzed, but there was 
no significant difference in the levels of anti-CII IgGs, IgG1, or IgG2a between 
the two groups of mice (Figure 5.12B). 
 
To determine the effect of in vivo administration of IL-35 on the IFN-g and IL-
17-producing lymphocytes, spleen cells were isolated on day 34 after treatment, 
and stimulated with PMA and ionomycin and analysed by intracellular staining. 
Spleen  cells  from  IL-35-treated  mice  produced  a  lower  percentage  of  IL-17-
secreting cells compared to that of the PBS-treated control mice. Interestingly,   194 
the  percentage  of  IFN-g  expressing  cells  in  IL-35  treated  mice  was  modestly 
enhanced compared to control mice (Figure 5.13).  
 
To elucidate the role of IL-35 in T cell function, a T cell Ag-recalling assay 
against  CII  was  conducted.  Proliferative  response  against  CII  of  mixed 
splenocyte cell culture was observed, but there was no difference between IL-35 
treated  mice  and  control  mice  (Figure  5.14A).  Likewise,  there  was  also  no 
difference between the two groups in the pattern of cytokines consisting of TNF-
a, IL-6, IL-12, and IL-17, secreted in the supernatants of cell culture (Figure 5.14 
C.D.E).  However,  there  was  a  slight  enhancement  of  IFN-g  detected  in  cell 
culture from IL-35 treated mice compared with control mice (Figure 5.14 B). 
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A.                                                                     B.         
 
 
 
 
 
     
 C.                                                                           D.               
         
 
 
 
 
 
 
Figure 5.10 IL-35 suppressed the disease progress of CIA in DBA/1 mice. 
 
Collagen-primed  DBA/I  mice  were  randomly  divided  into  groups  of  10, 
challenged  on  day  21,  and  given  10  daily  i.p.  injections  of  2  mg/200 ml  of 
EBI3/p35-Fc, or 200 ml of PBS starting on day 24 (Shown in arrow). Mice were 
monitored  for  disease  progression  as  indicated.  IL-35-treated  mice  developed 
significantly less arthritic incidence (A), less number of arthritic paws (B), less 
severe paw thickness (C) and lower clinical score (D) compared to control mice 
treated with PBS. Values are mean ± SEM. n=10, and are representative of two 
independent experiments, *, p< 0.05; **, p< 0.01 compared to PBS group.      
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A.            PBS    
 
 
 
 
B.          IL-35  
 
 
 
 
C.              
 
 
 
 
Figure 5.11 Administration of IL-35 significantly reduced joint pathology.  
 
At the end of IL-35 or PBS administration, hind limbs (Six mice /group) were 
removed, formalin-fixed, decalcified, and stained with H&E. Profound cartilage 
and  bone  erosion,  hyperplasia  and  cellular  infiltration  were  observed  in  the 
control  PBS  group  (A)  whereas  those  of  the  IL-35-treated  group  exhibited 
reduced histological evidence of destruction (B). Original magnification (A and 
B) is x50. (C) Histological appearances were scored (0-3) for the presence of 
bone erosion, synovial hyperplasia, and cellular infiltration (D). Data are mean ± 
SEM.*, p< 0.05 compared to PBS group. (This figure has already been published 
in Niedbala et al., 2007, as shown in Appendix 2) 
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Figure 5.12  Effect of IL-35 or PBS treatment on serum cytokines and serum 
anti-collagen Abs.  
Serum were collected after DBA/I mice were treated with either IL-35 or PBS on 
day 34. Levels of TNF-a, IFN-g, IL-1Ra, IL-6, IL-17, IL-12, and IL-10 were 
determined by Luminax (A). Data are mean ± SEM of individual mouse (n=6). 
(B) Collagen-specific total IgGs, IgG1 and IgG2a in serum were determined by 
ELISA. Serum samples were diluted 4000-fold, and data are expressed as mean 
absorbance (OD 630) ± SEM of individual mouse (n=6). There is no significance 
between two groups. 
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Figure 5.13 Intracelluar cytokine analysis of IFN-g and IL-17 secretion.  
 
Spleen cells from mice treated with IL-35 or PBS were stimulated with PMA and 
ionomycin and stained intracellularly for IL-17 and IFN-g. The spleen cells from 
the IL-35-treated mice show a reduced frequency of IL-17-producing cells but a 
higher frequency of IFN-g expressing cells. The number in quadrants represent 
the percentage of IL-17- or IFN-g expressing cells. 
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A.                                                                   B.  
 
 
 
 
C.                                                                  D.  
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Figure 5.14 Assessment of in vitro responses against collagen from mice treated 
with IL-35 or PBS.  
Spleen cells (pooled from 6 mice per group) were collected from IL-35 treated or 
PBS treated mice after 10 times of injections (day 34) and cultured with titrated 
concentrations  of  collagen    for  96  h.  T  cell  proliferation  (A),  which  was 
determined  by  [
3H]  thymidine  uptake,  is  expressed  as  mean  cpm  ±  SEM  of 
triplicate cultures. Supernatants from parallel cultures were collected after 72h. 
IFN-g (B), IL-6 (C), TNF-a (D), and IL-17(E) levels were measure by ELISA 
and expressed as mean ± SEM. There was no statistical difference between PBS 
and IL-35 treated group. 
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The therapeutic effect of IL-35 on CIA was further characterized. Firstly in order 
to exclude the possibility that the effect of IL-35 was due to the effect of the Fc 
fragment of the molecule, DBA/1 mice primed and boosted with CII were treated 
i.p. daily for 10 days with IL-35, EBI3-Fc, or PBS from day 24. Mice treated 
with  IL-35  developed  significantly  less  severe  disease  compared  to  the  PBS-
treated mice, but mice treated with EBI3-Fc developed diseases indistinguishable 
from PBS-treated mice (Figure 5.15 A). These data indicated that the effect of 
IL-35 was not due to the Fc fragments. Consistent with in vitro results which 
showed that EBI3-Fc had no effect on Th-17 cell differentiation.  
 
Next, a dose response study on the therapeutic effect of IL-35 on CIA was carried 
out. DBA/1 mice primed and boosted with CII were treated i.p. daily for 10 days 
with graded doses of IL-35. A daily dose of 2 mg per mouse of IL-35 was found 
to produce the best therapeutic effect; although the daily low dose of 0.4 mg of 
IL-35 was also effective (Figure 5.15 B).These results therefore demonstrated 
that IL-35 may be a new effective therapeutic agent against clinical rheumatoid 
arthritis. 
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A.                                                                    B.  
 
 
 
 
 
 
 
 
Figure 5.15 Further characterization of the therapeutic effect of IL-35 on CIA in 
DBA/1 mice. 
 
A. DBA/1 mice were primed and boosted with CII as shown in Figure 5.10. Mice 
were treated i.p. daily with IL-35 (2 mg per mouse), EBI3-Fc (2 mg per mouse), 
or PBS for 10 days form day 24 as indicated by the arrows. Mice were monitored 
for disease progression. IL-35 but not EBI3-Fc suppressed CIA. Values are mean 
± SEM. n=10,*,p< 0.05. ; **, p< 0.01 compared to PBS group.      
 
B. DBA/1 mice were primed and boosted with CII as in Figure 5.10 and treated 
i.p. daily with graded concentrations of IL-35 for 10 days starting from day 27 
(indicated  by  arrow).  Mice  were  monitored  for  disease  progression.  The 
suppression  of  CIA  by  IL-35  was  dose  dependent.  Values  are  mean  ±  SEM. 
n=10,*,p<  0.05  compared  to  PBS  group.  (This  figure  has  already  been  in 
publication as shown in appendix 2).    
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5.3 Conclusion and discussion 
 
EBI3 was reported in 1997 by Devergne group to associate non-covalently with 
IL-12 p35 to form a novel heterodmeric cytokine, and this novel cytokine has 
been officially designated as IL-35 in 2002 by the Interleukin Nomenclature and 
the HUGO Gene Nomenclature Committee. IL-12 p35 is constitutively expressed 
in most tissues, while EBI3 is mainly expressed in haematopoietic cells. The up-
regulated expression of EBI3 and IL-12 p35 were found in placental trophoblasts 
(Devergne et al., 2001). Trophoblasts are known to play an important role in 
maternal tolerance to the semi-allogeneic foetus (Jokhi et al., 1997; Le Bouteiller 
et  al.,  1999),  which  indicated  that  IL-35  may  be  involved  in  the 
immunosuppressive activity.  
 
IL-35 is a new member of the IL-12 family which includes IL-23 and IL-27. IL-
35 shares EBI3 with IL-27, and the data in this chapter demonstrated that IL-35 
has similarity with IL-27. However, this is not due to EBI3, because EBI3 on its 
own has no effect both in vitro and in vivo (Figure 5.1; 5.8 and 5.15 A). Like IL-
27, IL-35 can induce the proliferation as well as anti-proliferation of CD4
+ T 
cells in vitro, and the dual functional role of IL-35 may depend closely on the 
mode of T cell activation. With the in vitro combination of plate-bound anti-CD3 
and anti-CD28 co-stimulation, IL-35 induced the proliferation of effector T cells 
(Figure 5.1), and these activated T cells produced a high amount of IFN-g (Figure 
5.2 A). However, under in vitro APC and soluble anti-CD3 activation condition, 
IL-35  profoundly  suppressed  effector  CD4
+  T  cells  and  inhibited 
proinflammatory  cytokine  productions  including  IFN-g  (Figure  5.5). 
Furthermore,  IL-35  induced  the  proliferation  of  CD4
+CD25
+  T  cells  with  a   203 
significant elevation of the IL-10 cytokine productions under the costimulation of 
anti-CD3  and  anti-CD28  plus  IL-2  condition  (Figure  5.6),  and  these  IL-35-
expanded CD4
+CD25
+ T cells remained highly suppressive against the effector 
CD4
+CD25
-T cells (Figure 5.7). These results demonstrated that IL-35 may play 
a regulatory role in immune response. During strong antigenic challenge such as 
acute infections, IL-35 might be formed by the association of EBI3 and IL-12 
p35.  IL-35  might  preferentially  activate  Th1-like  cells  which  help  clear  the 
infection. Meanwhile, IL-35 might also expand Treg cells under acute infection. 
The  Treg  cells  would  prevent  collateral  damage  by  suppressing  the  residual 
effector  cells  during  the  ensuing  chronic  infective  phase.  Also,  IL-35  might 
directly  suppress  effector  T  cells  under  chronic  infections  or  inflammatory 
conditions. 
 
Recently discovered Th-17 cells, a unique subset of T cells, has been associated 
with  the  development  of  the  pathology  noted  in  a  variety  of  autoimmune 
diseases,  including  inflammatory  bowel  disease,  rheumatoid  arthritis, 
autoimmune encephalomyelitis, and multiple sclerosis (Lubberts 2004; Bettelli et 
al.,  2007).  IL-1b,  IL-6  and  TGF-b  promote  the  development  of  Th-17.  In 
contrast,  IFN-g,  IL-4 and  IL-2  can antagonize  Th-17 cells. As emphasized in 
chapter 4 and other publications, IL-27 mediates the inhibitory effect on Th-17 
cell  activity  (Stumhofer  2006;  Yoshimura  2006).  Data  reported  here 
demonstrated  that  IL-35  markedly  inhibited  the  generation  of  IL-17  from 
CD4
+CD25
- and CD4
+CD25
+ T cells (Figure 5.8). It is of interest to note that the 
inhibitory activity of IL-35 on Th-17 development might partly depend on its 
stimulatory effect on the production of IFN-g. Again, EBI3 alone does not inhibit   204 
Th17 differentiation. The mechanism, which IL-27 mediates suppression of Th17 
cell development, is mainly through STAT1 dependent pathway. To investigate 
the  mechanism  how  IL-35  inhibits  Th17  development,  the  receptors  of  IL-35 
needs to be identified. 
 
Since both Treg cells and Th17 cells are closely associated with the control of 
rheumatoid arthritis, the effects of IL-35 in murine collagen induced arthritis was 
investigated in this chapter. Administration of IL-35 effectively suppressed an 
established CIA in male DBA/1 mice (Figure 5.10). This suppressive effect was 
not due to Fc fusion part (Figure 5.15A). When compared to control mice, IL-35-
treated mice showed less cell infiltration into the synovium and reduced articular 
erosion (Figure 5.10). The inhibitory effect of IL-35 on CIA was reflected by the 
immunological responses of spleen cells in terms of the reduced frequency of IL-
17 postive cells and the increased frequency of IFN-γ positive cells (Figure 5.13). 
This  is  consistent  with  recent  reports  that  Th17  rather  than  Th1  is  the  key 
pathogenic driver of arthritic diseases. Together, these results suggested that IL-
35 may represent an alternative effective therapeutic agent against inflammatory 
diseases. The key physiological and pathophysiological roles of IL-35 in health 
and disease remain to be explored. 
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Chapter 6 
General Discussion 
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6.1 Cloning and expression of murine IL-27-Fc, IL-35-Fc, and human IL-35-
Fc with GS system 
 
Murine  IL-27-Fc,  IL-35-Fc,  IL-12-Fc  and  IL-23-Fc  have  been  constructed  in 
pSecTag2A expression vector in our lab before I started the project, but these 
recombinant  proteins  production  quantities  are  quite  low.  In  order  to  obtain 
sufficient quantities of murine IL-35-Fc and IL-27-Fc for in vivo model studies, a 
new  highly  efficient  mammalian  recombinant  expression  system  called  GS 
system  was  introduced.  PCR  was  employed  to  obtain  the  cDNA  fragments 
encoding  IL-35-Fc,  IL-12-Fc,  IL-27-Fc,  and  IL-23-Fc  from  pSecTag2A 
constructed vector。The restriction enzyme sites were introduced into both ends 
of the cDNA fragments that allowed them to clone into the PEE14.4-1 GS vector. 
Restriction  enzyme  mapping  showed  that  the  cloned  cDNA  fragments  had 
correct identities in the right orientations. The IL-35-Fc, IL-12-Fc, IL-27-Fc and 
IL-23-Fc  expression  constructs  were  transfected  to  CHO  cells,  and  the 
permanently transfected cell lines were selected using increasing concentrations 
of MSX in the glutamine free medium. Glutamine is an essential amino acid, and 
CHO cells growing in culture require glutamine for their growth and survival. GS 
is the only enzyme responsible for the biosynthesis of glutamine in CHO cells. 
MSX selectively inhibits the activity of the GS enzyme. It has been observed that 
the  low  concentration  of  MSX  (3mM)  is  lethal  to  normal  CHO  cells  in  the 
glutamine free medium. Interestingly, some CHO cells can be primed to live in 
the glutamine free medium with high concentrations of up to 5000mM MSX due 
to endogenous GS gene amplification (Sanders & Wilson 1984). Based on this 
principle, the GS vector was designed to contain GS gene. With the increased   207 
concentration of MSX, the GS gene alone with the gene of interest would be 
amplified. In our study, the maximum concentration of MSX of 500mM led to the 
highest number of amplified vector expression. The cells started to die when the 
concentration of MSX exceeded 500mM. The clones with the highest expression 
were screened using a specific human IgG1 Fc ELISA. The expression level from 
the  GS  system  was  10  times  higher  than  the  expression  level  from  the 
pSecTag2A  system.  However,  IL-27-Fc  and  IL-35-Fc  colonies  had  a  lower 
expression level compared to that of IL-12-Fc and IL-23-Fc colonies. Probably 
the  low  yields  of  IL-35-Fc  and  IL-27-Fc  were  due  to  their  physiological 
structures and synthesis, or that the GS system still has not efficiently increased 
their  protein  expression.  The  use  of  different  expression  vector  system  or 
different  promoters  may  increase  the  yield  of  murine  IL-35-Fc  and  IL-27-Fc 
production. Purification of the recombinant proteins was facilitated by the Econo-
Pac  protein  A  column.  The  molecular  weight  and  purity  of  the  murine 
recombinant proteins IL-35-Fc, IL-12-Fc, IL-27-Fc and IL-23-Fc were examined 
by SDS-PAGE and Coomassie blue gel staining. In vitro and in vivo studies have 
shown  that  these  recombinant  fusion  proteins  were  effective  in  immune 
responses.  
 
The  study  of  murine  IL-35  has  demonstrated  that  IL-35  is  a  novel  anti-
inflammatory cytokine suppressing the immune response. As a consequence for 
future  exploration,  the  human  IL-35  protein  was  constructed.  Human  cDNA 
fragments encoding EBI3 and p35 were cloned from human DC by RT-PCR. 
Silent mutation in both EBI3 and p35 cDNA fragments was obtained to avoid 
enzyme  restriction  sites  when  inserted  into  a  vector.  DNA  sequencing  was   208 
performed to confirm the sequences identities of EBI3 and p35. It has been found 
that  the  fusion  of  cytokines  to  immunoglobulin  Fc  regions  can  prolong  the 
biological  half-life  of  the  protein  in  vivo  (Wooley  et  al.,  1993).  Also,  a 
mammalian  expression  system  was  chosen  for  the  production  of  recombinant 
protein human IL-35-Fc because it possesses the proper protein-folding and post-
translational modification to express a functional Fc-fusion protein. Therefore, 
the cloned cDNA EBI3 and p35 have been joined together by a flexible linker, 
and linked to the cDNA fragment encoding human IgG Fc in pSecTag2A vector. 
The resulting cDNA construction of EBI3-p35-Fc was amplified by PCR and 
cloned into PEE14.4-1GS expression vector. DNA sequencing was performed to 
confirm the reading frame of EBI3-p35-Fc without any signal mutation during 
PCR amplification. Human IL-35-Fc expression construct vector was transfected 
into CHO cells, and the permanently transfected cell lines were selected using 
increasing concentrations of MSX in the glutamine free medium. The highest 
expression  clone  was  screened  using  a  specific  human  IgG1  Fc  ELISA.  The 
recombinant protein human IL-35-Fc has a molecular weight of 80 kd and could 
be detected by Western Blot analysis. The purity of human IL-35-Fc could be 
found in SDS-PAGE coomassie blue staining. The functional activities of human 
IL-35 are still unknown and need further studies. 
 
6.2 IL-27 and collagen-induced arthritis 
 
IL-27 is a heterodimeric cytokine belonging to a structurally related family that 
includes IL-12, IL-23, and IL-6. Major advances in understanding the biology of 
IL-27 have been achieved since its discovery in 2002.   209 
IL-27  is  mainly  produced  by  activated  macrophages  and  dendritic  cells.  The 
expression  of  IL-27  has  been  associated  with  autoimmune  diseases,  such  as 
patients with Crohn’s disease (Schmidt et al., 2005). The up-regulation of IL-27 
expression has been observed in sites of inflammation, such as the CNS resident 
cells during EAE and chronic T.gondii infection, the retina tissue of uveitis and 
multiple sclerosis (Li et al., 2005; Stumhofer et al., 2006; Fitzgerald et al., 2007; 
Amadi-Obi  et  al.,  2007).  IL-27p28  expression  has  been  detected  in  synovial 
tissues of RA patients in our laboratory (Niedbala et al., 2008), suggesting that 
IL-27 may be involved in chronic immunopathology of RA. However, p28 and 
EBI3  are  not  always  expressed  coordinately  (Pflanz  et  al.,  2002),  and  the 
detection of IL-27p28 expression alone is not proof of the expression of EBI3 in 
RA synovial tissues. Moreover, there are no synovial tissue samples from healthy 
control or osteoarthritis patients to compare the expression levels of IL-27 in RA 
patients. Due to the difficulties in human studies, the experiments in this thesis 
were designed to investigate the role of IL-27 in CIA, a murine model of RA.  
 
Initial studies focused on the role of IL-27 on the pro-inflammatory activities, but 
more  recent  studies  have  demonstrated  that  IL-27  mediates  anti-inflammatory 
responses  (summarized  in Batten  & Ghilardi 2007). The results in this thesis 
provided evidence in vivo for the pro- and anti-inflammatory properties of IL-27 
in the development of inflammatory arthritis. IL-27 effectively suppressed the 
disease development when exogenous  IL-27 was administered at the onset of 
CIA, but IL-27 did not inhibit the disease development, and even exacerbated the 
disease  severity  when  exogenous  IL-27  was  administered  to  mice  with 
established CIA.    210 
CIA model studies have demonstrated that several proinflammatory cytokines, 
including  TNF-a,  IL-1,  and  IL-6  play  key  roles  in  the  disease  development 
(Feldmann et al., 1996; Wooley et al., 1993; Takagi et al., 1998). Recent studies 
have  revealed  that  a  critical  role  of  IL-17  in  the  destructive  pathogenesis  of 
arthritis (Lubberts et al., 2002; Nakae et al., 2003). In the studies presented in 
chapter 4, diseases reduction by IL-27 administrated at the onset of CIA was 
associated with significantly reduced IL-17, IL-6 and IFN-g productions, while 
disease exacerbation by IL-27 administrated on established CIA was associated 
with  elevated  IL-6  and  IFN-g  production.  However,  it  is  unclear  how  these 
opposite effects of IL-27 happened. Moreover, the endogenous levels of IL-27 
during CIA development have not been examined yet. Probably the detection of 
endogenous  IL-27  at  various  phases  of  CIA  would  provide  important 
information on the mechanism how IL-27 modulates inflammatory responses. 
The availability of IL-27 knockout mice or transgenic mice might also provide 
useful tools to investigate the precise role of IL-27 in the development of CIA.  
 
Th17 cells play a crucial role in the inductive phase of CIA development (Nakae 
et  al.,  2003),  and  anti-IL-17  treatment  can  suppress  the  disease  development 
(Lubberts et al., 2004). Recent studies have found that IL-27 can antagonize the 
development of Th17 cells. In the murine models of EAE and chronic infection 
with T.gondii, the lack of IL-27 signaling resulted in an increased number of 
Th17  producing  CD4
+  T  cells,  associated  with  enhanced  CNS  inflammation 
(Batten  et  al.,  2006;  Stumhofer  et  al.,  2006).  Exogenous  IL-27  administered 
during the onset phase of disease significantly suppressed the development of 
EAE, associated with a decreased number of Th17 cells in the CNS (Fitzgerald   211 
et al., 2007).Consistent with these studies, the studies have been done in this 
thesis  have  shown  that  IL-27-treatment  at  the  onset  of  CIA  suppressed  the 
disease  development  and  inhibited  Th17  responses.  Levels  of  IL-17  were 
significantly reduced in the serum of IL-27-treated mice, and there were reduced 
number  of  IL-17-producing  cells  in  the  lymph  nodes  and  spleens  of  IL-27-
treated  mice  compared  to  PBS-treated  mice.  Moreover,  IL-27  administration 
effectively  suppressed  collagen-specific  response  corresponding  with  the 
inhibition of IL-17 production in vitro by lymph nodes and spleen cells. These 
results  indicated  that  IL-27  probably  systemically  inhibits  Th17  development 
during the diseases process. Th17 cells are mainly induced by IL-6 and TGF-b 
(Veldhoen et al., 2006). My studies also showed that IL-27 treatment at the onset 
of CIA reduced serum IL-6 production. The reduction of IL-6 production by IL-
27 may indirectly inhibit the development of Th17. Furthermore, IL-6 is known 
to efficiently block TGF-b-induced regulatory T cells induction (Kimura et al., 
2007), and it seems that the lower levels of IL-6 produced by mice treated with 
IL-27 at the onset of CIA may enhance the development of TGF-b inducible 
regulatory T cells. Furthermore, IL-27-treated mice at the early phase of CIA 
displayed  lower  collagen-specific  IgG2a  production  in  serum.  This  is  in 
contradiction with the reports that  IL-27 induced  IgG2a switching in  B cells 
(Yoshimoto et al., 2004). However, this is in agreement with recent studies that 
IL-17-deficient  mice  markedly  suppressed  CIA  associating  with  a  lower 
collagen-specific IgG2a production (Nakae et al., 2003). Thus, Collagen-specific 
B cell function during CIA may be due to the role of IL-17, not IL-27. These 
findings  suggested  that  IL-27  may  mainly  inhibit  the  development  of  Th17   212 
development  to  limit  collagen-specific  immune  response  and  the  destructive 
process in the early phase of CIA.  
 
Unexpectedly, my studies have shown that IL-17 production was not affected 
when exogenous IL-27 was administered to mice with established CIA. This is 
consistent with in vitro finding that IL-27 has no effect on differentiated Th17 
cells. It is possible that Th17 cells may be already polarized in the established 
CIA, and IL-27 may have no ability to regulate differentiated Th17 cells at the 
advanced disease stage of CIA. However, the clinical disease was exacerbated in 
the mice treated with IL-27 at the later phase of CIA. It is likely that IL-27 may 
induce different pathogenesis at the later phase of CIA. The elevated levels of 
IL-6 and IFN-g production in response to activation with collagen were observed 
in  the  spleen  cells  from  IL-27-treated  mice.  The  elevated  pro-inflammatory 
cytokine IL-6 may be a result of the effect of IL-27 on diseases exacerbation. 
Although IFN-gR deficient mice results in exacerbation of disease in CIA, the 
role  of  IFN-g  in  chronic  articular  inflammation  is  still  not  clear  (Chu  et  al., 
2007). Thus, further studies are required to elucidate the role of the elevated 
production  of  IFN-g  in  the  late  phase  of  CIA.  Besides  T  cells,  IL-27R  is 
expressed on monocytes, NK cells, mast cells, activated B cells and dendritic 
cells (Pflanz et al., 2002; 2004). Consistent with the broad expression profile of 
its receptor, IL-27 has effects on non-T cells (Pflanz et al., 2002; Larousserie et 
al., 2006; Wirtz et al., 2006). It is possible that the IL-27 may influence on non-
T cells to regulate CIA development. It would be important to further investigate 
the activities of IL-27 on established CIA.  
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Besides CIA model in our studies, IL-27 in arthritis has been studied in two 
other murine models. One study has shown that neutralization of IL-27p28 is 
beneficial for ongoing adjuvant-induced arthritis (Goldberg et al., 2004). It was 
suggested  that  IL-27  can  play  a  pro-inflammatory  role  in  adjuvant-induced 
arthritis. Another recent study has shown that the development of Proteoglycan 
(PG)-induced arthritis (PGIA) in IL-27R-/- mice was delayed and the severity 
was reduced in comparison with wild-type controls (Cao et al., 2008).  IL-27 had 
little  inhibitory  activity  on  IL-17  production  in  PGIA  model.  Diminished 
arthritis on IL-27R-/- mice was mainly associated with a decreased Th1 response 
(Cao et al., 2008). These studies and our findings demonstrated that the role of 
IL-27  in  arthritis  is  pleiotropic.  Depending  on  the  context  and  the  cytokine 
milieu, IL-27 may play either a pro-inflammatory or an anti-inflammatory role 
in the regulation of inflammatory responses. Currently, most of the studies have 
been  done  on  murine  IL-27;  few  studies  have  focused  on  human  IL-27. 
Although animal models resemble human diseases, there is no animal model 
identical  with  RA  in  humans.  The  studies  presented  in  chapter  4  provide 
important information on the role of IL-27 in arthritis, and whether IL-27 can be 
used as a therapeutic target in RA remains to be explored.  
 
6.3 IL-35 and inflammation 
 
IL-35 is a new member of the IL-12 family, as it shares EBI3 subunit with IL-
27,  and  it  also  shares  p35  subunit  with  IL-12.  Like  IL-27,  IL-35  has  both 
immune stimulatory and inhibitory effects on T cell response in vitro, depending 
on the cell activation condition. When the naïve CD4
+ T cells were activated 
with immobilized anti-CD3 and anti-CD28, the presence of IL-35 enhanced T   214 
cell  proliferation.  In  contrast,  when  naïve  CD4
+  T  cells  were  activated  with 
APCs and soluble anti-CD3, IL-35 profoundly inhibited the T cell proliferation. 
These opposite results suggested that IL-35 probably induced different signal 
pathways or costimulatory  events, which influenced the different outcome of 
immune response. A recent report has demonstrated that IL-35 contributes to 
Treg cell function. Treg cells can suppress the homeostatic expansion of effector 
T  cells.  The  suppressive  capacity  of  EBI3-/-  and  IL-12p35-/-  Treg  cells  was 
significantly reduced (Collison et al., 2007). The data presented in chapter 5 has 
shown that IL-35 expanded CD4
+CD25
+ T cells and maintained their capacities 
to suppress effector T cells in vitro. These results indicated that IL-35 represents 
a novel potential modulator for T cell response. IL-12 cytokine family members 
usually induce JAK/STAT signalling pathway to mediate biological responses. 
STAT3 has been shown to be indispensable to IL-27-mediated proliferation of 
CD4
+ T cells (Pflanz, et al., 2004; Kamiya, et al., 2004). Whether JAK/STAT 
pathway  deliver  the  signalling  for  IL-35  on  T  cell  response  remains  further 
investigation. 
 
Th1 immune response is essential for host defence against pathogens including 
some  bacterial,  parasites,  and  tumours.  In  contrast,  excess  of  Th1  immune 
response  may  cause  some  autoimmune  diseases  (Brombacher  et  al.,  2003). 
Proper initiation and maintenance of Th1 response during infection is tightly 
regulated  by  related  cytokines.  Published  reports  have  shown  that  early 
expression of EBI3 is critical for the induction phase of Th1 immunity. Th cells 
profile from EBI3-/- mice are significantly skewed toward Th2 (Zahn 2005). 
However, the results presented in chapter 5 have shown that EBI3 alone has no   215 
influence on Th1 differentiation in vitro. This indicated that EBI3 may associate 
with other partners to play an important role in initiating Th1 response. Since IL-
27  induces  Th1  differentiation  on  naïve CD4+ T  cells,  previous  publications 
always  interpreted  that  the  enhanced  Th2  response  from  EBI3-/-  mice  was 
related to the lack of IL-27 function. My studies have shown that IL-35 can also 
induce IFN-g production of naïve CD4
+ T cells. This suggested that IL-35 might 
play  a  potential  role  associated  with  EBI3  deficiency,  and  the  role  of  IL-27 
might be overestimated. It is possible that IL-35 and IL-27 together sensitize the 
naïve T cells to Th1 differentiation during the early phase of infection. IL-27 
induces Th1 differentiation mainly through T-bet / STAT-1 dependent signalling 
(Kamiya 2004). The data presented in chapter 5 has provided evidence that IL-
35 induced the T-bet expression and the expression of STAT-1 phosphorylation. 
It  will  therefore  be  important  to  determine  whether  IL-35-  induced  T-bet 
expression correlates with the phosphorylation of STAT-1. This also raises the 
question of the expression of IL-35 receptors. The p35 subunit of IL-35 is a 
component of IL-12, but IL-35 does not share the same receptor subunit IL-
12Rb2  as  described  in  previous  studies  (Devergne  et  al.,  1997).  The 
identification of IL-35 receptors would greatly improve our understanding of the 
biological behaviour of IL-35.  
 
Data  presented  in  chapter  5  demonstrated  that  IL-35  could  suppress  Th17 
differentiation  in  vitro.  This  is  consistent  with  the  current  finding  on  EBI3 
deficient  mice  (Yang  et  al.,  2008).  EBI3  deficient  Th17  cells  produce 
significantly higher levels of IL-17 than wild-type Th17 cells. However, our data 
has shown that Th17 development was not affected when EBI3 alone was added   216 
to in vitro culture. Recent studies also have demonstrated that IL-27 p28 alone 
can partially inhibit IL-17 in vitro, and that dimerization with EBI3 forming IL-
27 has a stronger ability to decrease Th-17 activity (Stumhofer et al., 2006). 
Although  very  little  is  known  about  the  function  of  IL-12  p35  alone,  the 
inhibition of Th17 development by IL-35 probably depends on EBI3 and p35 as 
a combined component. The mechanism, by which IL-27 mediates suppression 
of Th17 cell development, is mainly through STAT1 dependent pathway. The 
mechanism of IL-35 inhibiting Th17 development is still unclear. The induction 
of IFN-g by IL-35 might partly be involved in the ability of IL-35 to inhibit 
Th17 activity. 
 
IL-12 p35-/- mice have been reported to have enhanced joint swelling and joint 
pathology in CIA compared to wide-type mice, and the diseases exacerbation in 
IL-12p35-/- mice were correlated with the lack of function of IL-12 (Murphy et 
al., 2003). However, the results in chapter 5 presented the potential role of IL-35 
to down-regulate the progress of arthritis in CIA. Our studies indicated that the 
enhanced arthritic destruction in IL-12p35 deficient mice may be partly due to 
the lack of IL-35. In our studies, IL-35-treated arthritic mice showed a decreased 
number of IL-17-producing CD4
+ T cells but an increased number of IFN-g -
producing CD4
+ T cells. IL-35 is probably an important inhibitor of Th-17 cell 
differentiation  in  vivo. Interestingly,  serum  IL-10  was  up-regulated  in  IL-35-
treated  mice.  In  vitro  data  has  shown  that  IL-35  enhanced  IL-10  production 
produced by CD4
+CD25
+ T cells, which probably explained that IL-35 might 
induce  Treg  cells  to  produce  IL-10  in  vivo.  Although  IL-35  and  IL-27  has 
similarities, there is a crucial difference between IL-35 and IL-27 in CIA. While   217 
IL-35 was effective in suppressing an established CIA, IL-27 was effective only 
at the onset of the disease. Further investigation would elucidate the differences 
between IL-27 and IL-35 in CIA model.  
 
Thus,  IL-35  is  a  pro-inflammatory  factor  driving  Th1  response  in  the  initial 
phases of an immune response and helps clear the acute infection to prevent the 
onset of excessive autoimmune response. On the other hand, IL-35 is an anti- 
inflammatory  factor  maintaining  Treg  cells  function  and  inhibiting  Th17 
development to prevent chronic inflammatory damage. It is also important to 
note that IL-35 can suppress CIA, which may provide a novel therapeutic target 
in the treatment of human RA.  
 
6.4 Conclusion 
 
The present study is separated into three major components. Firstly, Murine IL-
27, IL-35 and human IL-35 were cloned and expressed. The second part of this 
project  had  focused  on  the  role  of  IL-27  in  CIA.  The  third  part  was  the 
exploration of the role of murine IL-35 in vitro and in vivo.  
 
Using GS mammalian expression system, recombinant murine IL-27-Fc, IL-35-
Fc, IL-23-Fc, and IL-12-Fc were successfully produced in sufficient quantities, 
and  the  biological  activities  of  IL-27-Fc,  IL-23-Fc,  and  IL-12-Fc  were 
functionally  well.  Human  recombinant  IL-35-Fc  was  successfully  cloned  and 
expressed in mammalian system. The production of human IL-35-Fc is needed 
for further study.   218 
 
Using murine collagen induced arthritis model, IL-27 was found to attenuate the 
disease  development  when  administrated  at  the  onset  of  the  disease,  but 
exacerbated the disease progression when administered in the established disease 
phase. These in vivo results were supported by in vitro results that IL-27 was able 
to inhibit Th17 differentiation from naïve CD4
+ T cells, but had little or no effect 
on  IL-17  production  by  polarised  Th17  cells.  The  conflicting  roles  of  IL-27 
would  mean  that  the  use  of  IL-27  as  an  effective  therapeutic  agent  against 
inflammatory diseases has to be careful. 
 
IL-35 was found to play an important role in immune regulation. IL-35 could 
expand Treg cells, but also directly suppress the proliferation of effector T cells. 
IL-35 could induce Th1 cell polarization, but inhibit Th17 cell differentiation. 
Furthermore, mice treated with IL-35 developed markedly less severe collagen 
induced arthritis. These results suggest that IL-35 may be a novel reagent against 
inflammatory diseases.  
 
6.5 Future studies 
 
Results from the studies presented in this thesis suggest a number of key areas 
which merit future investigation. 
  
￿  Identification of CIA phenotypes in IL-27 knockout mice and IL-35 knockout 
mice to analyse the role of endogenous IL-27 and IL-35 in CIA development. 
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￿  Identification  of  the  receptors  of  IL-35  and  subsequent  analysis  of  the 
molecular mechanism of IL-35 in T cell immune response, including Treg 
cells, Th1 cells, and Th17 cells. 
 
￿  Identification of the function of IL-35 in other chronic inflammatory diseases, 
such as EAE, colitis and diabetes. 
 
￿  Identification of the expression levels of IL-27 and IL-35 in synovial tissues 
in RA patients and comparison to the expression levels of IL-27 and IL-35 in 
normal synovial tissues or OA patients. 
 
￿  Identification of the function of human IL-35 in T cell responses in vitro to 
find out whether the function of human IL-35 is similar to murine IL-35, and 
subsequent study of human IL-35 in inflammatory diseases, such as RA. 
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